[
  {
    "id": "ind:fda.verzenio:0",
    "document_id": "doc:fda.verzenio",
    "indication": "desc:ind:fda.verzenio:0",
    "initial_approval_date": "2023-03-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
    "description": "desc:stmt:fda.verzenio:0",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor)"
  },
  {
    "id": "ind:fda.verzenio:1",
    "document_id": "doc:fda.verzenio",
    "indication": "desc:ind:fda.verzenio:1",
    "initial_approval_date": "2018-08-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208716s001lbl.pdf",
    "description": "desc:stmt:fda.verzenio:1",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Verzenio (abemaciclib) in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:fda.verzenio:2",
    "document_id": "doc:fda.verzenio",
    "indication": "desc:ind:fda.verzenio:2",
    "initial_approval_date": "2017-09-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf",
    "description": "desc:stmt:fda.verzenio:2",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Verzenio (abemaciclib) in combination with fulvestrant"
  },
  {
    "id": "ind:fda.verzenio:3",
    "document_id": "doc:fda.verzenio",
    "indication": "desc:ind:fda.verzenio:3",
    "initial_approval_date": "2017-09-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf",
    "description": "desc:stmt:fda.verzenio:3",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Verzenio (abemaciclib)"
  },
  {
    "id": "ind:fda.akeega:0",
    "document_id": "doc:fda.akeega",
    "indication": "desc:ind:fda.akeega:0",
    "initial_approval_date": "2023-08-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf",
    "description": "desc:stmt:fda.akeega:0",
    "raw_biomarkers": "deleterious or suspected deleterious BRCA-mutated (BRCAm)",
    "raw_cancer_type": "metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Akeega (abiraterone acetate and niraparib) in combination with prednisone"
  },
  {
    "id": "ind:fda.akeega:1",
    "document_id": "doc:fda.akeega",
    "indication": "desc:ind:fda.akeega:1",
    "initial_approval_date": "2025-12-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216793s001lbl.pdf",
    "description": "desc:stmt:fda.akeega:1",
    "raw_biomarkers": "deleterious or suspected deleterious BRCA2-mutated (BRCA2m)",
    "raw_cancer_type": "metastatic castration-sensitive prostate cancer",
    "raw_therapeutics": "Akeega (abiraterone acetate and niraparib) in combination with prednisone"
  },
  {
    "id": "ind:fda.krazati:0",
    "document_id": "doc:fda.krazati",
    "indication": "desc:ind:fda.krazati:0",
    "initial_approval_date": "2022-12-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf",
    "description": "desc:stmt:fda.krazati:0",
    "raw_biomarkers": "KRAS G12C",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Krazati (adagrasib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2022-12-20"
  },
  {
    "id": "ind:fda.kadcyla:0",
    "document_id": "doc:fda.kadcyla",
    "indication": "desc:ind:fda.kadcyla:0",
    "initial_approval_date": "2013-02-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf",
    "description": "desc:stmt:fda.kadcyla:0",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Kadcyla (ado-trastuzumab emtansine)"
  },
  {
    "id": "ind:fda.kadcyla:1",
    "document_id": "doc:fda.kadcyla",
    "indication": "desc:ind:fda.kadcyla:1",
    "initial_approval_date": "2019-05-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf",
    "description": "desc:stmt:fda.kadcyla:1",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Kadcyla (ado-trastuzumab emtansine)"
  },
  {
    "id": "ind:fda.gilotrif:0",
    "document_id": "doc:fda.gilotrif",
    "indication": "desc:ind:fda.gilotrif:0",
    "initial_approval_date": "2018-01-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf",
    "description": "desc:stmt:fda.gilotrif:0",
    "raw_biomarkers": "non-resistant EGFR mutations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Gilotrif (afatinib)"
  },
  {
    "id": "ind:fda.alecensa:0",
    "document_id": "doc:fda.alecensa",
    "indication": "desc:ind:fda.alecensa:0",
    "initial_approval_date": "2024-04-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf",
    "description": "desc:stmt:fda.alecensa:0",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Alecensa (alectinib)"
  },
  {
    "id": "ind:fda.alecensa:1",
    "document_id": "doc:fda.alecensa",
    "indication": "desc:ind:fda.alecensa:1",
    "initial_approval_date": "2017-11-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208434s003lbl.pdf",
    "description": "desc:stmt:fda.alecensa:1",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Alecensa (alectinib)",
    "date_regular_approval": "2017-11-06",
    "date_accelerated_approval": "2015-12-11"
  },
  {
    "id": "ind:fda.piqray:0",
    "document_id": "doc:fda.piqray",
    "indication": "desc:ind:fda.piqray:0",
    "initial_approval_date": "2024-01-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf",
    "description": "desc:stmt:fda.piqray:0",
    "raw_biomarkers": "HR+, HER2-negative, PIK3CA-mutated",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Piqray (alpelisib) in combination with fulvestrant"
  },
  {
    "id": "ind:fda.rybrevant:0",
    "document_id": "doc:fda.rybrevant",
    "indication": "desc:ind:fda.rybrevant:0",
    "initial_approval_date": "2024-03-01",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf",
    "description": "desc:stmt:fda.rybrevant:0",
    "raw_biomarkers": "EGFR exon 20 insertion mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab-vmjw) in combination with carboplatin and pemetrexed"
  },
  {
    "id": "ind:fda.rybrevant:1",
    "document_id": "doc:fda.rybrevant",
    "indication": "desc:ind:fda.rybrevant:1",
    "initial_approval_date": "2024-03-01",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf",
    "description": "desc:stmt:fda.rybrevant:1",
    "raw_biomarkers": "EGFR exon 20 insertion mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab-vmjw)",
    "date_regular_approval": "2024-03-01",
    "date_accelerated_approval": "2021-05-21"
  },
  {
    "id": "ind:fda.trisenox:0",
    "document_id": "doc:fda.trisenox",
    "indication": "desc:ind:fda.trisenox:0",
    "initial_approval_date": "2018-01-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021248s015lbledt.pdf",
    "description": "desc:stmt:fda.trisenox:0",
    "raw_biomarkers": "t(15;17) translocation or PML/RAR-alpha gene expression",
    "raw_cancer_type": "low-risk acute promyelocytic leukemia (APL)",
    "raw_therapeutics": "Trisenox (arsenic trioxide)"
  },
  {
    "id": "ind:fda.trisenox:1",
    "document_id": "doc:fda.trisenox",
    "indication": "desc:ind:fda.trisenox:1",
    "initial_approval_date": "2000-09-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21248lbl.pdf",
    "description": "desc:stmt:fda.trisenox:1",
    "raw_biomarkers": "t(15;17) translocation or PML/RAR-alpha gene expression",
    "raw_cancer_type": "acute promyelocytic leukemia (APL)",
    "raw_therapeutics": "Trisenox (arsenic trioxide)"
  },
  {
    "id": "ind:fda.scemblix:0",
    "document_id": "doc:fda.scemblix",
    "indication": "desc:ind:fda.scemblix:0",
    "initial_approval_date": "2022-10-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215358s001lbl.pdf",
    "description": "desc:stmt:fda.scemblix:0",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)",
    "raw_therapeutics": "Scemblix (asciminib)"
  },
  {
    "id": "ind:fda.scemblix:1",
    "document_id": "doc:fda.scemblix",
    "indication": "desc:ind:fda.scemblix:1",
    "initial_approval_date": "2021-10-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf",
    "description": "desc:stmt:fda.scemblix:1",
    "raw_biomarkers": "philadelphia chromosome-positive with the T315I mutation",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)",
    "raw_therapeutics": "Scemblix (asciminib)"
  },
  {
    "id": "ind:fda.tecentriq:0",
    "document_id": "doc:fda.tecentriq",
    "indication": "desc:ind:fda.tecentriq:0",
    "initial_approval_date": "2021-10-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761034Orig1s042lbl.pdf",
    "description": "desc:stmt:fda.tecentriq:0",
    "raw_biomarkers": "PD-L1 expression on >= 1% of tumor cells",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:fda.tecentriq:1",
    "document_id": "doc:fda.tecentriq",
    "indication": "desc:ind:fda.tecentriq:1",
    "initial_approval_date": "2020-05-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s027lbl.pdf",
    "description": "desc:stmt:fda.tecentriq:1",
    "raw_biomarkers": "PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%])",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:fda.tecentriq:2",
    "document_id": "doc:fda.tecentriq",
    "indication": "desc:ind:fda.tecentriq:2",
    "initial_approval_date": "2018-12-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761034s009lbl.pdf",
    "description": "desc:stmt:fda.tecentriq:2",
    "raw_biomarkers": "no EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic non-squamous non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel, and carboplatin"
  },
  {
    "id": "ind:fda.tecentriq:3",
    "document_id": "doc:fda.tecentriq",
    "indication": "desc:ind:fda.tecentriq:3",
    "initial_approval_date": "2019-12-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s021lbl.pdf",
    "description": "desc:stmt:fda.tecentriq:3",
    "raw_biomarkers": "no EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic non-squamous non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab) in combination with paclitaxel protein-bound and carboplatin"
  },
  {
    "id": "ind:fda.tecentriq:4",
    "document_id": "doc:fda.tecentriq",
    "indication": "desc:ind:fda.tecentriq:4",
    "initial_approval_date": "2017-04-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761034s001lbl.pdf",
    "description": "desc:stmt:fda.tecentriq:4",
    "raw_biomarkers": "EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:fda.tecentriq:5",
    "document_id": "doc:fda.tecentriq",
    "indication": "desc:ind:fda.tecentriq:5",
    "initial_approval_date": "2020-07-30",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s028lbl.pdf",
    "description": "desc:stmt:fda.tecentriq:5",
    "raw_biomarkers": "BRAF V600",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Tecentriq (atezolizumab) in combination with cobimetinib and vemurafenib"
  },
  {
    "id": "ind:fda.ayvakit:0",
    "document_id": "doc:fda.ayvakit",
    "indication": "desc:ind:fda.ayvakit:0",
    "initial_approval_date": "2021-06-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s006lbl.pdf",
    "description": "desc:stmt:fda.ayvakit:0",
    "raw_biomarkers": "PDGFRA exon 18 mutation, including PDGFRA D842V",
    "raw_cancer_type": "unresectable or metastatic GIST",
    "raw_therapeutics": "Ayvakit (avapritinib)"
  },
  {
    "id": "ind:fda.mektovi:0",
    "document_id": "doc:fda.mektovi",
    "indication": "desc:ind:fda.mektovi:0",
    "initial_approval_date": "2018-06-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf",
    "description": "desc:stmt:fda.mektovi:0",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Mektovi (binimetinib) in combination with encorafenib"
  },
  {
    "id": "ind:fda.mektovi:1",
    "document_id": "doc:fda.mektovi",
    "indication": "desc:ind:fda.mektovi:1",
    "initial_approval_date": "2023-10-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf",
    "description": "desc:stmt:fda.mektovi:1",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Mektovi (binimetinib) in combination with encorafenib"
  },
  {
    "id": "ind:fda.blincyto:0",
    "document_id": "doc:fda.blincyto",
    "indication": "desc:ind:fda.blincyto:0",
    "initial_approval_date": "2024-06-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf",
    "description": "desc:stmt:fda.blincyto:0",
    "raw_biomarkers": "CD19-positive",
    "raw_cancer_type": "b-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:fda.blincyto:1",
    "document_id": "doc:fda.blincyto",
    "indication": "desc:ind:fda.blincyto:1",
    "initial_approval_date": "2024-06-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf",
    "description": "desc:stmt:fda.blincyto:1",
    "raw_biomarkers": "CD19-positive",
    "raw_cancer_type": "b-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:fda.blincyto:2",
    "document_id": "doc:fda.blincyto",
    "indication": "desc:ind:fda.blincyto:2",
    "initial_approval_date": "2024-06-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf",
    "description": "desc:stmt:fda.blincyto:2",
    "raw_biomarkers": "CD19-positive philadelphia chromosome-negative",
    "raw_cancer_type": "b-cell precusor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:fda.bosulif:0",
    "document_id": "doc:fda.bosulif",
    "indication": "desc:ind:fda.bosulif:0",
    "initial_approval_date": "2023-09-23",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf",
    "description": "desc:stmt:fda.bosulif:0",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myelogenous leukemia (CML)",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:fda.bosulif:1",
    "document_id": "doc:fda.bosulif",
    "indication": "desc:ind:fda.bosulif:1",
    "initial_approval_date": "2023-09-23",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf",
    "description": "desc:stmt:fda.bosulif:1",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myelogenous leukemia (CML)",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:fda.adcetris:0",
    "document_id": "doc:fda.adcetris",
    "indication": "desc:ind:fda.adcetris:0",
    "initial_approval_date": "2023-06-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf",
    "description": "desc:stmt:fda.adcetris:0",
    "raw_biomarkers": "CD30-expressing",
    "raw_cancer_type": "systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified",
    "raw_therapeutics": "Adcetris (brentuximab vedotin) in combination with cyclophosphamide, doxorubicin, and prednisone"
  },
  {
    "id": "ind:fda.adcetris:1",
    "document_id": "doc:fda.adcetris",
    "indication": "desc:ind:fda.adcetris:1",
    "initial_approval_date": "2023-06-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf",
    "description": "desc:stmt:fda.adcetris:1",
    "raw_biomarkers": "CD30-expressing",
    "raw_cancer_type": "cutaneous analastplci large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin)"
  },
  {
    "id": "ind:fda.alunbrig:0",
    "document_id": "doc:fda.alunbrig",
    "indication": "desc:ind:fda.alunbrig:0",
    "initial_approval_date": "2020-05-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208772s008lbl.pdf",
    "description": "desc:stmt:fda.alunbrig:0",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Alunbrig (brigatinib)"
  },
  {
    "id": "ind:fda.xeloda:0",
    "document_id": "doc:fda.xeloda",
    "indication": "desc:ind:fda.xeloda:0",
    "initial_approval_date": "2022-12-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s045s046s047s048s049s050s051lbl.pdf",
    "description": "desc:stmt:fda.xeloda:0",
    "raw_biomarkers": "HER2-overexpressing",
    "raw_cancer_type": "metastatic gastric or gastroesophageal junction adenocarcinoma",
    "raw_therapeutics": "Xeloda (capecitabine)"
  },
  {
    "id": "ind:fda.truqap:0",
    "document_id": "doc:fda.truqap",
    "indication": "desc:ind:fda.truqap:0",
    "initial_approval_date": "2023-11-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf",
    "description": "desc:stmt:fda.truqap:0",
    "raw_biomarkers": "HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Truqaf (capivasertib) in combination with fulvestrant"
  },
  {
    "id": "ind:fda.tabrecta:0",
    "document_id": "doc:fda.tabrecta",
    "indication": "desc:ind:fda.tabrecta:0",
    "initial_approval_date": "2022-08-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf",
    "description": "desc:stmt:fda.tabrecta:0",
    "raw_biomarkers": "MET exon 14 skipping",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tabrecta (capmatinib)"
  },
  {
    "id": "ind:fda.libtayo:0",
    "document_id": "doc:fda.libtayo",
    "indication": "desc:ind:fda.libtayo:0",
    "initial_approval_date": "2022-11-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761097s014lbl.pdf",
    "description": "desc:stmt:fda.libtayo:0",
    "raw_biomarkers": "no EGFR, ALK or ROS1 aberrations",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Libtayo (cemiplimab) in combination with platinum-based chemotherapy"
  },
  {
    "id": "ind:fda.libtayo:1",
    "document_id": "doc:fda.libtayo",
    "indication": "desc:ind:fda.libtayo:1",
    "initial_approval_date": "2021-02-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf",
    "description": "desc:stmt:fda.libtayo:1",
    "raw_biomarkers": "high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] with no EGFR, ALK or ROS1 aberrations",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Libtayo (cemiplimab)"
  },
  {
    "id": "ind:fda.zykadia:0",
    "document_id": "doc:fda.zykadia",
    "indication": "desc:ind:fda.zykadia:0",
    "initial_approval_date": "2019-03-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf",
    "description": "desc:stmt:fda.zykadia:0",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Zykadia (ceritinib)"
  },
  {
    "id": "ind:fda.erbitux:0",
    "document_id": "doc:fda.erbitux",
    "indication": "desc:ind:fda.erbitux:0",
    "initial_approval_date": "2012-07-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s225lbl.pdf",
    "description": "desc:stmt:fda.erbitux:0",
    "raw_biomarkers": "K-Ras wild type, EGFR-expressing",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with FOLFIRI"
  },
  {
    "id": "ind:fda.erbitux:1",
    "document_id": "doc:fda.erbitux",
    "indication": "desc:ind:fda.erbitux:1",
    "initial_approval_date": "2012-07-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s225lbl.pdf",
    "description": "desc:stmt:fda.erbitux:1",
    "raw_biomarkers": "K-Ras wild-type, EGFR-expressing",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with irinotecan"
  },
  {
    "id": "ind:fda.erbitux:2",
    "document_id": "doc:fda.erbitux",
    "indication": "desc:ind:fda.erbitux:2",
    "initial_approval_date": "2012-07-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s225lbl.pdf",
    "description": "desc:stmt:fda.erbitux:2",
    "raw_biomarkers": "K-Ras wild type, EGFR-expressing",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab)"
  },
  {
    "id": "ind:fda.erbitux:3",
    "document_id": "doc:fda.erbitux",
    "indication": "desc:ind:fda.erbitux:3",
    "initial_approval_date": "2021-09-24",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf",
    "description": "desc:stmt:fda.erbitux:3",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with encorafenib"
  },
  {
    "id": "ind:fda.cotellic:0",
    "document_id": "doc:fda.cotellic",
    "indication": "desc:ind:fda.cotellic:0",
    "initial_approval_date": "2015-11-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf",
    "description": "desc:stmt:fda.cotellic:0",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Cotellic (cobimetinib) in combination with vemurafenib"
  },
  {
    "id": "ind:fda.xalkori:0",
    "document_id": "doc:fda.xalkori",
    "indication": "desc:ind:fda.xalkori:0",
    "initial_approval_date": "2017-07-21",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s021lbl.pdf",
    "description": "desc:stmt:fda.xalkori:0",
    "raw_biomarkers": "ALK or ROS1-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:fda.xalkori:1",
    "document_id": "doc:fda.xalkori",
    "indication": "desc:ind:fda.xalkori:1",
    "initial_approval_date": "2021-01-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202570s030lbl.pdf",
    "description": "desc:stmt:fda.xalkori:1",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "anaplastic large cell lymphoma (ALCL)",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:fda.xalkori:2",
    "document_id": "doc:fda.xalkori",
    "indication": "desc:ind:fda.xalkori:2",
    "initial_approval_date": "2022-07-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf",
    "description": "desc:stmt:fda.xalkori:2",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT)",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:fda.tafinlar:0",
    "document_id": "doc:fda.tafinlar",
    "indication": "desc:ind:fda.tafinlar:0",
    "initial_approval_date": "2013-05-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf",
    "description": "desc:stmt:fda.tafinlar:0",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Tafinlar (dabrafenib)"
  },
  {
    "id": "ind:fda.tafinlar:1",
    "document_id": "doc:fda.tafinlar",
    "indication": "desc:ind:fda.tafinlar:1",
    "initial_approval_date": "2015-11-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202806s004lbl.pdf",
    "description": "desc:stmt:fda.tafinlar:1",
    "raw_biomarkers": "BRAF V600E or BRAF V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Tafinlar (dabrafenib) in combination with trametinib"
  },
  {
    "id": "ind:fda.tafinlar:2",
    "document_id": "doc:fda.tafinlar",
    "indication": "desc:ind:fda.tafinlar:2",
    "initial_approval_date": "2018-04-30",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf",
    "description": "desc:stmt:fda.tafinlar:2",
    "raw_biomarkers": "BRAF V600E or BRAF V600K",
    "raw_cancer_type": "melanoma",
    "raw_therapeutics": "Tafinlar (dabrafenib) in combination with trametinib"
  },
  {
    "id": "ind:fda.tafinlar:3",
    "document_id": "doc:fda.tafinlar",
    "indication": "desc:ind:fda.tafinlar:3",
    "initial_approval_date": "2017-06-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202806s006lbl.pdf",
    "description": "desc:stmt:fda.tafinlar:3",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tafinlar (dabrafenib) in combination with trametinib"
  },
  {
    "id": "ind:fda.tafinlar:4",
    "document_id": "doc:fda.tafinlar",
    "indication": "desc:ind:fda.tafinlar:4",
    "initial_approval_date": "2018-05-04",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s010lbl.pdf",
    "description": "desc:stmt:fda.tafinlar:4",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "locally advanced or metastatic anaplastic thyroid cancer (ATC)",
    "raw_therapeutics": "Tafinlar (dabrafenib) in combination with trametinib"
  },
  {
    "id": "ind:fda.tafinlar:5",
    "document_id": "doc:fda.tafinlar",
    "indication": "desc:ind:fda.tafinlar:5",
    "initial_approval_date": "2022-06-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s022lbl.pdf",
    "description": "desc:stmt:fda.tafinlar:5",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "unresectable or metastatic solid tumors",
    "raw_therapeutics": "Tafinlar (dabrafenib) in combination with trametinib"
  },
  {
    "id": "ind:fda.tafinlar:6",
    "document_id": "doc:fda.tafinlar",
    "indication": "desc:ind:fda.tafinlar:6",
    "initial_approval_date": "2023-03-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf",
    "description": "desc:stmt:fda.tafinlar:6",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "low-grade glioma (LGG)",
    "raw_therapeutics": "Tafinlar (dabrafenib) in combination with trametinib"
  },
  {
    "id": "ind:fda.vizimpro:0",
    "document_id": "doc:fda.vizimpro",
    "indication": "desc:ind:fda.vizimpro:0",
    "initial_approval_date": "2018-09-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf",
    "description": "desc:stmt:fda.vizimpro:0",
    "raw_biomarkers": "EGFR exon 19 deletion or exon 21 L858R substitution mutations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Vizimpro (dacomitinib)"
  },
  {
    "id": "ind:fda.sprycel:0",
    "document_id": "doc:fda.sprycel",
    "indication": "desc:ind:fda.sprycel:0",
    "initial_approval_date": "2015-08-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021986s016s017lbledt.pdf",
    "description": "desc:stmt:fda.sprycel:0",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:fda.sprycel:1",
    "document_id": "doc:fda.sprycel",
    "indication": "desc:ind:fda.sprycel:1",
    "initial_approval_date": "2010-07-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf",
    "description": "desc:stmt:fda.sprycel:1",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:fda.sprycel:2",
    "document_id": "doc:fda.sprycel",
    "indication": "desc:ind:fda.sprycel:2",
    "initial_approval_date": "2006-06-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021986lbl.pdf",
    "description": "desc:stmt:fda.sprycel:2",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:fda.sprycel:3",
    "document_id": "doc:fda.sprycel",
    "indication": "desc:ind:fda.sprycel:3",
    "initial_approval_date": "2018-12-21",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf",
    "description": "desc:stmt:fda.sprycel:3",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "philadelphia chromosome-positive CML",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:fda.sprycel:4",
    "document_id": "doc:fda.sprycel",
    "indication": "desc:ind:fda.sprycel:4",
    "initial_approval_date": "2018-12-21",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf",
    "description": "desc:stmt:fda.sprycel:4",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "philadelphia chromosome-positive ALL",
    "raw_therapeutics": "Sprycel (dasatinib) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.jemperli:0",
    "document_id": "doc:fda.jemperli",
    "indication": "desc:ind:fda.jemperli:0",
    "initial_approval_date": "2023-07-31",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf",
    "description": "desc:stmt:fda.jemperli:0",
    "raw_biomarkers": "mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H)",
    "raw_cancer_type": "primary advanced or recurrent endometrial cancer",
    "raw_therapeutics": "Jemperli (dostarlimab) in combination with carboplatin and paclitaxel"
  },
  {
    "id": "ind:fda.jemperli:1",
    "document_id": "doc:fda.jemperli",
    "indication": "desc:ind:fda.jemperli:1",
    "initial_approval_date": "2023-02-09",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s003s004lbl.pdf",
    "description": "desc:stmt:fda.jemperli:1",
    "raw_biomarkers": "dMMR",
    "raw_cancer_type": "recurrent or advanced endometrial cancer",
    "raw_therapeutics": "Jemperli (dostarlimab)"
  },
  {
    "id": "ind:fda.jemperli:2",
    "document_id": "doc:fda.jemperli",
    "indication": "desc:ind:fda.jemperli:2",
    "initial_approval_date": "2022-04-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761174s002lbl.pdf",
    "description": "desc:stmt:fda.jemperli:2",
    "raw_biomarkers": "dMMR",
    "raw_cancer_type": "recurrent or advanced solid tumors",
    "raw_therapeutics": "Jemperli (dostarlimab)"
  },
  {
    "id": "ind:fda.imfinzi:0",
    "document_id": "doc:fda.imfinzi",
    "indication": "desc:ind:fda.imfinzi:0",
    "initial_approval_date": "2022-11-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s033lbl.pdf",
    "description": "desc:stmt:fda.imfinzi:0",
    "raw_biomarkers": "no sensitizing EGFR mutations or ALK genomic aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Imfinzi (durvalumab) in combination with tremelimumab-actl and platinum-based chemotherapy"
  },
  {
    "id": "ind:fda.imfinzi:1",
    "document_id": "doc:fda.imfinzi",
    "indication": "desc:ind:fda.imfinzi:1",
    "initial_approval_date": "2024-06-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s045lbl.pdf",
    "description": "desc:stmt:fda.imfinzi:1",
    "raw_biomarkers": "mismatch repair deficient (dMMR)",
    "raw_cancer_type": "primary advanced or recurrent endometrial cancer",
    "raw_therapeutics": "Imfinzi (durvalumab) in combination with carboplatin and paclitaxel"
  },
  {
    "id": "ind:fda.orserdu:0",
    "document_id": "doc:fda.orserdu",
    "indication": "desc:ind:fda.orserdu:0",
    "initial_approval_date": "2023-01-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s000correctedlbl.pdf",
    "description": "desc:stmt:fda.orserdu:0",
    "raw_biomarkers": "ER-positive, HER2-negative, ESR1-mutated",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Orserdu (elacestrant)"
  },
  {
    "id": "ind:fda.idhifa:0",
    "document_id": "doc:fda.idhifa",
    "indication": "desc:ind:fda.idhifa:0",
    "initial_approval_date": "2017-08-01",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf",
    "description": "desc:stmt:fda.idhifa:0",
    "raw_biomarkers": "IDH2 mutation",
    "raw_cancer_type": "relapsed or refractory acute myeloid leukemia (AML)",
    "raw_therapeutics": "Idhifa (enasidenib)"
  },
  {
    "id": "ind:fda.braftovi:0",
    "document_id": "doc:fda.braftovi",
    "indication": "desc:ind:fda.braftovi:0",
    "initial_approval_date": "2018-06-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf",
    "description": "desc:stmt:fda.braftovi:0",
    "raw_biomarkers": "BRAF V600E or BRAF V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with binimetinib"
  },
  {
    "id": "ind:fda.braftovi:1",
    "document_id": "doc:fda.braftovi",
    "indication": "desc:ind:fda.braftovi:1",
    "initial_approval_date": "2020-04-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf",
    "description": "desc:stmt:fda.braftovi:1",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with cetuximab"
  },
  {
    "id": "ind:fda.braftovi:2",
    "document_id": "doc:fda.braftovi",
    "indication": "desc:ind:fda.braftovi:2",
    "initial_approval_date": "2023-10-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf",
    "description": "desc:stmt:fda.braftovi:2",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with binimetinib"
  },
  {
    "id": "ind:fda.rozlytrek:0",
    "document_id": "doc:fda.rozlytrek",
    "indication": "desc:ind:fda.rozlytrek:0",
    "initial_approval_date": "2019-08-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf",
    "description": "desc:stmt:fda.rozlytrek:0",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Rozlytrek (entrectinib)"
  },
  {
    "id": "ind:fda.rozlytrek:1",
    "document_id": "doc:fda.rozlytrek",
    "indication": "desc:ind:fda.rozlytrek:1",
    "initial_approval_date": "2023-10-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009Correctedlbl.pdf",
    "description": "desc:stmt:fda.rozlytrek:1",
    "raw_biomarkers": "NTRK gene fusion",
    "raw_cancer_type": "solid tumors",
    "raw_therapeutics": "Rozlytrek (entrectinib)"
  },
  {
    "id": "ind:fda.balversa:0",
    "document_id": "doc:fda.balversa",
    "indication": "desc:ind:fda.balversa:0",
    "initial_approval_date": "2024-01-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf",
    "description": "desc:stmt:fda.balversa:0",
    "raw_biomarkers": "susceptible FGFR3 genetic alterations",
    "raw_cancer_type": "locally advanced or metastatic urothelial carcinoma (mUC)",
    "raw_therapeutics": "Balversa (erdafitinib)"
  },
  {
    "id": "ind:fda.tarceva:0",
    "document_id": "doc:fda.tarceva",
    "indication": "desc:ind:fda.tarceva:0",
    "initial_approval_date": "2016-10-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf",
    "description": "desc:stmt:fda.tarceva:0",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tarceva (erlotinib)"
  },
  {
    "id": "ind:fda.afinitor:0",
    "document_id": "doc:fda.afinitor",
    "indication": "desc:ind:fda.afinitor:0",
    "initial_approval_date": "2012-07-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf",
    "description": "desc:stmt:fda.afinitor:0",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Afinitor (everolimus)"
  },
  {
    "id": "ind:fda.faslodex:0",
    "document_id": "doc:fda.faslodex",
    "indication": "desc:ind:fda.faslodex:0",
    "initial_approval_date": "2017-08-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s034lbl.pdf",
    "description": "desc:stmt:fda.faslodex:0",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant)"
  },
  {
    "id": "ind:fda.faslodex:1",
    "document_id": "doc:fda.faslodex",
    "indication": "desc:ind:fda.faslodex:1",
    "initial_approval_date": "2002-04-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21344lbl.pdf",
    "description": "desc:stmt:fda.faslodex:1",
    "raw_biomarkers": "HR+",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant)"
  },
  {
    "id": "ind:fda.faslodex:2",
    "document_id": "doc:fda.faslodex",
    "indication": "desc:ind:fda.faslodex:2",
    "initial_approval_date": "2019-03-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021344s037lbl.pdf",
    "description": "desc:stmt:fda.faslodex:2",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant) in combination with ribociclib"
  },
  {
    "id": "ind:fda.faslodex:3",
    "document_id": "doc:fda.faslodex",
    "indication": "desc:ind:fda.faslodex:3",
    "initial_approval_date": "2017-08-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s035lbl.pdf",
    "description": "desc:stmt:fda.faslodex:3",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant) in combination with palbociclib or abemaciclib"
  },
  {
    "id": "ind:fda.lytgobi:0",
    "document_id": "doc:fda.lytgobi",
    "indication": "desc:ind:fda.lytgobi:0",
    "initial_approval_date": "2022-09-30",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801Orig1s000lbledt.pdf",
    "description": "desc:stmt:fda.lytgobi:0",
    "raw_biomarkers": "FGFR2 gene fusions or other rearrangements",
    "raw_cancer_type": "unresectable, locally or metastatic intrahepatic cholangiocarcinoma",
    "raw_therapeutics": "Lytgobi (futibatinib)"
  },
  {
    "id": "ind:fda.iressa:0",
    "document_id": "doc:fda.iressa",
    "indication": "desc:ind:fda.iressa:0",
    "initial_approval_date": "2015-07-13",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206995s000lbl.pdf",
    "description": "desc:stmt:fda.iressa:0",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 (L858R) substitution mutations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Iressa (gefitinib)"
  },
  {
    "id": "ind:fda.mylotarg:0",
    "document_id": "doc:fda.mylotarg",
    "indication": "desc:ind:fda.mylotarg:0",
    "initial_approval_date": "2020-06-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf",
    "description": "desc:stmt:fda.mylotarg:0",
    "raw_biomarkers": "CD33-positive",
    "raw_cancer_type": "acute myeloid leukemia",
    "raw_therapeutics": "Mylotarg (gemtuzumab ozogamicin)"
  },
  {
    "id": "ind:fda.mylotarg:1",
    "document_id": "doc:fda.mylotarg",
    "indication": "desc:ind:fda.mylotarg:1",
    "initial_approval_date": "2017-09-01",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf",
    "description": "desc:stmt:fda.mylotarg:1",
    "raw_biomarkers": "CD33-positive",
    "raw_cancer_type": "acute myeloid leukemia",
    "raw_therapeutics": "Mylotarg (gemtuzumab ozogamicin)"
  },
  {
    "id": "ind:fda.xospata:0",
    "document_id": "doc:fda.xospata",
    "indication": "desc:ind:fda.xospata:0",
    "initial_approval_date": "2018-11-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf",
    "description": "desc:stmt:fda.xospata:0",
    "raw_biomarkers": "FLT3 mutation",
    "raw_cancer_type": "relapsed or refractory acute myeloid leukemia",
    "raw_therapeutics": "Xospata (gilteritinib)"
  },
  {
    "id": "ind:fda.gleevec:0",
    "document_id": "doc:fda.gleevec",
    "indication": "desc:ind:fda.gleevec:0",
    "initial_approval_date": "2006-09-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s016lbl.pdf",
    "description": "desc:stmt:fda.gleevec:0",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myeloid leukemia",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:1",
    "document_id": "doc:fda.gleevec",
    "indication": "desc:ind:fda.gleevec:1",
    "initial_approval_date": "2003-04-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021588lbl.pdf",
    "description": "desc:stmt:fda.gleevec:1",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myeloid leukemia",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:2",
    "document_id": "doc:fda.gleevec",
    "indication": "desc:ind:fda.gleevec:2",
    "initial_approval_date": "2006-10-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf",
    "description": "desc:stmt:fda.gleevec:2",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive acute lymphoblastic leukemia",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:3",
    "document_id": "doc:fda.gleevec",
    "indication": "desc:ind:fda.gleevec:3",
    "initial_approval_date": "2013-01-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021588s037lbl.pdf",
    "description": "desc:stmt:fda.gleevec:3",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive acute lymphoblastic leukemia",
    "raw_therapeutics": "Gleevec (imatinib) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.gleevec:4",
    "document_id": "doc:fda.gleevec",
    "indication": "desc:ind:fda.gleevec:4",
    "initial_approval_date": "2006-10-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf",
    "description": "desc:stmt:fda.gleevec:4",
    "raw_biomarkers": "platelet-derived growth factor receptor (PDGFR) gene re-arrangements",
    "raw_cancer_type": "myelodyplastic/myeloproliferative diseases (MDS/MPD)",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:5",
    "document_id": "doc:fda.gleevec",
    "indication": "desc:ind:fda.gleevec:5",
    "initial_approval_date": "2006-10-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf",
    "description": "desc:stmt:fda.gleevec:5",
    "raw_biomarkers": "without the D816V c-Kit mutation or with the c-Kit mutational status unknown",
    "raw_cancer_type": "aggressive systemic mastocytosis (ASM)",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:6",
    "document_id": "doc:fda.gleevec",
    "indication": "desc:ind:fda.gleevec:6",
    "initial_approval_date": "2006-10-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf",
    "description": "desc:stmt:fda.gleevec:6",
    "raw_biomarkers": "FIP1L1-PDGFRa fusion kinase and for patients ... who are FIP1L1-PDGFRa fusion kinase negative or unknown",
    "raw_cancer_type": "hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:7",
    "document_id": "doc:fda.gleevec",
    "indication": "desc:ind:fda.gleevec:7",
    "initial_approval_date": "2003-04-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021588lbl.pdf",
    "description": "desc:stmt:fda.gleevec:7",
    "raw_biomarkers": "Kit (CD117) positive",
    "raw_cancer_type": "unresectable and/or metastatic maligant gastrointestinal stromal tumors (GIST)",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:8",
    "document_id": "doc:fda.gleevec",
    "indication": "desc:ind:fda.gleevec:8",
    "initial_approval_date": "2012-01-31",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021588s035lbl.pdf",
    "description": "desc:stmt:fda.gleevec:8",
    "raw_biomarkers": "Kit (CD117) positive",
    "raw_cancer_type": "GIST",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.truseltiq:0",
    "document_id": "doc:fda.truseltiq",
    "indication": "desc:ind:fda.truseltiq:0",
    "initial_approval_date": "2021-05-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf",
    "description": "desc:stmt:fda.truseltiq:0",
    "raw_biomarkers": "FGFR2 fusion or other rearrangement",
    "raw_cancer_type": "unresectable locally advanced or metastatic cholangiocarcinoma",
    "raw_therapeutics": "Truseltiq (infigratinib)"
  },
  {
    "id": "ind:fda.besponsa:0",
    "document_id": "doc:fda.besponsa",
    "indication": "desc:ind:fda.besponsa:0",
    "initial_approval_date": "2024-03-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf",
    "description": "desc:stmt:fda.besponsa:0",
    "raw_biomarkers": "CD22-positive",
    "raw_cancer_type": "B-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Besponsa (inotuzumab ozogamicin)"
  },
  {
    "id": "ind:fda.yervoy:0",
    "document_id": "doc:fda.yervoy",
    "indication": "desc:ind:fda.yervoy:0",
    "initial_approval_date": "2018-07-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125377s096lbl.pdf",
    "description": "desc:stmt:fda.yervoy:0",
    "raw_biomarkers": "microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab",
    "date_regular_approval": "2025-04-08",
    "date_accelerated_approval": "2018-07-10"
  },
  {
    "id": "ind:fda.yervoy:1",
    "document_id": "doc:fda.yervoy",
    "indication": "desc:ind:fda.yervoy:1",
    "initial_approval_date": "2020-05-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s109lbl.pdf",
    "description": "desc:stmt:fda.yervoy:1",
    "raw_biomarkers": "PD-L1 >= 1% and no EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab",
    "date_regular_approval": "2020-05-15",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.yervoy:2",
    "document_id": "doc:fda.yervoy",
    "indication": "desc:ind:fda.yervoy:2",
    "initial_approval_date": "2020-05-26",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s110lbl.pdf",
    "description": "desc:stmt:fda.yervoy:2",
    "raw_biomarkers": "no EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic or recurrent non-small cell lung cancer",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy",
    "date_regular_approval": "2020-05-26",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.tibsovo:0",
    "document_id": "doc:fda.tibsovo",
    "indication": "desc:ind:fda.tibsovo:0",
    "initial_approval_date": "2022-05-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf",
    "description": "desc:stmt:fda.tibsovo:0",
    "raw_biomarkers": "susceptible IDH1 mutation",
    "raw_cancer_type": "acute myeloid leukemia",
    "raw_therapeutics": "Tibsovo (ivosidenib) in combination with azacitidine or as monotherapy"
  },
  {
    "id": "ind:fda.tibsovo:1",
    "document_id": "doc:fda.tibsovo",
    "indication": "desc:ind:fda.tibsovo:1",
    "initial_approval_date": "2018-07-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf",
    "description": "desc:stmt:fda.tibsovo:1",
    "raw_biomarkers": "susceptible IDH1 mutation",
    "raw_cancer_type": "relapsed or refractory AML",
    "raw_therapeutics": "Tibsovo (ivosidenib)"
  },
  {
    "id": "ind:fda.tibsovo:2",
    "document_id": "doc:fda.tibsovo",
    "indication": "desc:ind:fda.tibsovo:2",
    "initial_approval_date": "2023-10-24",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf",
    "description": "desc:stmt:fda.tibsovo:2",
    "raw_biomarkers": "susceptible IDH1 mutation",
    "raw_cancer_type": "relapsed or refractory myelodysplastic syndromes",
    "raw_therapeutics": "Tibsovo (ivosidenib)"
  },
  {
    "id": "ind:fda.tibsovo:3",
    "document_id": "doc:fda.tibsovo",
    "indication": "desc:ind:fda.tibsovo:3",
    "initial_approval_date": "2021-08-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf",
    "description": "desc:stmt:fda.tibsovo:3",
    "raw_biomarkers": "susceptible IDH1 mutation",
    "raw_cancer_type": "locally advanced or metastatic cholangiocarcinoma",
    "raw_therapeutics": "Tibsovo (ivosidenib)"
  },
  {
    "id": "ind:fda.tykerb:0",
    "document_id": "doc:fda.tykerb",
    "indication": "desc:ind:fda.tykerb:0",
    "initial_approval_date": "2007-03-13",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022059lbl.pdf",
    "description": "desc:stmt:fda.tykerb:0",
    "raw_biomarkers": "HER2 overexpression",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Tykerb (lapatinib) in combination with capecitabine"
  },
  {
    "id": "ind:fda.tykerb:1",
    "document_id": "doc:fda.tykerb",
    "indication": "desc:ind:fda.tykerb:1",
    "initial_approval_date": "2010-01-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s3s6lbl.pdf",
    "description": "desc:stmt:fda.tykerb:1",
    "raw_biomarkers": "HR+, HER2 overexpression",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Tykerb (lapatinib) in combination with letrozole"
  },
  {
    "id": "ind:fda.vitrakvi:0",
    "document_id": "doc:fda.vitrakvi",
    "indication": "desc:ind:fda.vitrakvi:0",
    "initial_approval_date": "2018-11-26",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf",
    "description": "desc:stmt:fda.vitrakvi:0",
    "raw_biomarkers": "NTRK gene fusion",
    "raw_cancer_type": "solid tumors",
    "raw_therapeutics": "Vitrakvi (larotrectinib)",
    "date_regular_approval": "2025-04-09",
    "date_accelerated_approval": "2018-11-26"
  },
  {
    "id": "ind:fda.revlimid:0",
    "document_id": "doc:fda.revlimid",
    "indication": "desc:ind:fda.revlimid:0",
    "initial_approval_date": "2005-12-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021880lbl.pdf",
    "description": "desc:stmt:fda.revlimid:0",
    "raw_biomarkers": "5q deletion",
    "raw_cancer_type": "transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS)",
    "raw_therapeutics": "Revlimid (lenalidomide)"
  },
  {
    "id": "ind:fda.lorbrena:0",
    "document_id": "doc:fda.lorbrena",
    "indication": "desc:ind:fda.lorbrena:0",
    "initial_approval_date": "2021-03-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf",
    "description": "desc:stmt:fda.lorbrena:0",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Lorbrena (lorlatinib)"
  },
  {
    "id": "ind:fda.margenza:0",
    "document_id": "doc:fda.margenza",
    "indication": "desc:ind:fda.margenza:0",
    "initial_approval_date": "2020-12-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf",
    "description": "desc:stmt:fda.margenza:0",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Margenza (margetuximab-cmkb) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.rydapt:0",
    "document_id": "doc:fda.rydapt",
    "indication": "desc:ind:fda.rydapt:0",
    "initial_approval_date": "2017-04-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf",
    "description": "desc:stmt:fda.rydapt:0",
    "raw_biomarkers": "FLT3 mutation-positive",
    "raw_cancer_type": "acute myeloid leukemia",
    "raw_therapeutics": "Rydapt (midostaurin) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation"
  },
  {
    "id": "ind:fda.exkivity:0",
    "document_id": "doc:fda.exkivity",
    "indication": "desc:ind:fda.exkivity:0",
    "initial_approval_date": "2021-09-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf",
    "description": "desc:stmt:fda.exkivity:0",
    "raw_biomarkers": "EGFR exon 20 insertion mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Exkivity (mobocertinib)"
  },
  {
    "id": "ind:fda.nerlynx:0",
    "document_id": "doc:fda.nerlynx",
    "indication": "desc:ind:fda.nerlynx:0",
    "initial_approval_date": "2019-10-01",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208051s004lbl.pdf",
    "description": "desc:stmt:fda.nerlynx:0",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "early-stage breast cancer",
    "raw_therapeutics": "Nerlynx (neratinib)"
  },
  {
    "id": "ind:fda.nerlynx:1",
    "document_id": "doc:fda.nerlynx",
    "indication": "desc:ind:fda.nerlynx:1",
    "initial_approval_date": "2020-02-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208051s005s006lbl.pdf",
    "description": "desc:stmt:fda.nerlynx:1",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Nerlynx (neratinib) in combination with capecitabine"
  },
  {
    "id": "ind:fda.tasigna:0",
    "document_id": "doc:fda.tasigna",
    "indication": "desc:ind:fda.tasigna:0",
    "initial_approval_date": "2018-03-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022068s027lbl.pdf",
    "description": "desc:stmt:fda.tasigna:0",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myeloid (Ph+ CML)",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:fda.tasigna:1",
    "document_id": "doc:fda.tasigna",
    "indication": "desc:ind:fda.tasigna:1",
    "initial_approval_date": "2007-10-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022068lbl.pdf",
    "description": "desc:stmt:fda.tasigna:1",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "chronic phase or accelerated phase Ph+ CML",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:fda.tasigna:2",
    "document_id": "doc:fda.tasigna",
    "indication": "desc:ind:fda.tasigna:2",
    "initial_approval_date": "2018-03-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022068s027lbl.pdf",
    "description": "desc:stmt:fda.tasigna:2",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "Ph+ CML-CP and CML-AP",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:fda.zejula:0",
    "document_id": "doc:fda.zejula",
    "indication": "desc:ind:fda.zejula:0",
    "initial_approval_date": "2023-04-26",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf",
    "description": "desc:stmt:fda.zejula:0",
    "raw_biomarkers": "deleterious or suspected deleterious germline BRCA-mutated",
    "raw_cancer_type": "recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",
    "raw_therapeutics": "Zejula (niraparib)"
  },
  {
    "id": "ind:fda.opdivo:0",
    "document_id": "doc:fda.opdivo",
    "indication": "desc:ind:fda.opdivo:0",
    "initial_approval_date": "2024-10-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125554s127lbl.pdf",
    "description": "desc:stmt:fda.opdivo:0",
    "raw_biomarkers": "no known EGFR mutations or ALK rearrangement",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with platinum-doublet chemotherapy",
    "date_regular_approval": "2024-10-03",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.lynparza:0",
    "document_id": "doc:fda.lynparza",
    "indication": "desc:ind:fda.lynparza:0",
    "initial_approval_date": "2018-12-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf",
    "description": "desc:stmt:fda.lynparza:0",
    "raw_biomarkers": "deleterious or suspected deleterious germline or somatic BRCA-mutated",
    "raw_cancer_type": "advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:fda.lynparza:1",
    "document_id": "doc:fda.lynparza",
    "indication": "desc:ind:fda.lynparza:1",
    "initial_approval_date": "2020-05-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf",
    "description": "desc:stmt:fda.lynparza:1",
    "raw_biomarkers": "HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability",
    "raw_cancer_type": "advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab"
  },
  {
    "id": "ind:fda.lynparza:2",
    "document_id": "doc:fda.lynparza",
    "indication": "desc:ind:fda.lynparza:2",
    "initial_approval_date": "2023-09-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf",
    "description": "desc:stmt:fda.lynparza:2",
    "raw_biomarkers": "deleterious or suspected deleterious germline or somatic BRCA-mutated",
    "raw_cancer_type": "relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:fda.lynparza:3",
    "document_id": "doc:fda.lynparza",
    "indication": "desc:ind:fda.lynparza:3",
    "initial_approval_date": "2022-03-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf",
    "description": "desc:stmt:fda.lynparza:3",
    "raw_biomarkers": "deleterious or suspected deleterious gBRCAm, HER2-negative",
    "raw_cancer_type": "high risk early breast cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:fda.lynparza:4",
    "document_id": "doc:fda.lynparza",
    "indication": "desc:ind:fda.lynparza:4",
    "initial_approval_date": "2018-01-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf",
    "description": "desc:stmt:fda.lynparza:4",
    "raw_biomarkers": "deleterious or suspected deleterious gBRCAm, HER2-negative",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:fda.lynparza:5",
    "document_id": "doc:fda.lynparza",
    "indication": "desc:ind:fda.lynparza:5",
    "initial_approval_date": "2019-12-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558Orig1s010lblrpl.pdf",
    "description": "desc:stmt:fda.lynparza:5",
    "raw_biomarkers": "deleterious or suspected deleterious gBRCAm",
    "raw_cancer_type": "metastatic pancreatic adenocarcinoma",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:fda.lynparza:6",
    "document_id": "doc:fda.lynparza",
    "indication": "desc:ind:fda.lynparza:6",
    "initial_approval_date": "2020-05-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf",
    "description": "desc:stmt:fda.lynparza:6",
    "raw_biomarkers": "deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated",
    "raw_cancer_type": "metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:fda.lynparza:7",
    "document_id": "doc:fda.lynparza",
    "indication": "desc:ind:fda.lynparza:7",
    "initial_approval_date": "2023-05-31",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf",
    "description": "desc:stmt:fda.lynparza:7",
    "raw_biomarkers": "deleterious or suspected deleterious BRCA-mutated",
    "raw_cancer_type": "metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Lynparza (olaparib) in combination with abiraterone and prednisolone or prednisone"
  },
  {
    "id": "ind:fda.rezlidhia:0",
    "document_id": "doc:fda.rezlidhia",
    "indication": "desc:ind:fda.rezlidhia:0",
    "initial_approval_date": "2022-12-01",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf",
    "description": "desc:stmt:fda.rezlidhia:0",
    "raw_biomarkers": "susceptible IDH1 mutation",
    "raw_cancer_type": "relapsed or refractory acute myeloid leukemia (AML)",
    "raw_therapeutics": "Rezlidhia (olutasidenib)"
  },
  {
    "id": "ind:fda.tagrisso:0",
    "document_id": "doc:fda.tagrisso",
    "indication": "desc:ind:fda.tagrisso:0",
    "initial_approval_date": "2020-12-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf",
    "description": "desc:stmt:fda.tagrisso:0",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R mutations",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:fda.tagrisso:1",
    "document_id": "doc:fda.tagrisso",
    "indication": "desc:ind:fda.tagrisso:1",
    "initial_approval_date": "2018-04-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf",
    "description": "desc:stmt:fda.tagrisso:1",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R mutations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:fda.tagrisso:2",
    "document_id": "doc:fda.tagrisso",
    "indication": "desc:ind:fda.tagrisso:2",
    "initial_approval_date": "2024-02-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf",
    "description": "desc:stmt:fda.tagrisso:2",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy"
  },
  {
    "id": "ind:fda.tagrisso:3",
    "document_id": "doc:fda.tagrisso",
    "indication": "desc:ind:fda.tagrisso:3",
    "initial_approval_date": "2017-03-30",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208065s006lbl.pdf",
    "description": "desc:stmt:fda.tagrisso:3",
    "raw_biomarkers": "EGFR T790M",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:fda.ibrance:0",
    "document_id": "doc:fda.ibrance",
    "indication": "desc:ind:fda.ibrance:0",
    "initial_approval_date": "2019-09-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207103s015lbl.pdf",
    "description": "desc:stmt:fda.ibrance:0",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Ibrance (palbociclib) in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:fda.ibrance:1",
    "document_id": "doc:fda.ibrance",
    "indication": "desc:ind:fda.ibrance:1",
    "initial_approval_date": "2016-02-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207103s002lbl.pdf",
    "description": "desc:stmt:fda.ibrance:1",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Ibrance (palbociclib) in combination with fulvestrant"
  },
  {
    "id": "ind:fda.vectibix:0",
    "document_id": "doc:fda.vectibix",
    "indication": "desc:ind:fda.vectibix:0",
    "initial_approval_date": "2021-08-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf",
    "description": "desc:stmt:fda.vectibix:0",
    "raw_biomarkers": "wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use)",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Vectibix (panitumumab) in combination with folfox"
  },
  {
    "id": "ind:fda.vectibix:1",
    "document_id": "doc:fda.vectibix",
    "indication": "desc:ind:fda.vectibix:1",
    "initial_approval_date": "2021-08-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf",
    "description": "desc:stmt:fda.vectibix:1",
    "raw_biomarkers": "wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use)",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Vectibix (panitumumab)"
  },
  {
    "id": "ind:fda.keytruda:0",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:0",
    "initial_approval_date": "2018-08-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s035lbl.pdf",
    "description": "desc:stmt:fda.keytruda:0",
    "raw_biomarkers": "no EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic non-squamous non-small cell lung cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy"
  },
  {
    "id": "ind:fda.keytruda:1",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:1",
    "initial_approval_date": "2019-04-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s047lbl.pdf",
    "description": "desc:stmt:fda.keytruda:1",
    "raw_biomarkers": "no EGFR or ALK genomic tumor aberrations, and PD-L1 [Tumor Proportion Score (TPS) >= 1%",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:2",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:2",
    "raw_biomarkers": "PD-L1 [Tumor Proportion Score (TPS) >= 1%",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:3",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:3",
    "raw_biomarkers": "PD-L1 [Combined Positive Score (CPS)] >= 1%",
    "raw_cancer_type": "metastatic or unresectable, recurrent HNSCC",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:4",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:4",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:4",
    "raw_biomarkers": "MSI-H or dMMR",
    "raw_cancer_type": "unresectable or metastatic ... solid tumors",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:5",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:5",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:5",
    "raw_biomarkers": "MSI-H or dMMR",
    "raw_cancer_type": "unresectable or metastatic ... colorectal cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:6",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:6",
    "initial_approval_date": "2023-11-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s143lbl.pdf",
    "description": "desc:stmt:fda.keytruda:6",
    "raw_biomarkers": "HER2-positive... whose tumors express PD-L1 (CPS >= 1)",
    "raw_cancer_type": "locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocracinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy",
    "date_regular_approval": "2025-03-19",
    "date_accelerated_approval": "2023-11-16"
  },
  {
    "id": "ind:fda.keytruda:7",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:7",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:7",
    "raw_biomarkers": "HER2-negative",
    "raw_cancer_type": "locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocarcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy"
  },
  {
    "id": "ind:fda.keytruda:8",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:8",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:8",
    "raw_biomarkers": "PD-L1 (CPS >= 10)",
    "raw_cancer_type": "locally advanced or metastatic esophageal or gastroesophageal junction carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:9",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:9",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:9",
    "raw_biomarkers": "PD-L1 (CPS >= 1)",
    "raw_cancer_type": "persistent, recurrent, or metastatic cervical cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy and with or without bevacizumab"
  },
  {
    "id": "ind:fda.keytruda:10",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:10",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:10",
    "raw_biomarkers": "PD-L1 (CPS >= 1)",
    "raw_cancer_type": "recurrent or metastatic cervical cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:11",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:11",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:11",
    "raw_biomarkers": "pMMR or not MSI-H",
    "raw_cancer_type": "advanced endometrial carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with lenvatinib"
  },
  {
    "id": "ind:fda.keytruda:12",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:12",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:12",
    "raw_biomarkers": "MSI-H or dMMR",
    "raw_cancer_type": "advanced endometrial carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:13",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:13",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:13",
    "raw_biomarkers": "TMB-H [>= 10 mutations / megabase]",
    "raw_cancer_type": "unresectable or metastatic ... solid tumors",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:14",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:14",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:14",
    "raw_biomarkers": "triple-negative",
    "raw_cancer_type": "high-risk early-stage triple-negative breast cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.keytruda:15",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:15",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.keytruda:15",
    "raw_biomarkers": "triple-negative, PD-L1 (CPS >= 10)",
    "raw_cancer_type": "locally recurrent unresectable or metastatic triple-negative breast cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.keytruda:16",
    "document_id": "doc:fda.keytruda",
    "indication": "desc:ind:fda.keytruda:16",
    "initial_approval_date": "2025-06-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s180lbl.pdf",
    "description": "desc:stmt:fda.keytruda:16",
    "raw_biomarkers": "PD-L1 [Combined Positive Score (CPS) >= 1]",
    "raw_cancer_type": "head and neck squamous cell cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT), with or without cisplatin and then as a single agent."
  },
  {
    "id": "ind:fda.pemazyre:0",
    "document_id": "doc:fda.pemazyre",
    "indication": "desc:ind:fda.pemazyre:0",
    "initial_approval_date": "2020-04-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf",
    "description": "desc:stmt:fda.pemazyre:0",
    "raw_biomarkers": "FGFR2 fusion or other rearrangement",
    "raw_cancer_type": "unresectable locally advanced or metastatic cholangiocarcinoma",
    "raw_therapeutics": "Pemazyre (pemigatinib)"
  },
  {
    "id": "ind:fda.pemazyre:1",
    "document_id": "doc:fda.pemazyre",
    "indication": "desc:ind:fda.pemazyre:1",
    "initial_approval_date": "2022-08-26",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf",
    "description": "desc:stmt:fda.pemazyre:1",
    "raw_biomarkers": "FGFR1 rearrangement",
    "raw_cancer_type": "relapsed or refractory myeloid/lymphoid neoplasms (MLNs)",
    "raw_therapeutics": "Pemazyre (pemigatinib)"
  },
  {
    "id": "ind:fda.perjeta:0",
    "document_id": "doc:fda.perjeta",
    "indication": "desc:ind:fda.perjeta:0",
    "initial_approval_date": "2012-06-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf",
    "description": "desc:stmt:fda.perjeta:0",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and docetaxel"
  },
  {
    "id": "ind:fda.perjeta:1",
    "document_id": "doc:fda.perjeta",
    "indication": "desc:ind:fda.perjeta:1",
    "initial_approval_date": "2017-12-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf",
    "description": "desc:stmt:fda.perjeta:1",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)",
    "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
  },
  {
    "id": "ind:fda.perjeta:2",
    "document_id": "doc:fda.perjeta",
    "indication": "desc:ind:fda.perjeta:2",
    "initial_approval_date": "2017-12-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf",
    "description": "desc:stmt:fda.perjeta:2",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "early stage breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
  },
  {
    "id": "ind:fda.phesgo:0",
    "document_id": "doc:fda.phesgo",
    "indication": "desc:ind:fda.phesgo:0",
    "initial_approval_date": "2020-06-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf",
    "description": "desc:stmt:fda.phesgo:0",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)",
    "raw_therapeutics": "Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.phesgo:1",
    "document_id": "doc:fda.phesgo",
    "indication": "desc:ind:fda.phesgo:1",
    "initial_approval_date": "2020-06-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf",
    "description": "desc:stmt:fda.phesgo:1",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.phesgo:2",
    "document_id": "doc:fda.phesgo",
    "indication": "desc:ind:fda.phesgo:2",
    "initial_approval_date": "2020-06-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf",
    "description": "desc:stmt:fda.phesgo:2",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab and trastuzumab) in combination with docetaxel"
  },
  {
    "id": "ind:fda.iclusig:0",
    "document_id": "doc:fda.iclusig",
    "indication": "desc:ind:fda.iclusig:0",
    "initial_approval_date": "2024-03-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf",
    "description": "desc:stmt:fda.iclusig:0",
    "raw_biomarkers": "Ph+",
    "raw_cancer_type": "Ph+ ALL",
    "raw_therapeutics": "Iclusig (ponatinib) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.iclusig:1",
    "document_id": "doc:fda.iclusig",
    "indication": "desc:ind:fda.iclusig:1",
    "initial_approval_date": "2024-03-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf",
    "description": "desc:stmt:fda.iclusig:1",
    "raw_biomarkers": "Ph+ and T315I",
    "raw_cancer_type": "Ph+ ALL",
    "raw_therapeutics": "Iclusig (ponatinib)"
  },
  {
    "id": "ind:fda.iclusig:2",
    "document_id": "doc:fda.iclusig",
    "indication": "desc:ind:fda.iclusig:2",
    "initial_approval_date": "2016-11-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s022lbl.pdf",
    "description": "desc:stmt:fda.iclusig:2",
    "raw_biomarkers": "T315I-positive",
    "raw_cancer_type": "CML",
    "raw_therapeutics": "Iclusig (ponatinib)"
  },
  {
    "id": "ind:fda.gavreto:0",
    "document_id": "doc:fda.gavreto",
    "indication": "desc:ind:fda.gavreto:0",
    "initial_approval_date": "2023-08-09",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf",
    "description": "desc:stmt:fda.gavreto:0",
    "raw_biomarkers": "RET fusion-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Gavreto (pralsetinib)"
  },
  {
    "id": "ind:fda.gavreto:1",
    "document_id": "doc:fda.gavreto",
    "indication": "desc:ind:fda.gavreto:1",
    "initial_approval_date": "2021-11-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf",
    "description": "desc:stmt:fda.gavreto:1",
    "raw_biomarkers": "RET fusion-positive",
    "raw_cancer_type": "advanced or metastatic... thyroid cancer",
    "raw_therapeutics": "Gavreto (pralsetinib)"
  },
  {
    "id": "ind:fda.cyramza:0",
    "document_id": "doc:fda.cyramza",
    "indication": "desc:ind:fda.cyramza:0",
    "initial_approval_date": "2020-05-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125477s034lbl.pdf",
    "description": "desc:stmt:fda.cyramza:0",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 (L858R)",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Cyramza (ramucirumab) in combination with erlotinib"
  },
  {
    "id": "ind:fda.augtyro:0",
    "document_id": "doc:fda.augtyro",
    "indication": "desc:ind:fda.augtyro:0",
    "initial_approval_date": "2023-11-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf",
    "description": "desc:stmt:fda.augtyro:0",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Augtyro (repotrectinib)"
  },
  {
    "id": "ind:fda.augtyro:1",
    "document_id": "doc:fda.augtyro",
    "indication": "desc:ind:fda.augtyro:1",
    "initial_approval_date": "2024-06-13",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf",
    "description": "desc:stmt:fda.augtyro:1",
    "raw_biomarkers": "NTRK gene fusions",
    "raw_cancer_type": "solid tumors",
    "raw_therapeutics": "Augtyro (repotrectinib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2024-06-13"
  },
  {
    "id": "ind:fda.kisqali:0",
    "document_id": "doc:fda.kisqali",
    "indication": "desc:ind:fda.kisqali:0",
    "initial_approval_date": "2021-12-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf",
    "description": "desc:stmt:fda.kisqali:0",
    "raw_biomarkers": "HR-positive, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Kisqali (ribociclib) in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:fda.kisqali:1",
    "document_id": "doc:fda.kisqali",
    "indication": "desc:ind:fda.kisqali:1",
    "initial_approval_date": "2021-12-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf",
    "description": "desc:stmt:fda.kisqali:1",
    "raw_biomarkers": "HR-positive, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Kisqali (ribociclib) in combination with fulvestrant"
  },
  {
    "id": "ind:fda.rituxan:0",
    "document_id": "doc:fda.rituxan",
    "indication": "desc:ind:fda.rituxan:0",
    "initial_approval_date": "2018-04-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf",
    "description": "desc:stmt:fda.rituxan:0",
    "raw_biomarkers": "CD20-positive",
    "raw_cancer_type": "B-cell Non-Hodgkin's Lymphoma (NHL)",
    "raw_therapeutics": "Rituxan (rituximab)"
  },
  {
    "id": "ind:fda.rituxan:1",
    "document_id": "doc:fda.rituxan",
    "indication": "desc:ind:fda.rituxan:1",
    "initial_approval_date": "2018-04-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf",
    "description": "desc:stmt:fda.rituxan:1",
    "raw_biomarkers": "CD20-positive",
    "raw_cancer_type": "B-cell Non-Hodgkin's Lymphoma (NHL)",
    "raw_therapeutics": "Rituxan (rituximab) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.rituxan:2",
    "document_id": "doc:fda.rituxan",
    "indication": "desc:ind:fda.rituxan:2",
    "initial_approval_date": "2018-04-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf",
    "description": "desc:stmt:fda.rituxan:2",
    "raw_biomarkers": "CD20 positive",
    "raw_cancer_type": "Non-Hodgkin's Lymphoma (NHL)",
    "raw_therapeutics": "Rituxan (rituximab)"
  },
  {
    "id": "ind:fda.rituxan:3",
    "document_id": "doc:fda.rituxan",
    "indication": "desc:ind:fda.rituxan:3",
    "initial_approval_date": "2018-04-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf",
    "description": "desc:stmt:fda.rituxan:3",
    "raw_biomarkers": "CD20-positive",
    "raw_cancer_type": "diffuse large B-cell Non-Hodgkin's Lymhpoma (NHL)",
    "raw_therapeutics": "Rituxan (rituximab) in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens."
  },
  {
    "id": "ind:fda.rituxan:4",
    "document_id": "doc:fda.rituxan",
    "indication": "desc:ind:fda.rituxan:4",
    "initial_approval_date": "2021-12-02",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5465lbl.pdf",
    "description": "desc:stmt:fda.rituxan:4",
    "raw_biomarkers": "CD20-positive",
    "raw_cancer_type": "mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)",
    "raw_therapeutics": "Rituxan (rituximab) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.rituxan:5",
    "document_id": "doc:fda.rituxan",
    "indication": "desc:ind:fda.rituxan:5",
    "initial_approval_date": "2018-04-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf",
    "description": "desc:stmt:fda.rituxan:5",
    "raw_biomarkers": "CD20-positive",
    "raw_cancer_type": "Chronic Lymphocytic Leuekmia (CLL)",
    "raw_therapeutics": "Rituxan (rituximab) in combination with fludarabine and cyclophosphamide (FC)"
  },
  {
    "id": "ind:fda.rubraca:0",
    "document_id": "doc:fda.rubraca",
    "indication": "desc:ind:fda.rubraca:0",
    "initial_approval_date": "2018-04-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf",
    "description": "desc:stmt:fda.rubraca:0",
    "raw_biomarkers": "deleterious BRCA mutation (germline and/or somatic)",
    "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer",
    "raw_therapeutics": "Rubraca (rucaparib)"
  },
  {
    "id": "ind:fda.rubraca:1",
    "document_id": "doc:fda.rubraca",
    "indication": "desc:ind:fda.rubraca:1",
    "initial_approval_date": "2025-12-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf",
    "description": "desc:stmt:fda.rubraca:1",
    "raw_biomarkers": "deleterious BRCA mutation (germline and/or somatic)",
    "raw_cancer_type": "metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Rubraca (rucaparib)",
    "status": "Approved"
  },
  {
    "id": "ind:fda.trodelvy:0",
    "document_id": "doc:fda.trodelvy",
    "indication": "desc:ind:fda.trodelvy:0",
    "initial_approval_date": "2021-04-07",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s005s013lbl.pdf",
    "description": "desc:stmt:fda.trodelvy:0",
    "raw_biomarkers": "triple-negative breast cancer",
    "raw_cancer_type": "unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)",
    "raw_therapeutics": "Trodelvy (sacituzumab govitecan)"
  },
  {
    "id": "ind:fda.trodelvy:1",
    "document_id": "doc:fda.trodelvy",
    "indication": "desc:ind:fda.trodelvy:1",
    "initial_approval_date": "2023-02-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf",
    "description": "desc:stmt:fda.trodelvy:1",
    "raw_biomarkers": "HR-positive, HER2-negative (HC 0, IHC 1+, or IHC 2+/ISH-)",
    "raw_cancer_type": "locally advanced or metastatic ... breast cancer",
    "raw_therapeutics": "Trodelvy (sacituzumab govitecan)"
  },
  {
    "id": "ind:fda.retevmo:0",
    "document_id": "doc:fda.retevmo",
    "indication": "desc:ind:fda.retevmo:0",
    "initial_approval_date": "2020-05-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf",
    "description": "desc:stmt:fda.retevmo:0",
    "raw_biomarkers": "RET fusion",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Retevmo (selpercatinib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2020-05-08"
  },
  {
    "id": "ind:fda.retevmo:1",
    "document_id": "doc:fda.retevmo",
    "indication": "desc:ind:fda.retevmo:1",
    "initial_approval_date": "2024-05-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s012lbl.pdf",
    "description": "desc:stmt:fda.retevmo:1",
    "raw_biomarkers": "RET mutation",
    "raw_cancer_type": "advanced or metastatic medullary thyroid cancer",
    "raw_therapeutics": "Retevmo (selpercatinib)",
    "date_regular_approval": "2024-09-27",
    "date_accelerated_approval": "2024-05-29"
  },
  {
    "id": "ind:fda.retevmo:2",
    "document_id": "doc:fda.retevmo",
    "indication": "desc:ind:fda.retevmo:2",
    "initial_approval_date": "2024-05-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s012lbl.pdf",
    "description": "desc:stmt:fda.retevmo:2",
    "raw_biomarkers": "RET gene fusion",
    "raw_cancer_type": "advanced or metastatic thyroid cancer",
    "raw_therapeutics": "Retevmo (selpercatinib)",
    "date_regular_approval": "2024-06-12",
    "date_accelerated_approval": "2024-05-29"
  },
  {
    "id": "ind:fda.retevmo:3",
    "document_id": "doc:fda.retevmo",
    "indication": "desc:ind:fda.retevmo:3",
    "initial_approval_date": "2022-09-21",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s007lbl.pdf",
    "description": "desc:stmt:fda.retevmo:3",
    "raw_biomarkers": "RET gene fusion",
    "raw_cancer_type": "locally advanced or metastatic solid tumors",
    "raw_therapeutics": "Retevmo (selpercatinib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2022-09-21"
  },
  {
    "id": "ind:fda.lumakras:0",
    "document_id": "doc:fda.lumakras",
    "indication": "desc:ind:fda.lumakras:0",
    "initial_approval_date": "2021-05-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf",
    "description": "desc:stmt:fda.lumakras:0",
    "raw_biomarkers": "KRAS G12C",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Lumakras (sotorasib)"
  },
  {
    "id": "ind:fda.talzenna:0",
    "document_id": "doc:fda.talzenna",
    "indication": "desc:ind:fda.talzenna:0",
    "initial_approval_date": "2018-10-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf",
    "description": "desc:stmt:fda.talzenna:0",
    "raw_biomarkers": "deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Talzenna (talazoparib)"
  },
  {
    "id": "ind:fda.talzenna:1",
    "document_id": "doc:fda.talzenna",
    "indication": "desc:ind:fda.talzenna:1",
    "initial_approval_date": "2023-06-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf",
    "description": "desc:stmt:fda.talzenna:1",
    "raw_biomarkers": "HRR gene-mutated",
    "raw_cancer_type": "metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Talzenna (talazoparib) in combination with enzalutamide"
  },
  {
    "id": "ind:fda.tazverik:0",
    "document_id": "doc:fda.tazverik",
    "indication": "desc:ind:fda.tazverik:0",
    "initial_approval_date": "2023-11-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf",
    "description": "desc:stmt:fda.tazverik:0",
    "raw_biomarkers": "EZH2 mutation positive",
    "raw_cancer_type": "follicular lymphoma",
    "raw_therapeutics": "Tazverik (tazemetostat)"
  },
  {
    "id": "ind:fda.tepmetko:0",
    "document_id": "doc:fda.tepmetko",
    "indication": "desc:ind:fda.tepmetko:0",
    "initial_approval_date": "2021-02-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf",
    "description": "desc:stmt:fda.tepmetko:0",
    "raw_biomarkers": "MET exon 14 skipping alterations",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Tepmetko (tepotinib)",
    "date_regular_approval": "2024-02-15",
    "date_accelerated_approval": "2021-02-03"
  },
  {
    "id": "ind:fda.mekinist:0",
    "document_id": "doc:fda.mekinist",
    "indication": "desc:ind:fda.mekinist:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.mekinist:0",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Mekinist (trametinib)"
  },
  {
    "id": "ind:fda.mekinist:1",
    "document_id": "doc:fda.mekinist",
    "indication": "desc:ind:fda.mekinist:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.mekinist:1",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:fda.mekinist:2",
    "document_id": "doc:fda.mekinist",
    "indication": "desc:ind:fda.mekinist:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.mekinist:2",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "melanoma",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:fda.mekinist:3",
    "document_id": "doc:fda.mekinist",
    "indication": "desc:ind:fda.mekinist:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.mekinist:3",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:fda.mekinist:4",
    "document_id": "doc:fda.mekinist",
    "indication": "desc:ind:fda.mekinist:4",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.mekinist:4",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "locally advanced or metastatic anaplastic thyroid cancer",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:fda.mekinist:5",
    "document_id": "doc:fda.mekinist",
    "indication": "desc:ind:fda.mekinist:5",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.mekinist:5",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "unresectable or metastatic solid tumors",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:fda.mekinist:6",
    "document_id": "doc:fda.mekinist",
    "indication": "desc:ind:fda.mekinist:6",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:fda.mekinist:6",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "low-grade glioma (LGG)",
    "raw_therapeutics": "Mekinist (trametinib) i combination with dabrafenib"
  },
  {
    "id": "ind:fda.herceptin:0",
    "document_id": "doc:fda.herceptin",
    "indication": "desc:ind:fda.herceptin:0",
    "initial_approval_date": "2008-01-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103792s5175lbl.pdf",
    "description": "desc:stmt:fda.herceptin:0",
    "raw_biomarkers": "HER2-overexpressing",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:fda.herceptin:1",
    "document_id": "doc:fda.herceptin",
    "indication": "desc:ind:fda.herceptin:1",
    "initial_approval_date": "2010-10-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf",
    "description": "desc:stmt:fda.herceptin:1",
    "raw_biomarkers": "HER2-overexpressing",
    "raw_cancer_type": "metastatic gastric or gastroesophageal junction adenocarcinoma",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:fda.enhertu:0",
    "document_id": "doc:fda.enhertu",
    "indication": "desc:ind:fda.enhertu:0",
    "initial_approval_date": "2022-05-04",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s017s020lbl.pdf",
    "description": "desc:stmt:fda.enhertu:0",
    "raw_biomarkers": "HER2-positive (IHC 3+ or ISH positive)",
    "raw_cancer_type": "unresectable or metastatic breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)",
    "date_regular_approval": "2022-05-04",
    "date_accelerated_approval": "2019-12-20"
  },
  {
    "id": "ind:fda.enhertu:1",
    "document_id": "doc:fda.enhertu",
    "indication": "desc:ind:fda.enhertu:1",
    "initial_approval_date": "2022-08-05",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s022lbl.pdf",
    "description": "desc:stmt:fda.enhertu:1",
    "raw_biomarkers": "HER2-low (IHC 1+ or IHC2+/ISH-)",
    "raw_cancer_type": "unresectable or metastatic ... breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:fda.enhertu:2",
    "document_id": "doc:fda.enhertu",
    "indication": "desc:ind:fda.enhertu:2",
    "initial_approval_date": "2022-08-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s021lbl.pdf",
    "description": "desc:stmt:fda.enhertu:2",
    "raw_biomarkers": "HER2 (ERBB2) mutations",
    "raw_cancer_type": "unresectable or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2022-08-11"
  },
  {
    "id": "ind:fda.enhertu:3",
    "document_id": "doc:fda.enhertu",
    "indication": "desc:ind:fda.enhertu:3",
    "initial_approval_date": "2021-01-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf",
    "description": "desc:stmt:fda.enhertu:3",
    "raw_biomarkers": "HER2-positive (IHC 3+ or IHC 2+/ISH positive)",
    "raw_cancer_type": "locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:fda.enhertu:4",
    "document_id": "doc:fda.enhertu",
    "indication": "desc:ind:fda.enhertu:4",
    "initial_approval_date": "2024-04-05",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf",
    "description": "desc:stmt:fda.enhertu:4",
    "raw_biomarkers": "HER2-positive (IHC 3+)",
    "raw_cancer_type": "unresectable or metastatic solid tumors",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2022-08-11"
  },
  {
    "id": "ind:fda.enhertu:5",
    "document_id": "doc:fda.enhertu",
    "indication": "desc:ind:fda.enhertu:5",
    "initial_approval_date": "2025-12-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf",
    "description": "desc:stmt:fda.enhertu:5",
    "raw_biomarkers": "HER2-positive (IHC 3+ or ISH+)",
    "raw_cancer_type": "unresectable or metastatic solid tumors",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)",
    "date_regular_approval": "2025-12-15",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.imjudo:0",
    "document_id": "doc:fda.imjudo",
    "indication": "desc:ind:fda.imjudo:0",
    "initial_approval_date": "2022-11-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf",
    "description": "desc:stmt:fda.imjudo:0",
    "raw_biomarkers": "no sensitizing EGFR mutation or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Imjudo (tremelimumab-actl) in combination with durvalumab and platinum-based chemotherapy"
  },
  {
    "id": "ind:fda.tukysa:0",
    "document_id": "doc:fda.tukysa",
    "indication": "desc:ind:fda.tukysa:0",
    "initial_approval_date": "2020-04-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf",
    "description": "desc:stmt:fda.tukysa:0",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "advanced unresectable or metastatic breast cancer",
    "raw_therapeutics": "Tukysa (tucatinib) in combination with trastuzumab or capecitabine"
  },
  {
    "id": "ind:fda.tukysa:1",
    "document_id": "doc:fda.tukysa",
    "indication": "desc:ind:fda.tukysa:1",
    "initial_approval_date": "2023-01-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf",
    "description": "desc:stmt:fda.tukysa:1",
    "raw_biomarkers": "RAS wild-type, HER2-positive",
    "raw_cancer_type": "unresectable or metastatic colorectal cancer",
    "raw_therapeutics": "Tukysa (tucatinib) in combination with trastuzumab"
  },
  {
    "id": "ind:fda.zelboraf:0",
    "document_id": "doc:fda.zelboraf",
    "indication": "desc:ind:fda.zelboraf:0",
    "initial_approval_date": "2011-08-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf",
    "description": "desc:stmt:fda.zelboraf:0",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Zelboraf (vemurafenib)"
  },
  {
    "id": "ind:fda.zelboraf:1",
    "document_id": "doc:fda.zelboraf",
    "indication": "desc:ind:fda.zelboraf:1",
    "initial_approval_date": "2017-11-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf",
    "description": "desc:stmt:fda.zelboraf:1",
    "raw_biomarkers": "BRAF V600",
    "raw_cancer_type": "Erdheim-Chester Disease",
    "raw_therapeutics": "Zelboraf (vemurafenib)"
  },
  {
    "id": "ind:fda.tagrisso:4",
    "document_id": "doc:fda.tagrisso",
    "indication": "desc:ind:fda.tagrisso:4",
    "initial_approval_date": "2024-09-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s143lbl.pdf",
    "description": "desc:stmt:fda.tagrisso:4",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "osimertinib"
  },
  {
    "id": "ind:fda.rybrevant:2",
    "document_id": "doc:fda.rybrevant",
    "indication": "desc:ind:fda.rybrevant:2",
    "initial_approval_date": "2024-08-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf",
    "description": "desc:stmt:fda.rybrevant:2",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab-vmjw) in combination with lazertinib"
  },
  {
    "id": "ind:fda.lazcluze:0",
    "document_id": "doc:fda.lazcluze",
    "indication": "desc:ind:fda.lazcluze:0",
    "initial_approval_date": "2024-08-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf",
    "description": "desc:stmt:fda.lazcluze:0",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "lazertinib in combination with amivantamab"
  },
  {
    "id": "ind:fda.rybrevant:3",
    "document_id": "doc:fda.rybrevant",
    "indication": "desc:ind:fda.rybrevant:3",
    "initial_approval_date": "2024-09-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf",
    "description": "desc:stmt:fda.rybrevant:3",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "amivantamab in combination with carboplatin and pemetrexed"
  },
  {
    "id": "ind:fda.elahere:0",
    "document_id": "doc:fda.elahere",
    "indication": "desc:ind:fda.elahere:0",
    "initial_approval_date": "2024-03-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf",
    "description": "desc:stmt:fda.elahere:0",
    "raw_biomarkers": "folate receptor-alpha tumor expression",
    "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal",
    "raw_therapeutics": "mirvetuximab soravtansine-gynx"
  },
  {
    "id": "ind:fda.ojemda:0",
    "document_id": "doc:fda.ojemda",
    "indication": "desc:ind:fda.ojemda:0",
    "initial_approval_date": "2024-04-23",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf",
    "description": "desc:stmt:fda.ojemda:0",
    "raw_biomarkers": "BRAF fusion or rearrangement, or BRAF V600 mutation",
    "raw_cancer_type": "low-grade glioma (LGG)",
    "raw_therapeutics": "tovorafenib",
    "date_regular_approval": null,
    "date_accelerated_approval": "2024-04-23"
  },
  {
    "id": "ind:fda.imfinzi:2",
    "document_id": "doc:fda.imfinzi",
    "indication": "desc:ind:fda.imfinzi:2",
    "initial_approval_date": "2024-08-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf",
    "description": "desc:stmt:fda.imfinzi:2",
    "raw_biomarkers": "no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "durvalumab in combination with platinum-containing chemotherapy"
  },
  {
    "id": "ind:fda.krazati:1",
    "document_id": "doc:fda.krazati",
    "indication": "desc:ind:fda.krazati:1",
    "initial_approval_date": "2024-06-21",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216340s005lbl.pdf",
    "description": "desc:stmt:fda.krazati:1",
    "raw_biomarkers": "KRAS G12C",
    "raw_cancer_type": "colorectal cancer",
    "raw_therapeutics": "Krazati (adagrasib) in combination with cetuximab",
    "date_regular_approval": null,
    "date_accelerated_approval": "2024-06-21"
  },
  {
    "id": "ind:fda.voranigo:0",
    "document_id": "doc:fda.voranigo",
    "indication": "desc:ind:fda.voranigo:0",
    "initial_approval_date": "2024-08-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf",
    "description": "desc:stmt:fda.voranigo:0",
    "raw_biomarkers": "IDH1 or IDH2 mutations",
    "raw_cancer_type": "astrocytoma or oligodendroglioma",
    "raw_therapeutics": "vorasidenib"
  },
  {
    "id": "ind:fda.kisqali:2",
    "document_id": "doc:fda.kisqali",
    "indication": "desc:ind:fda.kisqali:2",
    "initial_approval_date": "2024-09-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf",
    "description": "desc:stmt:fda.kisqali:2",
    "raw_biomarkers": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "ribociclib in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:fda.opdivo:1",
    "document_id": "doc:fda.opdivo",
    "indication": "desc:ind:fda.opdivo:1",
    "initial_approval_date": "2020-05-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s080lbl.pdf",
    "description": "desc:stmt:fda.opdivo:1",
    "raw_biomarkers": "PD-L1 (>= 1%)",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "nivolumab in combination with ipilimumab",
    "date_regular_approval": "2020-05-15",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.opdivo:2",
    "document_id": "doc:fda.opdivo",
    "indication": "desc:ind:fda.opdivo:2",
    "initial_approval_date": "2020-05-26",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s082lbl.pdf",
    "description": "desc:stmt:fda.opdivo:2",
    "raw_biomarkers": "no EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "nivolumab in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy",
    "date_regular_approval": "2025-05-26",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.opdivo:3",
    "document_id": "doc:fda.opdivo",
    "indication": "desc:ind:fda.opdivo:3",
    "initial_approval_date": "2018-07-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s063lbl.pdf",
    "description": "desc:stmt:fda.opdivo:3",
    "raw_biomarkers": "microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)",
    "raw_cancer_type": "colorectal cancer",
    "raw_therapeutics": "nivolumab as a single agent",
    "date_regular_approval": "2024-04-08",
    "date_accelerated_approval": "2018-07-10"
  },
  {
    "id": "ind:fda.itovebi:0",
    "document_id": "doc:fda.itovebi",
    "indication": "desc:ind:fda.itovebi:0",
    "initial_approval_date": "2024-10-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf",
    "description": "desc:stmt:fda.itovebi:0",
    "raw_biomarkers": "PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "inavolisib in combination with palbociclib and fulvestrant"
  },
  {
    "id": "ind:fda.vyloy:0",
    "document_id": "doc:fda.vyloy",
    "indication": "desc:ind:fda.vyloy:0",
    "initial_approval_date": "2024-10-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf",
    "description": "desc:stmt:fda.vyloy:0",
    "raw_biomarkers": "human epidermal growth factor receptor 2 (HER2)-negative .. claudin (CLDN) 18.2 positive",
    "raw_cancer_type": "gastric or gastroesophageal junction adenocarcinoma",
    "raw_therapeutics": "zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy"
  },
  {
    "id": "ind:fda.ziihera:0",
    "document_id": "doc:fda.ziihera",
    "indication": "desc:ind:fda.ziihera:0",
    "initial_approval_date": "2024-11-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf",
    "description": "desc:stmt:fda.ziihera:0",
    "raw_biomarkers": "HER2-positive (IHC 3+)",
    "raw_cancer_type": "biliary tract cancer (BTC)",
    "raw_therapeutics": "zanidatamab",
    "date_regular_approval": null,
    "date_accelerated_approval": "2024-11-20"
  },
  {
    "id": "ind:fda.bizengri:0",
    "document_id": "doc:fda.bizengri",
    "indication": "desc:ind:fda.bizengri:0",
    "initial_approval_date": "2024-12-04",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf",
    "description": "desc:stmt:fda.bizengri:0",
    "raw_biomarkers": "NGR1 gene fusion",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "zenocutuzumab-zbco",
    "date_regular_approval": null,
    "date_accelerated_approval": "2024-12-04"
  },
  {
    "id": "ind:fda.bizengri:1",
    "document_id": "doc:fda.bizengri",
    "indication": "desc:ind:fda.bizengri:1",
    "initial_approval_date": "2024-12-04",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf",
    "description": "desc:stmt:fda.bizengri:1",
    "raw_biomarkers": "NRG1 gene fusion",
    "raw_cancer_type": "pancreatic adenocarcinoma",
    "raw_therapeutics": "zenocutuzumab-zbco",
    "date_regular_approval": null,
    "date_accelerated_approval": "2024-12-04"
  },
  {
    "id": "ind:fda.ensacove:0",
    "document_id": "doc:fda.ensacove",
    "indication": "desc:ind:fda.ensacove:0",
    "initial_approval_date": "2024-12-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf",
    "description": "desc:stmt:fda.ensacove:0",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "ensartinib"
  },
  {
    "id": "ind:fda.braftovi:3",
    "document_id": "doc:fda.braftovi",
    "indication": "desc:ind:fda.braftovi:3",
    "initial_approval_date": "2024-12-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf",
    "description": "desc:stmt:fda.braftovi:3",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with cetuximab and mFOLFOX6"
  },
  {
    "id": "ind:fda.scemblix:2",
    "document_id": "doc:fda.scemblix",
    "indication": "desc:ind:fda.scemblix:2",
    "initial_approval_date": "2024-10-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf",
    "description": "desc:stmt:fda.scemblix:2",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)",
    "raw_therapeutics": "Scemblix (asciminib)"
  },
  {
    "id": "ind:fda.revuforj:0",
    "document_id": "doc:fda.revuforj",
    "indication": "desc:ind:fda.revuforj:0",
    "initial_approval_date": "2024-11-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf",
    "description": "desc:stmt:fda.revuforj:0",
    "raw_biomarkers": "KMT2A translocation",
    "raw_cancer_type": "acute leukemia",
    "raw_therapeutics": "Revuforj (revumenib)"
  },
  {
    "id": "ind:fda.revuforj:1",
    "document_id": "doc:fda.revuforj",
    "indication": "desc:ind:fda.revuforj:1",
    "initial_approval_date": "2025-10-24",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218944s003lbl.pdf",
    "description": "desc:stmt:fda.revuforj:1",
    "raw_biomarkers": "susceptible NPM1 mutation",
    "raw_cancer_type": "acute myeloid leukemia",
    "raw_therapeutics": "Revuforj (revumenib)",
    "status": "Approved",
    "date_regular_approval": "2025-10-24",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.afinitor:1",
    "document_id": "doc:fda.afinitor",
    "indication": "desc:ind:fda.afinitor:1",
    "initial_approval_date": "2012-04-26",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s017lbl.pdf",
    "description": "desc:stmt:fda.afinitor:1",
    "raw_biomarkers": "TSC1/2",
    "raw_cancer_type": "renal angiomyolipoma",
    "raw_therapeutics": "everolimus",
    "date_regular_approval": "2016-02-16",
    "date_accelerated_approval": "2012-04-26"
  },
  {
    "id": "ind:fda.afinitor:2",
    "document_id": "doc:fda.afinitor",
    "indication": "desc:ind:fda.afinitor:2",
    "initial_approval_date": "2010-10-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022334s032,203985s010lbl.pdf",
    "description": "desc:stmt:fda.afinitor:2",
    "raw_biomarkers": "TSC1/2",
    "raw_cancer_type": "subependymal giant cell astrocytoma",
    "raw_therapeutics": "everolimus",
    "date_regular_approval": "2016-01-29",
    "date_accelerated_approval": "2010-10-29"
  },
  {
    "id": "ind:fda.opdivo:4",
    "document_id": "doc:fda.opdivo",
    "indication": "desc:ind:fda.opdivo:4",
    "initial_approval_date": "2018-07-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s063lbl.pdf",
    "description": "desc:stmt:fda.opdivo:4",
    "raw_biomarkers": "microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)",
    "raw_cancer_type": "colorectal cancer",
    "raw_therapeutics": "nivolumab in combination with ipilimumab",
    "date_regular_approval": "2025-04-08",
    "date_accelerated_approval": "2018-07-10"
  },
  {
    "id": "ind:fda.ibtrozi:0",
    "document_id": "doc:fda.ibtrozi",
    "indication": "desc:ind:fda.ibtrozi:0",
    "initial_approval_date": "2015-06-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf",
    "description": "desc:stmt:fda.ibtrozi:0",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "taletrectinib",
    "date_regular_approval": "2025-06-11",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.emrelis:0",
    "document_id": "doc:fda.emrelis",
    "indication": "desc:ind:fda.emrelis:0",
    "initial_approval_date": "2025-05-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf",
    "description": "desc:stmt:fda.emrelis:0",
    "raw_biomarkers": "high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining]",
    "raw_cancer_type": "non-squamous non-small cell lung cancer",
    "raw_therapeutics": "telisotuzumab vedotin",
    "date_regular_approval": null,
    "date_accelerated_approval": "2025-05-14"
  },
  {
    "id": "ind:fda.avmapki-fakzynja:0",
    "document_id": "doc:fda.avmapki-fakzynja",
    "indication": "desc:ind:fda.avmapki-fakzynja:0",
    "initial_approval_date": "2025-05-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf",
    "description": "desc:stmt:fda.avmapki-fakzynja:0",
    "raw_biomarkers": "KRAS-mutated",
    "raw_cancer_type": "low-grade serous ovarian cancer (LGSOC)",
    "raw_therapeutics": "avutometinib; defactinib",
    "date_regular_approval": null,
    "date_accelerated_approval": "2025-05-08"
  },
  {
    "id": "ind:fda.datroway:0",
    "document_id": "doc:fda.datroway",
    "indication": "desc:ind:fda.datroway:0",
    "initial_approval_date": "2025-06-23",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf",
    "description": "desc:stmt:fda.datroway:0",
    "raw_biomarkers": "EGFR-mutated",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Datroway (datopotamab deruxtecan-dlnk)",
    "date_regular_approval": "2025-06-23",
    "date_accelerated_approval": "2025-06-23",
    "status": "Accelerated"
  },
  {
    "id": "ind:fda.datroway:1",
    "document_id": "doc:fda.datroway",
    "indication": "desc:ind:fda.datroway:1",
    "initial_approval_date": "2025-01-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf",
    "description": "desc:stmt:fda.datroway:1",
    "raw_biomarkers": "(HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-)",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Datroway (datopotamab deruxtecan-dlnk)",
    "date_regular_approval": "2025-01-17",
    "date_accelerated_approval": null,
    "status": "Approved"
  },
  {
    "id": "ind:fda.zegfrovy:0",
    "document_id": "doc:fda.zegfrovy",
    "indication": "desc:ind:fda.zegfrovy:0",
    "initial_approval_date": "2025-07-02",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219839s000lbl.pdf",
    "description": "desc:stmt:fda.zegfrovy:0",
    "raw_biomarkers": "EGFR exon 20 insertion mutations",
    "raw_cancer_type": "non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Zegfrovy (sunvozertinib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2025-07-02",
    "status": "Accelerated"
  },
  {
    "id": "ind:fda.hernexeos:0",
    "document_id": "doc:fda.hernexeos",
    "indication": "desc:ind:fda.hernexeos:0",
    "initial_approval_date": "2025-08-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219042s000lbl.pdf",
    "description": "desc:stmt:fda.hernexeos:0",
    "raw_biomarkers": "HER2 (ERBB2) tyrosine kinase domain activating mutations",
    "raw_cancer_type": "non-squamous non-small cell lung cancer",
    "raw_therapeutics": "Hernexeos (zongertinib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2025-08-08",
    "status": "Accelerated"
  },
  {
    "id": "ind:ema.adcetris:0",
    "document_id": "doc:ema.adcetris",
    "indication": "desc:ind:ema.adcetris:0",
    "initial_approval_date": "2023-12-01",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/adcetris-h-c-002455-ii-0107-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.adcetris:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Hodgkin Lymphoma (HL)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin) in combination with doxorubicin, vinblastine, and dacarbazine"
  },
  {
    "id": "ind:ema.adcetris:1",
    "document_id": "doc:ema.adcetris",
    "indication": "desc:ind:ema.adcetris:1",
    "initial_approval_date": "2016-08-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/adcetris-h-c-2455-ii0025-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.adcetris:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Hodgkin Lymphoma (HL)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin)"
  },
  {
    "id": "ind:ema.adcetris:2",
    "document_id": "doc:ema.adcetris",
    "indication": "desc:ind:ema.adcetris:2",
    "initial_approval_date": "2012-07-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/adcetris-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.adcetris:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Hodgkin Lymphoma (HL)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin)"
  },
  {
    "id": "ind:ema.adcetris:3",
    "document_id": "doc:ema.adcetris",
    "indication": "desc:ind:ema.adcetris:3",
    "initial_approval_date": "2018-02-01",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/adcetris-h-c-002455-ii-0048-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.adcetris:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cutaneous T-cell lymphoma (CTCL)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin)"
  },
  {
    "id": "ind:ema.afinitor:0",
    "document_id": "doc:ema.afinitor",
    "indication": "desc:ind:ema.afinitor:0",
    "initial_approval_date": "2012-08-07",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/afinitor-h-c-1038-ii-0020-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.afinitor:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Afinitor (everolimus) in combination with exemestane"
  },
  {
    "id": "ind:ema.akeega:0",
    "document_id": "doc:ema.akeega",
    "indication": "desc:ind:ema.akeega:0",
    "initial_approval_date": "2023-06-02",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/akeega-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.akeega:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Akeega (abiraterone acetate and niraparib)"
  },
  {
    "id": "ind:ema.alecensa:0",
    "document_id": "doc:ema.alecensa",
    "indication": "desc:ind:ema.alecensa:0",
    "initial_approval_date": "2018-01-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/alecensa-h-c-4164-ii-0001-epar-assessment-report_en.pdf",
    "description": "desc:stmt:ema.alecensa:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Alecensa (alectinib)"
  },
  {
    "id": "ind:ema.alecensa:1",
    "document_id": "doc:ema.alecensa",
    "indication": "desc:ind:ema.alecensa:1",
    "initial_approval_date": "2017-04-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/alecensa-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.alecensa:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Alecensa (alectinib)"
  },
  {
    "id": "ind:ema.alecensa:2",
    "document_id": "doc:ema.alecensa",
    "indication": "desc:ind:ema.alecensa:2",
    "initial_approval_date": "2024-06-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/alecensa-h-c-004164-ii-0047-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.alecensa:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Alecensa (alectinib)"
  },
  {
    "id": "ind:ema.alunbrig:0",
    "document_id": "doc:ema.alunbrig",
    "indication": "desc:ind:ema.alunbrig:0",
    "initial_approval_date": "2020-06-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/alunbrig-h-c-4248-ii-0003-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.alunbrig:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Alunbrig (brigatinib)"
  },
  {
    "id": "ind:ema.alunbrig:1",
    "document_id": "doc:ema.alunbrig",
    "indication": "desc:ind:ema.alunbrig:1",
    "initial_approval_date": "2018-11-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/alunbrig-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.alunbrig:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Alunbrig (brigatinib)"
  },
  {
    "id": "ind:ema.avastin:0",
    "document_id": "doc:ema.avastin",
    "indication": "desc:ind:ema.avastin:0",
    "initial_approval_date": "2016-07-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/avastin-h-c-582-ii-0086-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.avastin:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Avastin (bevacizumab) in combination with erlotinib"
  },
  {
    "id": "ind:ema.ayvakyt:0",
    "document_id": "doc:ema.ayvakyt",
    "indication": "desc:ind:ema.ayvakyt:0",
    "initial_approval_date": "2020-09-30",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/ayvakyt-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.ayvakyt:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastrointestinal stromal tumours (GIST)",
    "raw_therapeutics": "Ayvakyt (avapritinib)"
  },
  {
    "id": "ind:ema.besponsa:0",
    "document_id": "doc:ema.besponsa",
    "indication": "desc:ind:ema.besponsa:0",
    "initial_approval_date": "2017-12-12",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/besponsa-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.besponsa:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Besponsa (inotuzumab ozogamicin)"
  },
  {
    "id": "ind:ema.blincyto:0",
    "document_id": "doc:ema.blincyto",
    "indication": "desc:ind:ema.blincyto:0",
    "initial_approval_date": "2021-01-22",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0030-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.blincyto:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:ema.blincyto:1",
    "document_id": "doc:ema.blincyto",
    "indication": "desc:ind:ema.blincyto:1",
    "initial_approval_date": "2019-02-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0011-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.blincyto:1",
    "raw_biomarkers": "Philadelphia chromosome negative CD19 positive",
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:ema.blincyto:2",
    "document_id": "doc:ema.blincyto",
    "indication": "desc:ind:ema.blincyto:2",
    "initial_approval_date": "2025-02-10",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0056-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.blincyto:2",
    "raw_biomarkers": "Philadelphia chromosome negative CD19 positive",
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:ema.blincyto:3",
    "document_id": "doc:ema.blincyto",
    "indication": "desc:ind:ema.blincyto:3",
    "initial_approval_date": "2025-02-10",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0056-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.blincyto:3",
    "raw_biomarkers": "Philadelphia chromosome negative CD19 positive",
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:ema.blincyto:4",
    "document_id": "doc:ema.blincyto",
    "indication": "desc:ind:ema.blincyto:4",
    "initial_approval_date": "2025-02-10",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0056-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.blincyto:4",
    "raw_biomarkers": "Philadelphia chromosome negative CD19 positive",
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:ema.bosulif:0",
    "document_id": "doc:ema.bosulif",
    "indication": "desc:ind:ema.bosulif:0",
    "initial_approval_date": "2025-08-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.bosulif:0",
    "raw_biomarkers": "Philadelphia chromosome-positive",
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:ema.bosulif:1",
    "document_id": "doc:ema.bosulif",
    "indication": "desc:ind:ema.bosulif:1",
    "initial_approval_date": "2025-08-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.bosulif:1",
    "raw_biomarkers": "Philadelphia chromosome-positive",
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:ema.bosulif:2",
    "document_id": "doc:ema.bosulif",
    "indication": "desc:ind:ema.bosulif:2",
    "initial_approval_date": "2025-08-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.bosulif:2",
    "raw_biomarkers": "Philadelphia chromosome-positive",
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:ema.braftovi:0",
    "document_id": "doc:ema.braftovi",
    "indication": "desc:ind:ema.braftovi:0",
    "initial_approval_date": "2018-10-12",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/braftovi-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.braftovi:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Encorafenib and Binimetinib"
  },
  {
    "id": "ind:ema.braftovi:1",
    "document_id": "doc:ema.braftovi",
    "indication": "desc:ind:ema.braftovi:1",
    "initial_approval_date": "2020-06-16",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/braftovi-h-c-4280-ws-1695-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.braftovi:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Encorafenib and Cetuximab"
  },
  {
    "id": "ind:ema.braftovi:2",
    "document_id": "doc:ema.braftovi",
    "indication": "desc:ind:ema.braftovi:2",
    "initial_approval_date": "2024-09-05",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/braftovi-h-c-4280-ws-2538-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.braftovi:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with binimetinib"
  },
  {
    "id": "ind:ema.caprelsa:0",
    "document_id": "doc:ema.caprelsa",
    "indication": "desc:ind:ema.caprelsa:0",
    "initial_approval_date": "2023-03-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/caprelsa-h-c-2315-ii-0043-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.caprelsa:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Medullary thyroid cancer",
    "raw_therapeutics": "Caprelsa (vandetanib)"
  },
  {
    "id": "ind:ema.cotellic:0",
    "document_id": "doc:ema.cotellic",
    "indication": "desc:ind:ema.cotellic:0",
    "initial_approval_date": "2015-12-10",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/cotellic-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.cotellic:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Cobimetinib and vemurafenib"
  },
  {
    "id": "ind:ema.cyramza:0",
    "document_id": "doc:ema.cyramza",
    "indication": "desc:ind:ema.cyramza:0",
    "initial_approval_date": "2020-02-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/cyramza-h-c-2829-ii-0033-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.cyramza:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Cyramza (ramucirumab) and erlotinib"
  },
  {
    "id": "ind:ema.taxotere:0",
    "document_id": "doc:ema.taxotere",
    "indication": "desc:ind:ema.taxotere:0",
    "initial_approval_date": "2005-12-22",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion/taxotere-epar-scientific-discussion_en.pdf",
    "description": "desc:stmt:ema.taxotere:0",
    "raw_biomarkers": "HER2 overexpression",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Taxotere (docetaxel)"
  },
  {
    "id": "ind:ema.enhertu:0",
    "document_id": "doc:ema.enhertu",
    "indication": "desc:ind:ema.enhertu:0",
    "initial_approval_date": "2022-08-02",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0014-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.enhertu:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:ema.enhertu:1",
    "document_id": "doc:ema.enhertu",
    "indication": "desc:ind:ema.enhertu:1",
    "initial_approval_date": "2023-02-16",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0022-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.enhertu:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:ema.enhertu:2",
    "document_id": "doc:ema.enhertu",
    "indication": "desc:ind:ema.enhertu:2",
    "initial_approval_date": "2023-11-29",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0027-epar-assessment-report_en.pdf",
    "description": "desc:stmt:ema.enhertu:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:ema.enhertu:3",
    "document_id": "doc:ema.enhertu",
    "indication": "desc:ind:ema.enhertu:3",
    "initial_approval_date": "2023-02-16",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0012-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.enhertu:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastric or gastroesophageal junction (GEJ) adenocarcinoma",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:ema.enhertu:4",
    "document_id": "doc:ema.enhertu",
    "indication": "desc:ind:ema.enhertu:4",
    "initial_approval_date": "2025-04-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0048-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.enhertu:4",
    "raw_biomarkers": "Hormone receptor (HR)-positive, HER2-low or HER2-ultralow",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:ema.erbitux:0",
    "document_id": "doc:ema.erbitux",
    "indication": "desc:ind:ema.erbitux:0",
    "initial_approval_date": "2008-09-10",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/erbitux-h-c-558-ii-0020-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.erbitux:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab)"
  },
  {
    "id": "ind:ema.erbitux:1",
    "document_id": "doc:ema.erbitux",
    "indication": "desc:ind:ema.erbitux:1",
    "initial_approval_date": "2008-09-10",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/erbitux-h-c-558-ii-0020-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.erbitux:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with irinotecan"
  },
  {
    "id": "ind:ema.erbitux:2",
    "document_id": "doc:ema.erbitux",
    "indication": "desc:ind:ema.erbitux:2",
    "initial_approval_date": "2012-02-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/erbitux-h-c-558-ii-0047-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.erbitux:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with 5-fluorouracil and oxaliplatin"
  },
  {
    "id": "ind:ema.faslodex:0",
    "document_id": "doc:ema.faslodex",
    "indication": "desc:ind:ema.faslodex:0",
    "initial_approval_date": "2009-02-18",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/faslodex-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.faslodex:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant)"
  },
  {
    "id": "ind:ema.faslodex:1",
    "document_id": "doc:ema.faslodex",
    "indication": "desc:ind:ema.faslodex:1",
    "initial_approval_date": "2018-01-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/faslodex-h-c-540-ii-0059-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.faslodex:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant) in combination with palbociclib"
  },
  {
    "id": "ind:ema.gavreto:0",
    "document_id": "doc:ema.gavreto",
    "indication": "desc:ind:ema.gavreto:0",
    "initial_approval_date": "2021-12-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/gavreto-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.gavreto:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Gavreto (pralsetinib)",
    "status": "Withdrawn"
  },
  {
    "id": "ind:ema.iressa:0",
    "document_id": "doc:ema.iressa",
    "indication": "desc:ind:ema.iressa:0",
    "initial_approval_date": "2009-07-22",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/iressa-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.iressa:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Iressa (gefitinib)"
  },
  {
    "id": "ind:ema.giotrif:0",
    "document_id": "doc:ema.giotrif",
    "indication": "desc:ind:ema.giotrif:0",
    "initial_approval_date": "2013-10-16",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/giotrif-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.giotrif:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Giotrif (afatinib)"
  },
  {
    "id": "ind:ema.herceptin:0",
    "document_id": "doc:ema.herceptin",
    "indication": "desc:ind:ema.herceptin:0",
    "initial_approval_date": "2005-10-21",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion/herceptin-epar-scientific-discussion_en.pdf",
    "description": "desc:stmt:ema.herceptin:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "metastatic breast cancer (MBC)",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:ema.herceptin:1",
    "document_id": "doc:ema.herceptin",
    "indication": "desc:ind:ema.herceptin:1",
    "initial_approval_date": "2005-10-21",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion/herceptin-epar-scientific-discussion_en.pdf",
    "description": "desc:stmt:ema.herceptin:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "metastatic breast cancer (MBC)",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:ema.herceptin:2",
    "document_id": "doc:ema.herceptin",
    "indication": "desc:ind:ema.herceptin:2",
    "initial_approval_date": "2005-10-21",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion/herceptin-epar-scientific-discussion_en.pdf",
    "description": "desc:stmt:ema.herceptin:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "metastatic breast cancer (MBC)",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:ema.herceptin:3",
    "document_id": "doc:ema.herceptin",
    "indication": "desc:ind:ema.herceptin:3",
    "initial_approval_date": "2007-08-08",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion-variation/herceptin-h-c-278-ii-0033-epar-scientific-discussion-variation_en.pdf",
    "description": "desc:stmt:ema.herceptin:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "metastatic breast cancer (MBC)",
    "raw_therapeutics": "Herceptin (trastuzumab) in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:ema.herceptin:4",
    "document_id": "doc:ema.herceptin",
    "indication": "desc:ind:ema.herceptin:4",
    "initial_approval_date": "2006-06-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion-variation/herceptin-h-c-278-ii-0026-epar-scientific-discussion-variation_en.pdf",
    "description": "desc:stmt:ema.herceptin:4",
    "raw_biomarkers": null,
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:ema.herceptin:5",
    "document_id": "doc:ema.herceptin",
    "indication": "desc:ind:ema.herceptin:5",
    "initial_approval_date": "2011-05-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/herceptin-h-c-278-ii-0053-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.herceptin:5",
    "raw_biomarkers": null,
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab) in combination with paclitaxel or docetaxel"
  },
  {
    "id": "ind:ema.herceptin:6",
    "document_id": "doc:ema.herceptin",
    "indication": "desc:ind:ema.herceptin:6",
    "initial_approval_date": "2011-05-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/herceptin-h-c-278-ii-0053-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.herceptin:6",
    "raw_biomarkers": null,
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab) in combination with adjuvant chemotherapy containing docetaxel and carboplatin"
  },
  {
    "id": "ind:ema.herceptin:7",
    "document_id": "doc:ema.herceptin",
    "indication": "desc:ind:ema.herceptin:7",
    "initial_approval_date": "2012-05-07",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/herceptin-h-c-278-ii-0057-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.herceptin:7",
    "raw_biomarkers": null,
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab) in combination with neoadjuvant chemotherapy"
  },
  {
    "id": "ind:ema.herceptin:8",
    "document_id": "doc:ema.herceptin",
    "indication": "desc:ind:ema.herceptin:8",
    "initial_approval_date": "2010-03-01",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/herceptin-h-c-278-ii-0047-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.herceptin:8",
    "raw_biomarkers": null,
    "raw_cancer_type": "adenocracinoma of the stomach or gastroesophageal junction",
    "raw_therapeutics": "Herceptin (trastuzumab) in combination with capecitabine or 5-fluorouracil and cisplatin"
  },
  {
    "id": "ind:ema.ibrance:0",
    "document_id": "doc:ema.ibrance",
    "indication": "desc:ind:ema.ibrance:0",
    "initial_approval_date": "2016-11-25",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/ibrance-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.ibrance:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Ibrance (palbociclib) in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:ema.ibrance:1",
    "document_id": "doc:ema.ibrance",
    "indication": "desc:ind:ema.ibrance:1",
    "initial_approval_date": "2016-11-25",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/ibrance-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.ibrance:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Ibrance (palbociclib) in combination with fulvestrant"
  },
  {
    "id": "ind:ema.glivec:0",
    "document_id": "doc:ema.glivec",
    "indication": "desc:ind:ema.glivec:0",
    "initial_approval_date": "2005-10-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion/glivec-epar-scientific-discussion_en.pdf",
    "description": "desc:stmt:ema.glivec:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myeloid Leukemia",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:1",
    "document_id": "doc:ema.glivec",
    "indication": "desc:ind:ema.glivec:1",
    "initial_approval_date": "2005-10-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion/glivec-epar-scientific-discussion_en.pdf",
    "description": "desc:stmt:ema.glivec:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myeloid Leukemia",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:2",
    "document_id": "doc:ema.glivec",
    "indication": "desc:ind:ema.glivec:2",
    "initial_approval_date": "2013-07-24",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/glivec-h-c-406-ii-0080-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.glivec:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:3",
    "document_id": "doc:ema.glivec",
    "indication": "desc:ind:ema.glivec:3",
    "initial_approval_date": "2007-03-05",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion-variation/glivec-h-c-406-ii-0031-epar-scientific-discussion-variation_en.pdf",
    "description": "desc:stmt:ema.glivec:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:4",
    "document_id": "doc:ema.glivec",
    "indication": "desc:ind:ema.glivec:4",
    "initial_approval_date": "2007-03-05",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion-variation/glivec-h-c-406-ii-0032-epar-scientific-discussion-variation_en.pdf",
    "description": "desc:stmt:ema.glivec:4",
    "raw_biomarkers": null,
    "raw_cancer_type": "Myelodysplastic/myeloproliferative diseases (MDS/MPD)",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:5",
    "document_id": "doc:ema.glivec",
    "indication": "desc:ind:ema.glivec:5",
    "initial_approval_date": "2007-05-08",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion-variation/glivec-h-c-406-ii-0035-epar-scientific-discussion-variation_en.pdf",
    "description": "desc:stmt:ema.glivec:5",
    "raw_biomarkers": null,
    "raw_cancer_type": "Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL)",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:6",
    "document_id": "doc:ema.glivec",
    "indication": "desc:ind:ema.glivec:6",
    "initial_approval_date": "2005-10-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion/glivec-epar-scientific-discussion_en.pdf",
    "description": "desc:stmt:ema.glivec:6",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastrointestinal Stromal Tumor (GIST)",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:7",
    "document_id": "doc:ema.glivec",
    "indication": "desc:ind:ema.glivec:7",
    "initial_approval_date": "2009-08-17",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/glivec-h-c-406-ii-0048-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.glivec:7",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastrointestinal Stromal Tumor (GIST)",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.iclusig:0",
    "document_id": "doc:ema.iclusig",
    "indication": "desc:ind:ema.iclusig:0",
    "initial_approval_date": "2013-07-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/iclusig-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.iclusig:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myeloid Leukemia",
    "raw_therapeutics": "Iclusig (ponatinib)"
  },
  {
    "id": "ind:ema.iclusig:1",
    "document_id": "doc:ema.iclusig",
    "indication": "desc:ind:ema.iclusig:1",
    "initial_approval_date": "2013-07-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/iclusig-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.iclusig:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) ",
    "raw_therapeutics": "Iclusig (ponatinib)"
  },
  {
    "id": "ind:ema.imfinzi:0",
    "document_id": "doc:ema.imfinzi",
    "indication": "desc:ind:ema.imfinzi:0",
    "initial_approval_date": "2018-10-30",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/imfinzi-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.imfinzi:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Imfinzi (durvalumab)"
  },
  {
    "id": "ind:ema.imfinzi:1",
    "document_id": "doc:ema.imfinzi",
    "indication": "desc:ind:ema.imfinzi:1",
    "initial_approval_date": "2023-04-14",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-4771-ii-0041-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.imfinzi:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Imfinzi (durvalumab) in combination with tremelimumab and platinum-based chemotherapy."
  },
  {
    "id": "ind:ema.imfinzi:2",
    "document_id": "doc:ema.imfinzi",
    "indication": "desc:ind:ema.imfinzi:2",
    "initial_approval_date": "2024-08-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-1049-ws-2463-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.imfinzi:2",
    "raw_biomarkers": "mismatch repair deficient (dMMR) or mismatch repair proficient (pMMR).",
    "raw_cancer_type": "Endometrial cancer",
    "raw_therapeutics": "Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi (durvalumab) as monotherapy for endometrial cancer that is mismatch repair deficient (dMMR) or Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi (durvalumab) in combination with olaparib for endometrial cancer that is mismatch repair proficient (pMMR)."
  },
  {
    "id": "ind:ema.imfinzi:3",
    "document_id": "doc:ema.imfinzi",
    "indication": "desc:ind:ema.imfinzi:3",
    "initial_approval_date": "2025-06-18",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-004771-ii-0064-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.imfinzi:3",
    "raw_biomarkers": "no EGFR mutations or ALK rearrangements",
    "raw_cancer_type": "NSCLC",
    "raw_therapeutics": "IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment"
  },
  {
    "id": "ind:ema.imjudo:0",
    "document_id": "doc:ema.imjudo",
    "indication": "desc:ind:ema.imjudo:0",
    "initial_approval_date": "2023-09-22",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imjudo-h-c-006016-ii-0001-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.imjudo:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Imjudo (tremelimumab) in combination with durvalumab and platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.jemperli:0",
    "document_id": "doc:ema.jemperli",
    "indication": "desc:ind:ema.jemperli:0",
    "initial_approval_date": "2024-01-12",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/jemperli-h-c-005204-ii-0023-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.jemperli:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Endometrial cancer (EC)",
    "raw_therapeutics": "Jemperli (dostarlimab) in combination with carboplatin and paclixtaxel",
    "status": "Superseded"
  },
  {
    "id": "ind:ema.jemperli:1",
    "document_id": "doc:ema.jemperli",
    "indication": "desc:ind:ema.jemperli:1",
    "initial_approval_date": "2021-05-03",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/jemperli-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.jemperli:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Endometrial cancer (EC)",
    "raw_therapeutics": "Jemperli (dostarlimab) in combination with carboplatin and paclixtaxel"
  },
  {
    "id": "ind:ema.keytruda:0",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:0",
    "initial_approval_date": "2017-03-02",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0011-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "non-small cell lung carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:1",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:1",
    "initial_approval_date": "2018-10-10",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0043-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "non-small cell lung carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy"
  },
  {
    "id": "ind:ema.keytruda:2",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:2",
    "initial_approval_date": "2020-06-18",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0057-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "non-small cell lung carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:3",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:3",
    "initial_approval_date": "2021-03-31",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0052-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "urothelial carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:4",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:4",
    "initial_approval_date": "2019-11-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0065-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:4",
    "raw_biomarkers": null,
    "raw_cancer_type": "head and neck squamous cell carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:5",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:5",
    "initial_approval_date": "2018-10-10",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0042-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:5",
    "raw_biomarkers": null,
    "raw_cancer_type": "head and neck squamous cell carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:6",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:6",
    "initial_approval_date": "2021-01-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0091-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:6",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:7",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:7",
    "initial_approval_date": "2022-05-17",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003820-ii-0109-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:7",
    "raw_biomarkers": null,
    "raw_cancer_type": "Endometrial carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:8",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:8",
    "initial_approval_date": "2022-05-17",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003820-ii-0109-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:8",
    "raw_biomarkers": null,
    "raw_cancer_type": "gastric, small intestine, or biliary cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:9",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:9",
    "initial_approval_date": "2021-07-23",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0097-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:9",
    "raw_biomarkers": null,
    "raw_cancer_type": "Oesophageal carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy"
  },
  {
    "id": "ind:ema.keytruda:10",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:10",
    "initial_approval_date": "2022-05-23",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003820-ii-0110-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:10",
    "raw_biomarkers": null,
    "raw_cancer_type": "Triple-negative breast cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:11",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:11",
    "initial_approval_date": "2021-10-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0099-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:11",
    "raw_biomarkers": null,
    "raw_cancer_type": "Triple-negative breast cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy"
  },
  {
    "id": "ind:ema.keytruda:12",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:12",
    "initial_approval_date": "2022-05-17",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003820-ii-0117-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:12",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cervical cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy with or without bevacizumab"
  },
  {
    "id": "ind:ema.keytruda:13",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:13",
    "initial_approval_date": "2023-09-06",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003820-ii-0133-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:13",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastric or gastro-esophagael junction (GEJ) adenocracinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy"
  },
  {
    "id": "ind:ema.keytruda:14",
    "document_id": "doc:ema.keytruda",
    "indication": "desc:ind:ema.keytruda:14",
    "initial_approval_date": "2023-12-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003820-ii-0135-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.keytruda:14",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastric or gastro-esophagael junction (GEJ) adenocracinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with fluoropyrimidine and platinum-containing chemotherapy"
  },
  {
    "id": "ind:ema.kadcyla:0",
    "document_id": "doc:ema.kadcyla",
    "indication": "desc:ind:ema.kadcyla:0",
    "initial_approval_date": "2020-01-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/kadcyla-epar-h-c-2389-ii-0045-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.kadcyla:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Kadcyla (trastuzumab emtansine)"
  },
  {
    "id": "ind:ema.kadcyla:1",
    "document_id": "doc:ema.kadcyla",
    "indication": "desc:ind:ema.kadcyla:1",
    "initial_approval_date": "2013-12-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/kadcyla-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.kadcyla:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Kadcyla (trastuzumab emtansine)"
  },
  {
    "id": "ind:ema.kisqali:0",
    "document_id": "doc:ema.kisqali",
    "indication": "desc:ind:ema.kisqali:0",
    "initial_approval_date": "2019-01-30",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/kisqali-h-c-4213-ii-0004-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.kisqali:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Kisqali (ribociclib) in combination with an aromatase inhibitor or fulvestrant"
  },
  {
    "id": "ind:ema.kisqali:1",
    "document_id": "doc:ema.kisqali",
    "indication": "desc:ind:ema.kisqali:1",
    "initial_approval_date": "2024-12-16",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/kisqali-h-c-004213-ii-0045-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.kisqali:1",
    "raw_biomarkers": "(HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Kisqali (ribociclib) in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:ema.krazati:0",
    "document_id": "doc:ema.krazati",
    "indication": "desc:ind:ema.krazati:0",
    "initial_approval_date": "2024-03-13",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/krazati-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.krazati:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Krazati (adagrasib)"
  },
  {
    "id": "ind:ema.libtayo:0",
    "document_id": "doc:ema.libtayo",
    "indication": "desc:ind:ema.libtayo:0",
    "initial_approval_date": "2021-07-02",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/libtayo-h-c-004844-ii-0011-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.libtayo:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Libtayo (cemiplimab)"
  },
  {
    "id": "ind:ema.libtayo:1",
    "document_id": "doc:ema.libtayo",
    "indication": "desc:ind:ema.libtayo:1",
    "initial_approval_date": "2023-05-17",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/libtayo-h-c-004844-ii-0028-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.libtayo:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Libtayo (cemiplimab) in combination with platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.lorviqua:0",
    "document_id": "doc:ema.lorviqua",
    "indication": "desc:ind:ema.lorviqua:0",
    "initial_approval_date": "2025-06-23",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/lorviqua-h-c-4646-ii-0015-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.lorviqua:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Lorviqua (lorlatinib)"
  },
  {
    "id": "ind:ema.lorviqua:1",
    "document_id": "doc:ema.lorviqua",
    "indication": "desc:ind:ema.lorviqua:1",
    "initial_approval_date": "2019-06-17",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/lorviqua-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.lorviqua:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Lorviqua (lorlatinib)"
  },
  {
    "id": "ind:ema.lumykras:0",
    "document_id": "doc:ema.lumykras",
    "indication": "desc:ind:ema.lumykras:0",
    "initial_approval_date": "2022-03-31",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/lumykras-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.lumykras:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Lumykras (sotorasib)"
  },
  {
    "id": "ind:ema.lynparza:0",
    "document_id": "doc:ema.lynparza",
    "indication": "desc:ind:ema.lynparza:0",
    "initial_approval_date": "2019-07-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/lynparza-h-c-003726-ii-0023-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.lynparza:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:ema.lynparza:1",
    "document_id": "doc:ema.lynparza",
    "indication": "desc:ind:ema.lynparza:1",
    "initial_approval_date": "2020-11-06",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/lynparza-h-c-3726-ii-0035-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.lynparza:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab"
  },
  {
    "id": "ind:ema.lynparza:2",
    "document_id": "doc:ema.lynparza",
    "indication": "desc:ind:ema.lynparza:2",
    "initial_approval_date": "2019-06-04",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/lynparza-h-c-3726-ii-0020-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.lynparza:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:ema.lynparza:3",
    "document_id": "doc:ema.lynparza",
    "indication": "desc:ind:ema.lynparza:3",
    "initial_approval_date": "2022-10-03",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/lynparza-h-c-3726-ii-0051-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.lynparza:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:ema.lynparza:4",
    "document_id": "doc:ema.lynparza",
    "indication": "desc:ind:ema.lynparza:4",
    "initial_approval_date": "2020-07-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/lynparza-h-c-003726-ii-0033-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.lynparza:4",
    "raw_biomarkers": null,
    "raw_cancer_type": "Adenocarcinoma of the pancreas",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:ema.lynparza:5",
    "document_id": "doc:ema.lynparza",
    "indication": "desc:ind:ema.lynparza:5",
    "initial_approval_date": "2020-11-06",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/lynparza-h-c-3726-ii-0036-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.lynparza:5",
    "raw_biomarkers": null,
    "raw_cancer_type": "Prostate cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:ema.lynparza:6",
    "document_id": "doc:ema.lynparza",
    "indication": "desc:ind:ema.lynparza:6",
    "initial_approval_date": "2024-08-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/lynparza-h-c-ws2463-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.lynparza:6",
    "raw_biomarkers": null,
    "raw_cancer_type": "Endometrial cancer",
    "raw_therapeutics": "Lynparza (olaparib) in combination with durvalumab for maintence treatment, after not progressing on first-line treatment with durvalumab in combination with carboplatin and paclitaxel"
  },
  {
    "id": "ind:ema.lytgobi:0",
    "document_id": "doc:ema.lytgobi",
    "indication": "desc:ind:ema.lytgobi:0",
    "initial_approval_date": "2023-07-18",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/lytgobi-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.lytgobi:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cholangiocarcinoma",
    "raw_therapeutics": "Lytgobi (futibatinib)"
  },
  {
    "id": "ind:ema.mabthera:0",
    "document_id": "doc:ema.mabthera",
    "indication": "desc:ind:ema.mabthera:0",
    "initial_approval_date": "2006-09-29",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion/mabthera-epar-scientific-discussion_en.pdf",
    "description": "desc:stmt:ema.mabthera:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "diffuse large B cell non-Hodgkin's lymphoma",
    "raw_therapeutics": "MabThera (rituximab) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)"
  },
  {
    "id": "ind:ema.mabthera:1",
    "document_id": "doc:ema.mabthera",
    "indication": "desc:ind:ema.mabthera:1",
    "initial_approval_date": "2020-03-16",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/mabthera-h-c-165-ii-0168-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.mabthera:1",
    "raw_biomarkers": "CD20 positive",
    "raw_cancer_type": "diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL)",
    "raw_therapeutics": "MabThera (rituximab) in combination with chemotherapy"
  },
  {
    "id": "ind:ema.mekinist:0",
    "document_id": "doc:ema.mekinist",
    "indication": "desc:ind:ema.mekinist:0",
    "initial_approval_date": "2015-11-04",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/mekinist-h-c-2643-ws-0736-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.mekinist:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "trametinib as a monotherapy or in combination with dabrafenib"
  },
  {
    "id": "ind:ema.mekinist:1",
    "document_id": "doc:ema.mekinist",
    "indication": "desc:ind:ema.mekinist:1",
    "initial_approval_date": "2018-09-07",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/mekinist-h-c-2643-ws-1274-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.mekinist:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:ema.mekinist:2",
    "document_id": "doc:ema.mekinist",
    "indication": "desc:ind:ema.mekinist:2",
    "initial_approval_date": "2017-06-06",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/mekinist-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.mekinist:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:ema.mektovi:0",
    "document_id": "doc:ema.mektovi",
    "indication": "desc:ind:ema.mektovi:0",
    "initial_approval_date": "2018-10-12",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.mektovi:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Mektovi (binimetinib) in combination with encorafenib"
  },
  {
    "id": "ind:ema.mektovi:1",
    "document_id": "doc:ema.mektovi",
    "indication": "desc:ind:ema.mektovi:1",
    "initial_approval_date": "2024-09-05",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/mektovi-h-c-4579-ws-2538-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.mektovi:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Mektovi (binimetinib) in combination with encorafenib"
  },
  {
    "id": "ind:ema.mylotarg:0",
    "document_id": "doc:ema.mylotarg",
    "indication": "desc:ind:ema.mylotarg:0",
    "initial_approval_date": "2018-05-04",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/mylotarg-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.mylotarg:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute myeloid leukaemia",
    "raw_therapeutics": "Mylotarg (gemtuzumab ozogamicin) in combination with daunorubicin (DNR) and cytarabine (AraC)"
  },
  {
    "id": "ind:ema.nerlynx:0",
    "document_id": "doc:ema.nerlynx",
    "indication": "desc:ind:ema.nerlynx:0",
    "initial_approval_date": "2018-09-12",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/nerlynx-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.nerlynx:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Nerlynx (neratinib)"
  },
  {
    "id": "ind:ema.opdivo:0",
    "document_id": "doc:ema.opdivo",
    "indication": "desc:ind:ema.opdivo:0",
    "initial_approval_date": "2020-11-25",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-3985-ws-1783-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.opdivo:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab and 2 cycles of platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.opdivo:1",
    "document_id": "doc:ema.opdivo",
    "indication": "desc:ind:ema.opdivo:1",
    "initial_approval_date": "2023-07-18",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-003985-ii-0117-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.opdivo:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.opdivo:2",
    "document_id": "doc:ema.opdivo",
    "indication": "desc:ind:ema.opdivo:2",
    "initial_approval_date": "2022-04-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-003985-ii-0100-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.opdivo:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Urothelial carcinoma",
    "raw_therapeutics": "Opdivo (nivolumab)"
  },
  {
    "id": "ind:ema.opdivo:3",
    "document_id": "doc:ema.opdivo",
    "indication": "desc:ind:ema.opdivo:3",
    "initial_approval_date": "2021-07-07",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-3985-ws-1840-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.opdivo:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab"
  },
  {
    "id": "ind:ema.opdivo:4",
    "document_id": "doc:ema.opdivo",
    "indication": "desc:ind:ema.opdivo:4",
    "initial_approval_date": "2022-04-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-ws-2113-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.opdivo:4",
    "raw_biomarkers": null,
    "raw_cancer_type": "Oesophageal squamous cell carcinoma",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab"
  },
  {
    "id": "ind:ema.opdivo:5",
    "document_id": "doc:ema.opdivo",
    "indication": "desc:ind:ema.opdivo:5",
    "initial_approval_date": "2022-04-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-003985-ii-0107-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.opdivo:5",
    "raw_biomarkers": null,
    "raw_cancer_type": "Oesophageal squamous cell carcinoma",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy"
  },
  {
    "id": "ind:ema.opdivo:6",
    "document_id": "doc:ema.opdivo",
    "indication": "desc:ind:ema.opdivo:6",
    "initial_approval_date": "2021-10-29",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-003985-ii-0096-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.opdivo:6",
    "raw_biomarkers": null,
    "raw_cancer_type": "gastric, gastro-oesophageal junction or oesophageal adenocarcinoma",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy"
  },
  {
    "id": "ind:ema.opdivo:7",
    "document_id": "doc:ema.opdivo",
    "indication": "desc:ind:ema.opdivo:7",
    "initial_approval_date": "2025-01-13",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-ws-2672-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.opdivo:7",
    "raw_biomarkers": "mismatch repair deficient or microsatellite instability-high",
    "raw_cancer_type": "colorectal cancer",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab"
  },
  {
    "id": "ind:ema.opdivo:8",
    "document_id": "doc:ema.opdivo",
    "indication": "desc:ind:ema.opdivo:8",
    "initial_approval_date": "2025-06-02",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-003985-ii-0140-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.opdivo:8",
    "raw_biomarkers": "PD-L1 expression >= 1%",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.opdualag:0",
    "document_id": "doc:ema.opdualag",
    "indication": "desc:ind:ema.opdualag:0",
    "initial_approval_date": "2022-09-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/opdualag-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.opdualag:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Opdualag (relatlimab / nivolumab)"
  },
  {
    "id": "ind:ema.orserdu:0",
    "document_id": "doc:ema.orserdu",
    "indication": "desc:ind:ema.orserdu:0",
    "initial_approval_date": "2023-10-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/orserdu-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.orserdu:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Orserdu (elacestrant)"
  },
  {
    "id": "ind:ema.pemazyre:0",
    "document_id": "doc:ema.pemazyre",
    "indication": "desc:ind:ema.pemazyre:0",
    "initial_approval_date": "2021-05-04",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/pemazyre-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.pemazyre:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cholangiocarcinoma",
    "raw_therapeutics": "Orserdu (elacestrant)"
  },
  {
    "id": "ind:ema.perjeta:0",
    "document_id": "doc:ema.perjeta",
    "indication": "desc:ind:ema.perjeta:0",
    "initial_approval_date": "2015-08-14",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/perjeta-h-c-2547-ii-0010-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.perjeta:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
  },
  {
    "id": "ind:ema.perjeta:1",
    "document_id": "doc:ema.perjeta",
    "indication": "desc:ind:ema.perjeta:1",
    "initial_approval_date": "2018-06-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/perjeta-h-c-002547-ii-0034-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.perjeta:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
  },
  {
    "id": "ind:ema.perjeta:2",
    "document_id": "doc:ema.perjeta",
    "indication": "desc:ind:ema.perjeta:2",
    "initial_approval_date": "2013-04-05",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/perjeta-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.perjeta:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and docetaxel"
  },
  {
    "id": "ind:ema.phesgo:0",
    "document_id": "doc:ema.phesgo",
    "indication": "desc:ind:ema.phesgo:0",
    "initial_approval_date": "2021-01-13",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/phesgo-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.phesgo:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
  },
  {
    "id": "ind:ema.phesgo:1",
    "document_id": "doc:ema.phesgo",
    "indication": "desc:ind:ema.phesgo:1",
    "initial_approval_date": "2021-01-13",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/phesgo-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.phesgo:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
  },
  {
    "id": "ind:ema.phesgo:2",
    "document_id": "doc:ema.phesgo",
    "indication": "desc:ind:ema.phesgo:2",
    "initial_approval_date": "2021-01-13",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/phesgo-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.phesgo:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with docetaxel"
  },
  {
    "id": "ind:ema.piqray:0",
    "document_id": "doc:ema.piqray",
    "indication": "desc:ind:ema.piqray:0",
    "initial_approval_date": "2020-07-30",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/piqray-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.piqray:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Piqray (alpelisib) in combination with fulvestrant"
  },
  {
    "id": "ind:ema.retsevmo:0",
    "document_id": "doc:ema.retsevmo",
    "indication": "desc:ind:ema.retsevmo:0",
    "initial_approval_date": "2022-11-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/retsevmo-h-c-005375-ii-0011-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.retsevmo:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Retsevmo (selpercatinib)"
  },
  {
    "id": "ind:ema.retsevmo:1",
    "document_id": "doc:ema.retsevmo",
    "indication": "desc:ind:ema.retsevmo:1",
    "initial_approval_date": "2024-03-14",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/retsevmo-h-c-005375-ii-0021-epar-assessment-report-extension_en.pdf",
    "description": "desc:stmt:ema.retsevmo:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Thyroid cancer",
    "raw_therapeutics": "Retsevmo (selpercatinib)"
  },
  {
    "id": "ind:ema.retsevmo:2",
    "document_id": "doc:ema.retsevmo",
    "indication": "desc:ind:ema.retsevmo:2",
    "initial_approval_date": "2022-11-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/retsevmo-h-c-005375-ii-0014-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.retsevmo:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Medullary thyroid cancer",
    "raw_therapeutics": "Retsevmo (selpercatinib)"
  },
  {
    "id": "ind:ema.retsevmo:3",
    "document_id": "doc:ema.retsevmo",
    "indication": "desc:ind:ema.retsevmo:3",
    "initial_approval_date": "2024-05-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/retsevmo-h-c-005375-ii-0022-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.retsevmo:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "Any solid tumor",
    "raw_therapeutics": "Retsevmo (selpercatinib)"
  },
  {
    "id": "ind:ema.revlimid:0",
    "document_id": "doc:ema.revlimid",
    "indication": "desc:ind:ema.revlimid:0",
    "initial_approval_date": "2013-07-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/revlimid-h-c-717-ii-0056-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.revlimid:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "myelodysplastic syndromes",
    "raw_therapeutics": "Revlimid (lenalidomide)"
  },
  {
    "id": "ind:ema.rozlytrek:0",
    "document_id": "doc:ema.rozlytrek",
    "indication": "desc:ind:ema.rozlytrek:0",
    "initial_approval_date": "2020-09-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/rozlytrek-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.rozlytrek:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Rozlytrek (entrectinib)"
  },
  {
    "id": "ind:ema.rozlytrek:1",
    "document_id": "doc:ema.rozlytrek",
    "indication": "desc:ind:ema.rozlytrek:1",
    "initial_approval_date": "2024-07-03",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/rozlytrek-h-c-004936-x-0017-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.rozlytrek:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Any solid tumor",
    "raw_therapeutics": "Rozlytrek (entrectinib)"
  },
  {
    "id": "ind:ema.rydapt:0",
    "document_id": "doc:ema.rydapt",
    "indication": "desc:ind:ema.rydapt:0",
    "initial_approval_date": "2017-10-25",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/rydapt-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.rydapt:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute myeloid leukaemia",
    "raw_therapeutics": "Rydapt (midostaurin)"
  },
  {
    "id": "ind:ema.scemblix:0",
    "document_id": "doc:ema.scemblix",
    "indication": "desc:ind:ema.scemblix:0",
    "initial_approval_date": "2022-09-07",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/scemblix-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.scemblix:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myeloid Leukemia",
    "raw_therapeutics": "Scemblix (asciminib)"
  },
  {
    "id": "ind:ema.spexotras:0",
    "document_id": "doc:ema.spexotras",
    "indication": "desc:ind:ema.spexotras:0",
    "initial_approval_date": "2024-01-17",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/spexotras-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.spexotras:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "low-grade glioma",
    "raw_therapeutics": "Spexotras (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:ema.spexotras:1",
    "document_id": "doc:ema.spexotras",
    "indication": "desc:ind:ema.spexotras:1",
    "initial_approval_date": "2024-01-17",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/spexotras-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.spexotras:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "high-grade glioma",
    "raw_therapeutics": "Spexotras (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:ema.sprycel:0",
    "document_id": "doc:ema.sprycel",
    "indication": "desc:ind:ema.sprycel:0",
    "initial_approval_date": "2010-12-22",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/sprycel-h-709-ii-0023-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.sprycel:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Sprycel (dasatinib [anhydrous])"
  },
  {
    "id": "ind:ema.sprycel:1",
    "document_id": "doc:ema.sprycel",
    "indication": "desc:ind:ema.sprycel:1",
    "initial_approval_date": "2006-11-30",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion/sprycel-epar-scientific-discussion_en.pdf",
    "description": "desc:stmt:ema.sprycel:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML)",
    "raw_therapeutics": "Sprycel (dasatinib [anhydrous])"
  },
  {
    "id": "ind:ema.sprycel:2",
    "document_id": "doc:ema.sprycel",
    "indication": "desc:ind:ema.sprycel:2",
    "initial_approval_date": "2018-07-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/sprycel-h-c-000709-x-0056-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.sprycel:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Sprycel (dasatinib [anhydrous])"
  },
  {
    "id": "ind:ema.sprycel:3",
    "document_id": "doc:ema.sprycel",
    "indication": "desc:ind:ema.sprycel:3",
    "initial_approval_date": "2019-03-29",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/sprycel-h-c-709-ii-0059-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.sprycel:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Sprycel (dasatinib [anhydrous]) in combination with chemotherapy"
  },
  {
    "id": "ind:ema.tabrecta:0",
    "document_id": "doc:ema.tabrecta",
    "indication": "desc:ind:ema.tabrecta:0",
    "initial_approval_date": "2022-09-21",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/tabrecta-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.tabrecta:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tabrecta (capmatinib)"
  },
  {
    "id": "ind:ema.tafinlar:0",
    "document_id": "doc:ema.tafinlar",
    "indication": "desc:ind:ema.tafinlar:0",
    "initial_approval_date": "2015-11-03",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tafinlar-h-c-2604-ws-0736-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tafinlar:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Tafinlar (dabrafenib)"
  },
  {
    "id": "ind:ema.tafinlar:1",
    "document_id": "doc:ema.tafinlar",
    "indication": "desc:ind:ema.tafinlar:1",
    "initial_approval_date": "2018-09-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tafinlar-h-c-ws-1274-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tafinlar:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Tafinlar (dabrafenib)"
  },
  {
    "id": "ind:ema.tafinlar:2",
    "document_id": "doc:ema.tafinlar",
    "indication": "desc:ind:ema.tafinlar:2",
    "initial_approval_date": "2017-05-22",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tafinlar-h-c-ws-0996-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tafinlar:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tafinlar (dabrafenib)"
  },
  {
    "id": "ind:ema.tagrisso:0",
    "document_id": "doc:ema.tagrisso",
    "indication": "desc:ind:ema.tagrisso:0",
    "initial_approval_date": "2021-07-01",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tagrisso-h-c-004124-ii-0039-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tagrisso:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:ema.tagrisso:1",
    "document_id": "doc:ema.tagrisso",
    "indication": "desc:ind:ema.tagrisso:1",
    "initial_approval_date": "2018-07-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tagrisso-h-c-4124-ii-0019-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tagrisso:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:ema.tagrisso:2",
    "document_id": "doc:ema.tagrisso",
    "indication": "desc:ind:ema.tagrisso:2",
    "initial_approval_date": "2016-02-17",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/tagrisso-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.tagrisso:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:ema.tagrisso:3",
    "document_id": "doc:ema.tagrisso",
    "indication": "desc:ind:ema.tagrisso:3",
    "initial_approval_date": "2024-07-23",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tagrisso-h-c-004124-ii-0053-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tagrisso:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.tagrisso:4",
    "document_id": "doc:ema.tagrisso",
    "indication": "desc:ind:ema.tagrisso:4",
    "initial_approval_date": "2025-01-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf",
    "description": "desc:stmt:ema.tagrisso:4",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 (L858R)",
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:ema.talzenna:0",
    "document_id": "doc:ema.talzenna",
    "indication": "desc:ind:ema.talzenna:0",
    "initial_approval_date": "2019-07-08",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/talzenna-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.talzenna:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Talzenna (talazoparib)"
  },
  {
    "id": "ind:ema.tarceva:0",
    "document_id": "doc:ema.tarceva",
    "indication": "desc:ind:ema.tarceva:0",
    "initial_approval_date": "2011-11-14",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tarceva-h-c-618-ii-0020-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tarceva:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tarceva (erlotinib)"
  },
  {
    "id": "ind:ema.tarceva:1",
    "document_id": "doc:ema.tarceva",
    "indication": "desc:ind:ema.tarceva:1",
    "initial_approval_date": "2016-03-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tarceva-h-c-618-ii-0043-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tarceva:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tarceva (erlotinib)"
  },
  {
    "id": "ind:ema.tasigna:0",
    "document_id": "doc:ema.tasigna",
    "indication": "desc:ind:ema.tasigna:0",
    "initial_approval_date": "2018-04-16",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tasigna-h-c-798-x-0088-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tasigna:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:ema.tasigna:1",
    "document_id": "doc:ema.tasigna",
    "indication": "desc:ind:ema.tasigna:1",
    "initial_approval_date": "2007-11-29",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion/tasigna-epar-scientific-discussion_en.pdf",
    "description": "desc:stmt:ema.tasigna:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:ema.tasigna:2",
    "document_id": "doc:ema.tasigna",
    "indication": "desc:ind:ema.tasigna:2",
    "initial_approval_date": "2018-04-16",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tasigna-h-c-798-x-0088-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tasigna:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:ema.tecentriq:0",
    "document_id": "doc:ema.tecentriq",
    "indication": "desc:ind:ema.tecentriq:0",
    "initial_approval_date": "2018-07-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tecentriq-h-c-004143-ii-0010-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tecentriq:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "urothelial carcinoma",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:ema.tecentriq:1",
    "document_id": "doc:ema.tecentriq",
    "indication": "desc:ind:ema.tecentriq:1",
    "initial_approval_date": "2022-08-02",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tecentriq-h-c-h004143-ii-0064-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tecentriq:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:ema.tecentriq:2",
    "document_id": "doc:ema.tecentriq",
    "indication": "desc:ind:ema.tecentriq:2",
    "initial_approval_date": "2019-06-17",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tecentriq-h-c-004143-ii-0007-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tecentriq:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel, and carboplatin"
  },
  {
    "id": "ind:ema.tecentriq:3",
    "document_id": "doc:ema.tecentriq",
    "indication": "desc:ind:ema.tecentriq:3",
    "initial_approval_date": "2019-10-23",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tecentriq-h-c-004143-ii-0019-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tecentriq:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab) in combination with nab-paclitaxel and carboplatin"
  },
  {
    "id": "ind:ema.tecentriq:4",
    "document_id": "doc:ema.tecentriq",
    "indication": "desc:ind:ema.tecentriq:4",
    "initial_approval_date": "2021-07-01",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tecentriq-h-c-004143-ii-0033-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tecentriq:4",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:ema.tecentriq:5",
    "document_id": "doc:ema.tecentriq",
    "indication": "desc:ind:ema.tecentriq:5",
    "initial_approval_date": "2017-09-29",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/tecentriq-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.tecentriq:5",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:ema.tecentriq:6",
    "document_id": "doc:ema.tecentriq",
    "indication": "desc:ind:ema.tecentriq:6",
    "initial_approval_date": "2019-10-23",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tecentriq-h-c-004143-x-0017-epar-assessment-report-extension_en.pdf",
    "description": "desc:stmt:ema.tecentriq:6",
    "raw_biomarkers": null,
    "raw_cancer_type": "Triple-negative breast cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab) in combination with nab-paclitaxel"
  },
  {
    "id": "ind:ema.tepmetko:0",
    "document_id": "doc:ema.tepmetko",
    "indication": "desc:ind:ema.tepmetko:0",
    "initial_approval_date": "2022-05-05",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/tepmetko-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.tepmetko:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tepmetko (tepotinib)"
  },
  {
    "id": "ind:ema.tibsovo:0",
    "document_id": "doc:ema.tibsovo",
    "indication": "desc:ind:ema.tibsovo:0",
    "initial_approval_date": "2023-05-12",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/tibsovo-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.tibsovo:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute myeloid leukaemia",
    "raw_therapeutics": "Tibsovo (ivosidenib) in combination with azacitidine"
  },
  {
    "id": "ind:ema.tibsovo:1",
    "document_id": "doc:ema.tibsovo",
    "indication": "desc:ind:ema.tibsovo:1",
    "initial_approval_date": "2023-05-12",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/tibsovo-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.tibsovo:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cholangiocarcinoma",
    "raw_therapeutics": "Tibsovo (ivosidenib)"
  },
  {
    "id": "ind:ema.tremelimumab-astrazeneca:0",
    "document_id": "doc:ema.tremelimumab-astrazeneca",
    "indication": "desc:ind:ema.tremelimumab-astrazeneca:0",
    "initial_approval_date": "2023-04-04",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/tremelimumab-astrazeneca-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.tremelimumab-astrazeneca:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tremelimumab AstraZeneca (tremelimumab) in combination with durvalumab and platinum-based chemotherapy",
    "status": "Withdrawn"
  },
  {
    "id": "ind:ema.trisenox:0",
    "document_id": "doc:ema.trisenox",
    "indication": "desc:ind:ema.trisenox:0",
    "initial_approval_date": "2017-01-25",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/trisenox-h-c-388-ii-0058-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.trisenox:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "acute promyelocytic leukaemia",
    "raw_therapeutics": "Trisenox (arsenic trioxide)"
  },
  {
    "id": "ind:ema.trodelvy:0",
    "document_id": "doc:ema.trodelvy",
    "indication": "desc:ind:ema.trodelvy:0",
    "initial_approval_date": "2011-11-24",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/trodelvy-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.trodelvy:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "unresectable or metastatic breast cancer",
    "raw_therapeutics": "Trodelvy (sacituzumab govitecan)"
  },
  {
    "id": "ind:ema.trodelvy:1",
    "document_id": "doc:ema.trodelvy",
    "indication": "desc:ind:ema.trodelvy:1",
    "initial_approval_date": "2023-08-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/trodelvy-h-c-005182-ii-0020-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.trodelvy:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Trodelvy (sacituzumab govitecan)"
  },
  {
    "id": "ind:ema.tukysa:0",
    "document_id": "doc:ema.tukysa",
    "indication": "desc:ind:ema.tukysa:0",
    "initial_approval_date": "2021-02-18",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/tukysa-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.tukysa:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Tukysa (tucatinib) in combination with trastuzumab and capecitabine"
  },
  {
    "id": "ind:ema.tyverb:0",
    "document_id": "doc:ema.tyverb",
    "indication": "desc:ind:ema.tyverb:0",
    "initial_approval_date": "2010-06-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tyverb-h-c-795-ii-0004-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tyverb:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Tyverb (lapatinib) in combination with capecitabine"
  },
  {
    "id": "ind:ema.tyverb:1",
    "document_id": "doc:ema.tyverb",
    "indication": "desc:ind:ema.tyverb:1",
    "initial_approval_date": "2013-08-14",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tyverb-h-c-795-ii-0022-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tyverb:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Tyverb (lapatinib) in combination with trastuzumab and chemotherapy"
  },
  {
    "id": "ind:ema.tyverb:2",
    "document_id": "doc:ema.tyverb",
    "indication": "desc:ind:ema.tyverb:2",
    "initial_approval_date": "2010-06-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tyverb-h-c-795-ii-0004-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tyverb:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Tyverb (lapatinib) in combination with an aromataste inhibitor"
  },
  {
    "id": "ind:ema.vectibix:0",
    "document_id": "doc:ema.vectibix",
    "indication": "desc:ind:ema.vectibix:0",
    "initial_approval_date": "2015-05-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/vectibix-h-c-741-ii-0065-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.vectibix:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Vectibix (panitumumab)"
  },
  {
    "id": "ind:ema.vectibix:1",
    "document_id": "doc:ema.vectibix",
    "indication": "desc:ind:ema.vectibix:1",
    "initial_approval_date": "2011-12-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/vectibix-h-c-741-ii-0017-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.vectibix:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Vectibix (panitumumab)"
  },
  {
    "id": "ind:ema.vectibix:2",
    "document_id": "doc:ema.vectibix",
    "indication": "desc:ind:ema.vectibix:2",
    "initial_approval_date": "2013-09-06",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/vectibix-h-c-741-ii-0050-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.vectibix:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Vectibix (panitumumab)"
  },
  {
    "id": "ind:ema.venclyxto:0",
    "document_id": "doc:ema.venclyxto",
    "indication": "desc:ind:ema.venclyxto:0",
    "initial_approval_date": "2016-12-21",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/venclyxto-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.venclyxto:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)",
    "raw_therapeutics": "Venclyxto (venetoclax)"
  },
  {
    "id": "ind:ema.venclyxto:1",
    "document_id": "doc:ema.venclyxto",
    "indication": "desc:ind:ema.venclyxto:1",
    "initial_approval_date": "2016-12-21",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/venclyxto-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.venclyxto:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)",
    "raw_therapeutics": "Venclyxto (venetoclax)"
  },
  {
    "id": "ind:ema.verzenios:0",
    "document_id": "doc:ema.verzenios",
    "indication": "desc:ind:ema.verzenios:0",
    "initial_approval_date": "2022-04-21",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/verzenios-h-c-004302-ii-0013-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.verzenios:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy"
  },
  {
    "id": "ind:ema.verzenios:1",
    "document_id": "doc:ema.verzenios",
    "indication": "desc:ind:ema.verzenios:1",
    "initial_approval_date": "2018-10-29",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/verzenios-epar-public-assessment-report_en.pdf-0",
    "description": "desc:stmt:ema.verzenios:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy"
  },
  {
    "id": "ind:ema.vitrakvi:0",
    "document_id": "doc:ema.vitrakvi",
    "indication": "desc:ind:ema.vitrakvi:0",
    "initial_approval_date": "2019-10-24",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/vitrakvi-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.vitrakvi:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Any solid tumor",
    "raw_therapeutics": "Vitrakvi (larotrectinib)"
  },
  {
    "id": "ind:ema.vizimpro:0",
    "document_id": "doc:ema.vizimpro",
    "indication": "desc:ind:ema.vizimpro:0",
    "initial_approval_date": "2019-06-05",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/vizimpro-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.vizimpro:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Vizimpro (dacomitinib)"
  },
  {
    "id": "ind:ema.xalkori:0",
    "document_id": "doc:ema.xalkori",
    "indication": "desc:ind:ema.xalkori:0",
    "initial_approval_date": "2016-01-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/xalkori-h-c-2489-ii-0024-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.xalkori:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:ema.xalkori:1",
    "document_id": "doc:ema.xalkori",
    "indication": "desc:ind:ema.xalkori:1",
    "initial_approval_date": "2012-11-14",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/xalkori-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.xalkori:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:ema.xalkori:2",
    "document_id": "doc:ema.xalkori",
    "indication": "desc:ind:ema.xalkori:2",
    "initial_approval_date": "2016-09-29",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/xalkori-h-c-2489-ii-0039-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.xalkori:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:ema.xalkori:3",
    "document_id": "doc:ema.xalkori",
    "indication": "desc:ind:ema.xalkori:3",
    "initial_approval_date": "2024-09-24",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/xalkori-h-c-002489-x-0080-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.xalkori:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "anaplastic large cell lymphoma",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:ema.xalkori:4",
    "document_id": "doc:ema.xalkori",
    "indication": "desc:ind:ema.xalkori:4",
    "initial_approval_date": "2024-09-24",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/xalkori-h-c-002489-x-0080-g-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.xalkori:4",
    "raw_biomarkers": null,
    "raw_cancer_type": "Inflammatory myofibroblastic tumour (IMT)",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:ema.xospata:0",
    "document_id": "doc:ema.xospata",
    "indication": "desc:ind:ema.xospata:0",
    "initial_approval_date": "2019-11-08",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/xospata-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.xospata:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute myeloid leukaemia",
    "raw_therapeutics": "Xospata (gilteritinib)"
  },
  {
    "id": "ind:ema.yervoy:0",
    "document_id": "doc:ema.yervoy",
    "indication": "desc:ind:ema.yervoy:0",
    "initial_approval_date": "2020-11-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/yervoy-h-c-ws-1783-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.yervoy:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.yervoy:1",
    "document_id": "doc:ema.yervoy",
    "indication": "desc:ind:ema.yervoy:1",
    "initial_approval_date": "2021-06-29",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/yervoy-h-c-002213-ws-1840-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.yervoy:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab"
  },
  {
    "id": "ind:ema.yervoy:2",
    "document_id": "doc:ema.yervoy",
    "indication": "desc:ind:ema.yervoy:2",
    "initial_approval_date": "2022-04-20",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/yervoy-h-c-ws2113-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.yervoy:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Oesophageal squamous cell carcinoma",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab"
  },
  {
    "id": "ind:ema.yervoy:3",
    "document_id": "doc:ema.yervoy",
    "indication": "desc:ind:ema.yervoy:3",
    "initial_approval_date": "2025-01-13",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/yervoy-h-c-ws2672-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.yervoy:3",
    "raw_biomarkers": "mismatch repair deficient or microsatellite instability-high",
    "raw_cancer_type": "colorectal cancer",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab"
  },
  {
    "id": "ind:ema.zelboraf:0",
    "document_id": "doc:ema.zelboraf",
    "indication": "desc:ind:ema.zelboraf:0",
    "initial_approval_date": "2012-03-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/zelboraf-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.zelboraf:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Zelboraf (vemurafenib)"
  },
  {
    "id": "ind:ema.zydelig:0",
    "document_id": "doc:ema.zydelig",
    "indication": "desc:ind:ema.zydelig:0",
    "initial_approval_date": "2014-10-14",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/zydelig-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.zydelig:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)",
    "raw_therapeutics": "Zydelig (idelalisib) in combination with rituximab"
  },
  {
    "id": "ind:ema.zykadia:0",
    "document_id": "doc:ema.zykadia",
    "indication": "desc:ind:ema.zykadia:0",
    "initial_approval_date": "2017-08-31",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/zykadia-h-c-3819-ii-0012-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.zykadia:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Zykadia (ceritinib)"
  },
  {
    "id": "ind:ema.zykadia:1",
    "document_id": "doc:ema.zykadia",
    "indication": "desc:ind:ema.zykadia:1",
    "initial_approval_date": "2015-06-04",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/zykadia-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.zykadia:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Zykadia (ceritinib)"
  },
  {
    "id": "ind:ema.tevimbra:0",
    "document_id": "doc:ema.tevimbra",
    "indication": "desc:ind:ema.tevimbra:0",
    "initial_approval_date": "2024-07-25",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tevimbra-h-c-005919-ii-0008-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tevimbra:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tevimbra (tislelizumab) in combination with pemetrexed and platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.tevimbra:1",
    "document_id": "doc:ema.tevimbra",
    "indication": "desc:ind:ema.tevimbra:1",
    "initial_approval_date": "2024-12-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tevimbra-h-c-005919-ii-0003-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tevimbra:1",
    "raw_biomarkers": "PD-L1 with a TAP score >= 5%",
    "raw_cancer_type": "Oesophageal squamous cell carcinoma (OSCC)",
    "raw_therapeutics": "Tevimbra, in combination with platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.tevimbra:2",
    "document_id": "doc:ema.tevimbra",
    "indication": "desc:ind:ema.tevimbra:2",
    "initial_approval_date": "2024-12-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tevimbra-h-c-005919-ii-0006-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.tevimbra:2",
    "raw_biomarkers": "PD-L1 with a TAP score >= 5%",
    "raw_cancer_type": "gastric or gastroesophageal junction",
    "raw_therapeutics": "Tevimbra in combination with platinum and fluoropyrimidine-based chemotherapy"
  },
  {
    "id": "ind:ema.rybrevant:0",
    "document_id": "doc:ema.rybrevant",
    "indication": "desc:ind:ema.rybrevant:0",
    "initial_approval_date": "2025-06-12",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/rybrevant-h-c-005454-x-0014-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.rybrevant:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab) in combination with carboplatin and pemetrexed"
  },
  {
    "id": "ind:ema.rybrevant:1",
    "document_id": "doc:ema.rybrevant",
    "indication": "desc:ind:ema.rybrevant:1",
    "initial_approval_date": "2022-02-01",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/rybrevant-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.rybrevant:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab)"
  },
  {
    "id": "ind:ema.rybrevant:2",
    "document_id": "doc:ema.rybrevant",
    "indication": "desc:ind:ema.rybrevant:2",
    "initial_approval_date": "2024-09-13",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/rybrevant-h-c-005454-ii-0011-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.rybrevant:2",
    "raw_biomarkers": "EGFR Exon 19 deletions or Exon 21 L858R",
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab) in combination with carboplatin and pemetrexed"
  },
  {
    "id": "ind:ema.rybrevant:3",
    "document_id": "doc:ema.rybrevant",
    "indication": "desc:ind:ema.rybrevant:3",
    "initial_approval_date": "2025-03-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/rybrevant-h-c-005454-ii-0013-epar-assessment-report-variation_en.pdf",
    "description": "desc:stmt:ema.rybrevant:3",
    "raw_biomarkers": "EGFR Exon 19 deletions or Exon 21 L858R",
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab) in combination with lazertinib"
  },
  {
    "id": "ind:ema.truqap:0",
    "document_id": "doc:ema.truqap",
    "indication": "desc:ind:ema.truqap:0",
    "initial_approval_date": "2024-07-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/truqap-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.truqap:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Truqap (capivasertib) in combination with fulvestrant"
  },
  {
    "id": "ind:ema.balversa:0",
    "document_id": "doc:ema.balversa",
    "indication": "desc:ind:ema.balversa:0",
    "initial_approval_date": "2024-08-29",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/balversa-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.balversa:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "urothelial carcinoma",
    "raw_therapeutics": "Balversa (erdafitinib)"
  },
  {
    "id": "ind:ema.vyloy:0",
    "document_id": "doc:ema.vyloy",
    "indication": "desc:ind:ema.vyloy:0",
    "initial_approval_date": "2024-09-23",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/vyloy-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.vyloy:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastric or gastroesophageal junction (GEJ) adenocarcinoma",
    "raw_therapeutics": "Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy"
  },
  {
    "id": "ind:ema.augtyro:0",
    "document_id": "doc:ema.augtyro",
    "indication": "desc:ind:ema.augtyro:0",
    "initial_approval_date": "2025-01-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/augtyro-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.augtyro:0",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Augtyro (repotrectinib)"
  },
  {
    "id": "ind:ema.augtyro:1",
    "document_id": "doc:ema.augtyro",
    "indication": "desc:ind:ema.augtyro:1",
    "initial_approval_date": "2025-01-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/augtyro-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.augtyro:1",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Augtyro (repotrectinib)"
  },
  {
    "id": "ind:ema.lazcluze:0",
    "document_id": "doc:ema.lazcluze",
    "indication": "desc:ind:ema.lazcluze:0",
    "initial_approval_date": "2025-03-17",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/lazcluze-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.lazcluze:0",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Lazcluze (lazertinib) in combination with amivantamab"
  },
  {
    "id": "ind:ema.elahere:0",
    "document_id": "doc:ema.elahere",
    "indication": "desc:ind:ema.elahere:0",
    "initial_approval_date": "2024-12-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/elahere-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.elahere:0",
    "raw_biomarkers": "folate receptor-alpha (FDalpha) positive",
    "raw_cancer_type": "high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer",
    "raw_therapeutics": "mirvetuximab soravtansine"
  },
  {
    "id": "ind:ema.itovebi:0",
    "document_id": "doc:ema.itovebi",
    "indication": "desc:ind:ema.itovebi:0",
    "initial_approval_date": "2025-08-27",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/itovebi-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.itovebi:0",
    "raw_biomarkers": "PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "inavolisib in combination with palbocicliab and fulvestrant"
  },
  {
    "id": "ind:ema.ziihera:0",
    "document_id": "doc:ema.ziihera",
    "indication": "desc:ind:ema.ziihera:0",
    "initial_approval_date": "2025-07-03",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/ziihera-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.ziihera:0",
    "raw_biomarkers": "HER2-positive (IHC3+)",
    "raw_cancer_type": "biliary tract cancer (BTC)",
    "raw_therapeutics": "Ziihera (zanidatamab)"
  },
  {
    "id": "ind:hc.adcetris:0",
    "document_id": "doc:hc.adcetris",
    "indication": "desc:ind:hc.adcetris:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.adcetris:0",
    "raw_biomarkers": "CD30-expressing",
    "raw_cancer_type": "systemic anaplastic large cell lymphoma (sALCL), CD30-expression peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), CD30-expression angioimmunoblastic T-cell lymphoma (AITL)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, and prednisone (CHP)"
  },
  {
    "id": "ind:hc.adcetris:1",
    "document_id": "doc:hc.adcetris",
    "indication": "desc:ind:hc.adcetris:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.adcetris:1",
    "raw_biomarkers": "CD30-expressing",
    "raw_cancer_type": "CD30-Expressing Mycosis Fungoides (MF)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin)"
  },
  {
    "id": "ind:hc.afinitor:0",
    "document_id": "doc:hc.afinitor",
    "indication": "desc:ind:hc.afinitor:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.afinitor:0",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced breast cancer",
    "raw_therapeutics": "Afinitor (everolimus) in combination with exemestane"
  },
  {
    "id": "ind:hc.akeega:0",
    "document_id": "doc:hc.akeega",
    "indication": "desc:ind:hc.akeega:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.akeega:0",
    "raw_biomarkers": "deleterious or suspected deleterious BRCA mutated (germline and/or somatic)",
    "raw_cancer_type": "metastatic castration resistant prostate cancer",
    "raw_therapeutics": "Akeega (niraparib and abiraterone acetate) with prednisone or prednisolone"
  },
  {
    "id": "ind:hc.alecensaro:0",
    "document_id": "doc:hc.alecensaro",
    "indication": "desc:ind:hc.alecensaro:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.alecensaro:0",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Alecensaro (alectinib)"
  },
  {
    "id": "ind:hc.alunbrig:0",
    "document_id": "doc:hc.alunbrig",
    "indication": "desc:ind:hc.alunbrig:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.alunbrig:0",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Alunbrig (brigatinib)"
  },
  {
    "id": "ind:hc.augtyro:0",
    "document_id": "doc:hc.augtyro",
    "indication": "desc:ind:hc.augtyro:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.augtyro:0",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Augtyro (repotrectinib)"
  },
  {
    "id": "ind:hc.balversa:0",
    "document_id": "doc:hc.balversa",
    "indication": "desc:ind:hc.balversa:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.balversa:0",
    "raw_biomarkers": "susceptible FGFR3 genetic alterations",
    "raw_cancer_type": "locally advanced unresectable or metastatic urothelial carcinoman (UC)",
    "raw_therapeutics": "Balversa (erdafitinib)"
  },
  {
    "id": "ind:hc.besponsa:0",
    "document_id": "doc:hc.besponsa",
    "indication": "desc:ind:hc.besponsa:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.besponsa:0",
    "raw_biomarkers": "CD22-positive",
    "raw_cancer_type": "B-cell precursor acute lymphoblastic leukemia",
    "raw_therapeutics": "Besponsa (inotuzumab ozogamicin)"
  },
  {
    "id": "ind:hc.blincyto:0",
    "document_id": "doc:hc.blincyto",
    "indication": "desc:ind:hc.blincyto:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.blincyto:0",
    "raw_biomarkers": "philadelphia chromosone-negative, CD19-positive",
    "raw_cancer_type": "B-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:hc.blincyto:1",
    "document_id": "doc:hc.blincyto",
    "indication": "desc:ind:hc.blincyto:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.blincyto:1",
    "raw_biomarkers": "philadelphia chromosome-negative, CD19-positive",
    "raw_cancer_type": "B-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:hc.blincyto:2",
    "document_id": "doc:hc.blincyto",
    "indication": "desc:ind:hc.blincyto:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.blincyto:2",
    "raw_biomarkers": "CD19-positive",
    "raw_cancer_type": "B-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:hc.blincyto:3",
    "document_id": "doc:hc.blincyto",
    "indication": "desc:ind:hc.blincyto:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.blincyto:3",
    "raw_biomarkers": "philadelphia chromosome-negative, CD19-positive",
    "raw_cancer_type": "B-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:hc.bosulif:0",
    "document_id": "doc:hc.bosulif",
    "indication": "desc:ind:hc.bosulif:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.bosulif:0",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "chronic myelogenous leukemia",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:hc.bosulif:1",
    "document_id": "doc:hc.bosulif",
    "indication": "desc:ind:hc.bosulif:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.bosulif:1",
    "raw_biomarkers": "philadelphia chromosone-positive (Ph+)",
    "raw_cancer_type": "chronic myelogenous leukemia",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:hc.braftovi:0",
    "document_id": "doc:hc.braftovi",
    "indication": "desc:ind:hc.braftovi:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.braftovi:0",
    "raw_biomarkers": "BRAF V600E or BRAF V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with binimetinib"
  },
  {
    "id": "ind:hc.braftovi:1",
    "document_id": "doc:hc.braftovi",
    "indication": "desc:ind:hc.braftovi:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.braftovi:1",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic colorectal cancer (mCRC)",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with cetuximab"
  },
  {
    "id": "ind:hc.cotellic:0",
    "document_id": "doc:hc.cotellic",
    "indication": "desc:ind:hc.cotellic:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.cotellic:0",
    "raw_biomarkers": "BRAF V600 mutation",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Cotellic in combination with vemurafenib"
  },
  {
    "id": "ind:hc.enhertu:0",
    "document_id": "doc:hc.enhertu",
    "indication": "desc:ind:hc.enhertu:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.enhertu:0",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "unresectable or metastatic breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:hc.enhertu:1",
    "document_id": "doc:hc.enhertu",
    "indication": "desc:ind:hc.enhertu:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.enhertu:1",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "unresectable or metastatic breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:hc.enhertu:2",
    "document_id": "doc:hc.enhertu",
    "indication": "desc:ind:hc.enhertu:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.enhertu:2",
    "raw_biomarkers": "HER2-low (IHC 1+ or IHC 2+/ISH-)",
    "raw_cancer_type": "unresectable or metastatic breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:hc.enhertu:3",
    "document_id": "doc:hc.enhertu",
    "indication": "desc:ind:hc.enhertu:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.enhertu:3",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:hc.erbitux:0",
    "document_id": "doc:hc.erbitux",
    "indication": "desc:ind:hc.erbitux:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.erbitux:0",
    "raw_biomarkers": "EGFR-expressing, K-Ras wild type",
    "raw_cancer_type": "metastatic colorectal carcinoma (mCRC)",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin)"
  },
  {
    "id": "ind:hc.erbitux:1",
    "document_id": "doc:hc.erbitux",
    "indication": "desc:ind:hc.erbitux:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.erbitux:1",
    "raw_biomarkers": "EGFR-expressing, K-Ras wild type",
    "raw_cancer_type": "metastatic colorectal carcinoma (mCRC)",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with irinotecan"
  },
  {
    "id": "ind:hc.erbitux:2",
    "document_id": "doc:hc.erbitux",
    "indication": "desc:ind:hc.erbitux:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.erbitux:2",
    "raw_biomarkers": "EGFR-expressing, K-Ras wild type",
    "raw_cancer_type": "metastatic colorectal carcinoma (mCRC)",
    "raw_therapeutics": "Erbitux (cetuximab) as a single agent"
  },
  {
    "id": "ind:hc.erbitux:3",
    "document_id": "doc:hc.erbitux",
    "indication": "desc:ind:hc.erbitux:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.erbitux:3",
    "raw_biomarkers": "EGFR-expressing, K-Ras wild type",
    "raw_cancer_type": "metastatic colorectal carcinoma (mCRC)",
    "raw_therapeutics": "Erbitux (cetuximab) as a single agent"
  },
  {
    "id": "ind:hc.faslodex:0",
    "document_id": "doc:hc.faslodex",
    "indication": "desc:ind:hc.faslodex:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.faslodex:0",
    "raw_biomarkers": "estrogen receptor-positive (ER+), HER2-negative",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant)"
  },
  {
    "id": "ind:hc.giotrif:0",
    "document_id": "doc:hc.giotrif",
    "indication": "desc:ind:hc.giotrif:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.giotrif:0",
    "raw_biomarkers": "EGFR Del 19, EGFR exon 21 L858R",
    "raw_cancer_type": "metastatic adenocarcinoma of the lung",
    "raw_therapeutics": "Giotrif (afatinib)"
  },
  {
    "id": "ind:hc.gleevec:0",
    "document_id": "doc:hc.gleevec",
    "indication": "desc:ind:hc.gleevec:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.gleevec:0",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "chronic myeloid leukemia",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:1",
    "document_id": "doc:hc.gleevec",
    "indication": "desc:ind:hc.gleevec:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.gleevec:1",
    "raw_biomarkers": "Philadelphia chromosome-positive",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:2",
    "document_id": "doc:hc.gleevec",
    "indication": "desc:ind:hc.gleevec:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.gleevec:2",
    "raw_biomarkers": "Philadelphia chromosome-positive",
    "raw_cancer_type": "acute lymphoblastic leukemia",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:3",
    "document_id": "doc:hc.gleevec",
    "indication": "desc:ind:hc.gleevec:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.gleevec:3",
    "raw_biomarkers": "Philadelphia chromosome-positive",
    "raw_cancer_type": "acute lymphoblastic leukemia (Ph+ALL)",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:4",
    "document_id": "doc:hc.gleevec",
    "indication": "desc:ind:hc.gleevec:4",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.gleevec:4",
    "raw_biomarkers": "DGFR gene re-arrangements",
    "raw_cancer_type": "myelodysplastic/myeloproliferative diseases (MDS/MPD)",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:5",
    "document_id": "doc:hc.gleevec",
    "indication": "desc:ind:hc.gleevec:5",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.gleevec:5",
    "raw_biomarkers": "without D816V c-Kit mutation or with the c-Kit mutational status unknown",
    "raw_cancer_type": "systemic mastocytosis (ASM and SMAHNMD)",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:6",
    "document_id": "doc:hc.gleevec",
    "indication": "desc:ind:hc.gleevec:6",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.gleevec:6",
    "raw_biomarkers": "FIP1L1::PDGFRA rearrangement",
    "raw_cancer_type": "advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:7",
    "document_id": "doc:hc.gleevec",
    "indication": "desc:ind:hc.gleevec:7",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.gleevec:7",
    "raw_biomarkers": "Kit (CD117) positive",
    "raw_cancer_type": "unresectable and/or metastatic malignant gastrointestinal stromal tumors",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:8",
    "document_id": "doc:hc.gleevec",
    "indication": "desc:ind:hc.gleevec:8",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.gleevec:8",
    "raw_biomarkers": "Kit (CD117) positive",
    "raw_cancer_type": "gastrointestinal stromal tumors (GIST)",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.herceptin:0",
    "document_id": "doc:hc.herceptin",
    "indication": "desc:ind:hc.herceptin:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.herceptin:0",
    "raw_biomarkers": "HER2-overexpressing",
    "raw_cancer_type": "early stage breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:hc.herceptin:1",
    "document_id": "doc:hc.herceptin",
    "indication": "desc:ind:hc.herceptin:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.herceptin:1",
    "raw_biomarkers": "HER2 overexpression",
    "raw_cancer_type": "early stage breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab), paclitaxel, docetaxel"
  },
  {
    "id": "ind:hc.herceptin:2",
    "document_id": "doc:hc.herceptin",
    "indication": "desc:ind:hc.herceptin:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.herceptin:2",
    "raw_biomarkers": "HER2 overexpression",
    "raw_cancer_type": "early stage breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab), docetaxel, carboplatin"
  },
  {
    "id": "ind:hc.herceptin:3",
    "document_id": "doc:hc.herceptin",
    "indication": "desc:ind:hc.herceptin:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.herceptin:3",
    "raw_biomarkers": "HER2-overexpressing",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:hc.herceptin:4",
    "document_id": "doc:hc.herceptin",
    "indication": "desc:ind:hc.herceptin:4",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.herceptin:4",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab), pertuzumab, docetaxel"
  },
  {
    "id": "ind:hc.herceptin:5",
    "document_id": "doc:hc.herceptin",
    "indication": "desc:ind:hc.herceptin:5",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.herceptin:5",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic adenocarcinoma of the stomach or gastro-esophageal junction",
    "raw_therapeutics": "Herceptin (trastuzumab), capecitabine, 5-fluorouracil, cisplatin"
  },
  {
    "id": "ind:hc.ibrance:0",
    "document_id": "doc:hc.ibrance",
    "indication": "desc:ind:hc.ibrance:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.ibrance:0",
    "raw_biomarkers": "HR-positive, HER2-negative",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Ibrance (palbociclib), aromatase inhibitor"
  },
  {
    "id": "ind:hc.ibrance:1",
    "document_id": "doc:hc.ibrance",
    "indication": "desc:ind:hc.ibrance:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.ibrance:1",
    "raw_biomarkers": "HR-positive, HER2-negative",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Ibrance (palbociclib), fulvestrant"
  },
  {
    "id": "ind:hc.iclusig:0",
    "document_id": "doc:hc.iclusig",
    "indication": "desc:ind:hc.iclusig:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.iclusig:0",
    "raw_biomarkers": "T315I mutation positive",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Iclusig (ponatinib)"
  },
  {
    "id": "ind:hc.iclusig:1",
    "document_id": "doc:hc.iclusig",
    "indication": "desc:ind:hc.iclusig:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.iclusig:1",
    "raw_biomarkers": "Philadelphia chromosome positive, T315I mutation positive",
    "raw_cancer_type": "acute lymphoblastic leukemia (Ph+ ALL)",
    "raw_therapeutics": "Iclusig (ponatinib)"
  },
  {
    "id": "ind:hc.imfinzi:0",
    "document_id": "doc:hc.imfinzi",
    "indication": "desc:ind:hc.imfinzi:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.imfinzi:0",
    "raw_biomarkers": "no sensitizing EGFR mutations or ALK genomic aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Imfinzi (durvalumab), tremelimumab, platinum-based chemotherapy"
  },
  {
    "id": "ind:hc.imfinzi:1",
    "document_id": "doc:hc.imfinzi",
    "indication": "desc:ind:hc.imfinzi:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.imfinzi:1",
    "raw_biomarkers": "mismatch repair deficient (dMMR)",
    "raw_cancer_type": "primary advanced or recurrent endometrial cancer",
    "raw_therapeutics": "Imfinzi (durvalumab), carboplatin, paclitaxel"
  },
  {
    "id": "ind:hc.iressa:0",
    "document_id": "doc:hc.iressa",
    "indication": "desc:ind:hc.iressa:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.iressa:0",
    "raw_biomarkers": "activating mutations of EGFR",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Iressa (gefitinib)"
  },
  {
    "id": "ind:hc.itovebi:0",
    "document_id": "doc:hc.itovebi",
    "indication": "desc:ind:hc.itovebi:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.itovebi:0",
    "raw_biomarkers": "PIK3CA-mutated, HR-positive, HER2-negative",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Itovebi (inavolisib), palbociclib, fulvestrant"
  },
  {
    "id": "ind:hc.jemperli:0",
    "document_id": "doc:hc.jemperli",
    "indication": "desc:ind:hc.jemperli:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.jemperli:0",
    "raw_biomarkers": "mismatch repair deficient (dMMR), microsatellite instability-high (MSI-H)",
    "raw_cancer_type": "recurrent or advanced endometrial cancer",
    "raw_therapeutics": "Jemperli (dostarlimab)"
  },
  {
    "id": "ind:hc.kadcyla:0",
    "document_id": "doc:hc.kadcyla",
    "indication": "desc:ind:hc.kadcyla:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.kadcyla:0",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Kadcyla (trastuzumab emtansine)"
  },
  {
    "id": "ind:hc.kadcyla:1",
    "document_id": "doc:hc.kadcyla",
    "indication": "desc:ind:hc.kadcyla:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.kadcyla:1",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Kadcyla (trastuzumab emtansine)"
  },
  {
    "id": "ind:hc.keytruda:0",
    "document_id": "doc:hc.keytruda",
    "indication": "desc:ind:hc.keytruda:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.keytruda:0",
    "raw_biomarkers": "BRAF V600 mutation",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:hc.keytruda:1",
    "document_id": "doc:hc.keytruda",
    "indication": "desc:ind:hc.keytruda:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.keytruda:1",
    "raw_biomarkers": "PD-L1 (TPS \u2265 1%), EGFR genomic tumour aberrations, ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-small cell lung carcinoma (NSCLC)",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:hc.keytruda:2",
    "document_id": "doc:hc.keytruda",
    "indication": "desc:ind:hc.keytruda:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.keytruda:2",
    "raw_biomarkers": "no EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-squamous non-small cell lung carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab), pemetrexed, platinum chemotherapy"
  },
  {
    "id": "ind:hc.keytruda:3",
    "document_id": "doc:hc.keytruda",
    "indication": "desc:ind:hc.keytruda:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.keytruda:3",
    "raw_biomarkers": "PD-L1 (TPS \u2265 1%)",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:hc.keytruda:4",
    "document_id": "doc:hc.keytruda",
    "indication": "desc:ind:hc.keytruda:4",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.keytruda:4",
    "raw_biomarkers": "MSI-H or dMMR",
    "raw_cancer_type": "metastatic colorectal cancer (CRC)",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:hc.keytruda:5",
    "document_id": "doc:hc.keytruda",
    "indication": "desc:ind:hc.keytruda:5",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.keytruda:5",
    "raw_biomarkers": "MSI-H or dMMR ",
    "raw_cancer_type": "unresectable or metastatic MSI-H or dMMR solid tumors",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:hc.keytruda:6",
    "document_id": "doc:hc.keytruda",
    "indication": "desc:ind:hc.keytruda:6",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.keytruda:6",
    "raw_biomarkers": "not MSI-H or dMMR",
    "raw_cancer_type": "advanced endometrial carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab), lenvatinib"
  },
  {
    "id": "ind:hc.keytruda:7",
    "document_id": "doc:hc.keytruda",
    "indication": "desc:ind:hc.keytruda:7",
    "initial_approval_date": null,
    "initial_approval_url": " ",
    "description": "desc:stmt:hc.keytruda:7",
    "raw_biomarkers": "PD-L1 (CPS \u2265 1)",
    "raw_cancer_type": " metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC)",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:hc.keytruda:8",
    "document_id": "doc:hc.keytruda",
    "indication": "desc:ind:hc.keytruda:8",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.keytruda:8",
    "raw_biomarkers": "HER2-positive, PD-L1 (CPS \u2265 1)",
    "raw_cancer_type": " locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab), trastuzumab, fluoropyrimidine, platinum-containing chemotherapy"
  },
  {
    "id": "ind:hc.keytruda:9",
    "document_id": "doc:hc.keytruda",
    "indication": "desc:ind:hc.keytruda:9",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.keytruda:9",
    "raw_biomarkers": "HER2-negative",
    "raw_cancer_type": " locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.",
    "raw_therapeutics": "Keytruda (pembrolizumab), fluoropyrimidine, platinum-containing chemotherapy"
  },
  {
    "id": "ind:hc.keytruda:10",
    "document_id": "doc:hc.keytruda",
    "indication": "desc:ind:hc.keytruda:10",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.keytruda:10",
    "raw_biomarkers": "PD-L1 (CPS) >= 10",
    "raw_cancer_type": "locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC)",
    "raw_therapeutics": "Keytruda (pembrolizumab), chemotherapy"
  },
  {
    "id": "ind:hc.keytruda:11",
    "document_id": "doc:hc.keytruda",
    "indication": "desc:ind:hc.keytruda:11",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.keytruda:11",
    "raw_biomarkers": "PD-L1 (CPS \u2265 1)",
    "raw_cancer_type": "persistent, recurrent, or metastatic cervical cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab), chemotherapy, bevacizumab"
  },
  {
    "id": "ind:hc.kisqali:0",
    "document_id": "doc:hc.kisqali",
    "indication": "desc:ind:hc.kisqali:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.kisqali:0",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Kisqali (ribociclib), aromatase inhibitor"
  },
  {
    "id": "ind:hc.kisqali:1",
    "document_id": "doc:hc.kisqali",
    "indication": "desc:ind:hc.kisqali:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.kisqali:1",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Kisqali (ribociclib), fulvestrant"
  },
  {
    "id": "ind:hc.lazcluze:0",
    "document_id": "doc:hc.lazcluze",
    "indication": "desc:ind:hc.lazcluze:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.lazcluze:0",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Lazcluze (lazertinib), amivantamab"
  },
  {
    "id": "ind:hc.libtayo:0",
    "document_id": "doc:hc.libtayo",
    "indication": "desc:ind:hc.libtayo:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.libtayo:0",
    "raw_biomarkers": "PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] with no EGFR, ALK or ROS1 aberrations",
    "raw_cancer_type": "non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Libtayo (Cemiplimab)"
  },
  {
    "id": "ind:hc.libtayo:1",
    "document_id": "doc:hc.libtayo",
    "indication": "desc:ind:hc.libtayo:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.libtayo:1",
    "raw_biomarkers": "No EGFR, ALK, or ROS1 aberrations",
    "raw_cancer_type": "non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Libtayo (cemiplimab) in combination with platinum-based chemotherapy"
  },
  {
    "id": "ind:hc.lorbrena:0",
    "document_id": "doc:hc.lorbrena",
    "indication": "desc:ind:hc.lorbrena:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.lorbrena:0",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Lorbrena (lorlatinib)"
  },
  {
    "id": "ind:hc.lorbrena:1",
    "document_id": "doc:hc.lorbrena",
    "indication": "desc:ind:hc.lorbrena:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.lorbrena:1",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Lorbrena (lorlatinib)"
  },
  {
    "id": "ind:hc.lumakras:0",
    "document_id": "doc:hc.lumakras",
    "indication": "desc:ind:hc.lumakras:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.lumakras:0",
    "raw_biomarkers": "KRAS p.G12C",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Lumakras (sotorasib)"
  },
  {
    "id": "ind:hc.lynparza:0",
    "document_id": "doc:hc.lynparza",
    "indication": "desc:ind:hc.lynparza:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.lynparza:0",
    "raw_biomarkers": "deleterious or suspected deleterious gBRCAm, HER2-negative",
    "raw_cancer_type": "high risk early breast cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:hc.lynparza:1",
    "document_id": "doc:hc.lynparza",
    "indication": "desc:ind:hc.lynparza:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.lynparza:1",
    "raw_biomarkers": "deleterious or suspected deleterious gBRCAm, HER2-negative",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:hc.lynparza:2",
    "document_id": "doc:hc.lynparza",
    "indication": "desc:ind:hc.lynparza:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.lynparza:2",
    "raw_biomarkers": "BRCA-mutated",
    "raw_cancer_type": "advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:hc.lynparza:3",
    "document_id": "doc:hc.lynparza",
    "indication": "desc:ind:hc.lynparza:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.lynparza:3",
    "raw_biomarkers": "HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability",
    "raw_cancer_type": "advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib), bevacizumab"
  },
  {
    "id": "ind:hc.lynparza:4",
    "document_id": "doc:hc.lynparza",
    "indication": "desc:ind:hc.lynparza:4",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.lynparza:4",
    "raw_biomarkers": "deleterious or suspected deleterious germline BRCA-mutated (gBRCAm)",
    "raw_cancer_type": "metastatic adenocarcinoma of the pancreas",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:hc.lynparza:5",
    "document_id": "doc:hc.lynparza",
    "indication": "desc:ind:hc.lynparza:5",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.lynparza:5",
    "raw_biomarkers": "deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation",
    "raw_cancer_type": " metastatic castrationresistant Prostate Cancer (mCRPC)",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:hc.lynparza:6",
    "document_id": "doc:hc.lynparza",
    "indication": "desc:ind:hc.lynparza:6",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.lynparza:6",
    "raw_biomarkers": "germline and/or somatic BRCA mutation",
    "raw_cancer_type": "metastatic castration-resistant prostate cancer (mCRPC)",
    "raw_therapeutics": "Lynparza (olaparib), abiraterone, prednisone or prednisolone"
  },
  {
    "id": "ind:hc.mekinist:0",
    "document_id": "doc:hc.mekinist",
    "indication": "desc:ind:hc.mekinist:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.mekinist:0",
    "raw_biomarkers": "BRAF V600E or V600K mutation",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Mekinist (trametinib) monotherapy or dabrafenib"
  },
  {
    "id": "ind:hc.mekinist:1",
    "document_id": "doc:hc.mekinist",
    "indication": "desc:ind:hc.mekinist:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.mekinist:1",
    "raw_biomarkers": "BRAF V600E or V600K mutation",
    "raw_cancer_type": "melanoma",
    "raw_therapeutics": "Mekinist (trametinib), dabrafenib"
  },
  {
    "id": "ind:hc.mekinist:2",
    "document_id": "doc:hc.mekinist",
    "indication": "desc:ind:hc.mekinist:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.mekinist:2",
    "raw_biomarkers": "BRAF V600E mutation",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Mekinist (trametinib), dabrafenib"
  },
  {
    "id": "ind:hc.mekinist:3",
    "document_id": "doc:hc.mekinist",
    "indication": "desc:ind:hc.mekinist:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.mekinist:3",
    "raw_biomarkers": "BRAF V600E mutation",
    "raw_cancer_type": "low-grade glioma (LGG)",
    "raw_therapeutics": "Mekinist (trametinib), dabrafenib"
  },
  {
    "id": "ind:hc.mekinist:4",
    "document_id": "doc:hc.mekinist",
    "indication": "desc:ind:hc.mekinist:4",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.mekinist:4",
    "raw_biomarkers": "BRAF V600E mutation",
    "raw_cancer_type": "high-grade glioma (HGG)",
    "raw_therapeutics": "Mekinist (trametinib), dabrafenib"
  },
  {
    "id": "ind:hc.mektovi:0",
    "document_id": "doc:hc.mektovi",
    "indication": "desc:ind:hc.mektovi:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.mektovi:0",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma ",
    "raw_therapeutics": "Mektovi (binimetinib), encorafenib"
  },
  {
    "id": "ind:hc.mylotarg:0",
    "document_id": "doc:hc.mylotarg",
    "indication": "desc:ind:hc.mylotarg:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.mylotarg:0",
    "raw_biomarkers": "CD33-positive",
    "raw_cancer_type": "acute myeloid leukeia (AML)",
    "raw_therapeutics": "Mylotarg (gemtuzumab ozogamicin), daunorubicin (DNR), cytarabine (AraC)"
  },
  {
    "id": "ind:hc.nerlynx:0",
    "document_id": "doc:hc.nerlynx",
    "indication": "desc:ind:hc.nerlynx:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.nerlynx:0",
    "raw_biomarkers": "HR+, HER2-overexpressed/amplified",
    "raw_cancer_type": "early-stage breast cancer",
    "raw_therapeutics": "Nerlynx (neratinib)"
  },
  {
    "id": "ind:hc.nerlynx:1",
    "document_id": "doc:hc.nerlynx",
    "indication": "desc:ind:hc.nerlynx:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.nerlynx:1",
    "raw_biomarkers": "HER2-overexpressed/amplified",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Nerlynx (neratinib), capecitabine"
  },
  {
    "id": "ind:hc.opdivo:0",
    "document_id": "doc:hc.opdivo",
    "indication": "desc:ind:hc.opdivo:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.opdivo:0",
    "raw_biomarkers": "BRAF V600 mutation-positive,",
    "raw_cancer_type": " unresectable or metastatic melanoma",
    "raw_therapeutics": "Opdivo (nivolumab)"
  },
  {
    "id": "ind:hc.opdivo:1",
    "document_id": "doc:hc.opdivo",
    "indication": "desc:ind:hc.opdivo:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.opdivo:1",
    "raw_biomarkers": "EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": " locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Opdivo (nivolumab)"
  },
  {
    "id": "ind:hc.opdivo:2",
    "document_id": "doc:hc.opdivo",
    "indication": "desc:ind:hc.opdivo:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.opdivo:2",
    "raw_biomarkers": " PD-L1 \u2265 1% with no EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Opdivo (nivolumab), ipilimumab"
  },
  {
    "id": "ind:hc.opdivo:3",
    "document_id": "doc:hc.opdivo",
    "indication": "desc:ind:hc.opdivo:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.opdivo:3",
    "raw_biomarkers": "no EGFR or ALK tumour genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Opdivo (nivolumab), ipilimumab, 2 cycles of platinum-doublet chemotherapy"
  },
  {
    "id": "ind:hc.opdivo:4",
    "document_id": "doc:hc.opdivo",
    "indication": "desc:ind:hc.opdivo:4",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.opdivo:4",
    "raw_biomarkers": "MSI-H or dMMR",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Opdivo (nivolumab), ipilimumab"
  },
  {
    "id": "ind:hc.opdivo:5",
    "document_id": "doc:hc.opdivo",
    "indication": "desc:ind:hc.opdivo:5",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.opdivo:5",
    "raw_biomarkers": "HER2-negative",
    "raw_cancer_type": "negative advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma",
    "raw_therapeutics": "Opdivo (nivolumab), fluoropyrimidine-, platinum-containing chemotherapy"
  },
  {
    "id": "ind:hc.opdivo:6",
    "document_id": "doc:hc.opdivo",
    "indication": "desc:ind:hc.opdivo:6",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.opdivo:6",
    "raw_biomarkers": "PD-L1 \u2265 1%",
    "raw_cancer_type": "unresectable or metastatic esophageal squamous cell carcinoma (ESCC)",
    "raw_therapeutics": "Opdivo (nivolumab), ipilimumab"
  },
  {
    "id": "ind:hc.opdivo:7",
    "document_id": "doc:hc.opdivo",
    "indication": "desc:ind:hc.opdivo:7",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.opdivo:7",
    "raw_biomarkers": "PD-L1 \u2265 1%",
    "raw_cancer_type": "unresectable or metastatic esophageal squamous cell carcinoma (ESCC)",
    "raw_therapeutics": "Opdivo (nivolumab), fluoropyrimidine-, platinum-containing chemotherapy"
  },
  {
    "id": "ind:hc.pemazyre:0",
    "document_id": "doc:hc.pemazyre",
    "indication": "desc:ind:hc.pemazyre:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.pemazyre:0",
    "raw_biomarkers": "FGFR2 fusion or rearrangement",
    "raw_cancer_type": "unresectable locally advanced or metastatic cholangiocarcinoma",
    "raw_therapeutics": "Pemazyre (pemigatinib)"
  },
  {
    "id": "ind:hc.perjeta:0",
    "document_id": "doc:hc.perjeta",
    "indication": "desc:ind:hc.perjeta:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.perjeta:0",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "early stage breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab), trastuzumab, chemotherapy"
  },
  {
    "id": "ind:hc.perjeta:1",
    "document_id": "doc:hc.perjeta",
    "indication": "desc:ind:hc.perjeta:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.perjeta:1",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab), trastuzumab, docetaxel"
  },
  {
    "id": "ind:hc.phesgo:0",
    "document_id": "doc:hc.phesgo",
    "indication": "desc:ind:hc.phesgo:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.phesgo:0",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "locally advanced, inflammatory, or early stage breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab and trastuzumab), chemotherapy"
  },
  {
    "id": "ind:hc.phesgo:1",
    "document_id": "doc:hc.phesgo",
    "indication": "desc:ind:hc.phesgo:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.phesgo:1",
    "raw_biomarkers": "HR-negative, HER2-positive",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab and trastuzumab), chemotherapy"
  },
  {
    "id": "ind:hc.phesgo:2",
    "document_id": "doc:hc.phesgo",
    "indication": "desc:ind:hc.phesgo:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.phesgo:2",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab and trastuzumab), docetaxel"
  },
  {
    "id": "ind:hc.piqray:0",
    "document_id": "doc:hc.piqray",
    "indication": "desc:ind:hc.piqray:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.piqray:0",
    "raw_biomarkers": "PIK3CA-mutated, hormone receptor-positive, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Piqray (alpelisib), fulvestrant"
  },
  {
    "id": "ind:hc.retevmo:0",
    "document_id": "doc:hc.retevmo",
    "indication": "desc:ind:hc.retevmo:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.retevmo:0",
    "raw_biomarkers": "RET fusion-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Retevmo (selpercatinib)"
  },
  {
    "id": "ind:hc.retevmo:1",
    "document_id": "doc:hc.retevmo",
    "indication": "desc:ind:hc.retevmo:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.retevmo:1",
    "raw_biomarkers": "RET-mutant",
    "raw_cancer_type": "unresectable advanced or metastatic medullary thyroid cancer (MTC)",
    "raw_therapeutics": "Retevmo (selpercatinib)"
  },
  {
    "id": "ind:hc.retevmo:2",
    "document_id": "doc:hc.retevmo",
    "indication": "desc:ind:hc.retevmo:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.retevmo:2",
    "raw_biomarkers": "RET fusion-positive",
    "raw_cancer_type": "advanced or metastatic differentiated thyroid carcinoma",
    "raw_therapeutics": "Retevmo (selpercatinib)"
  },
  {
    "id": "ind:hc.revlimid:0",
    "document_id": "doc:hc.revlimid",
    "indication": "desc:ind:hc.revlimid:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.revlimid:0",
    "raw_biomarkers": "5q deletion",
    "raw_cancer_type": "transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes",
    "raw_therapeutics": "Revlimid (lenalidomide)"
  },
  {
    "id": "ind:hc.rituxan:0",
    "document_id": "doc:hc.rituxan",
    "indication": "desc:ind:hc.rituxan:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.rituxan:0",
    "raw_biomarkers": "CD20 positive",
    "raw_cancer_type": "relapsed or refractory low-grade or follicular B-cell non-Hodgkin\u2019s lymphoma",
    "raw_therapeutics": "RITUXAN (rituximab for injection)"
  },
  {
    "id": "ind:hc.rituxan:1",
    "document_id": "doc:hc.rituxan",
    "indication": "desc:ind:hc.rituxan:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.rituxan:1",
    "raw_biomarkers": "CD20 positive",
    "raw_cancer_type": "diffuse large B-cell non-Hodgkin\u2019s lymphoma (DLBCL)",
    "raw_therapeutics": "RITUXAN (rituximab for injection), CHOP chemotherapy"
  },
  {
    "id": "ind:hc.rituxan:2",
    "document_id": "doc:hc.rituxan",
    "indication": "desc:ind:hc.rituxan:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.rituxan:2",
    "raw_biomarkers": "CD20 positive",
    "raw_cancer_type": "Stage III/IV follicular B-cell non-Hodgkin's lymphoma",
    "raw_therapeutics": "RITUXAN (rituximab for injection), CVP chemotherapy"
  },
  {
    "id": "ind:hc.rozlytrek:0",
    "document_id": "doc:hc.rozlytrek",
    "indication": "desc:ind:hc.rozlytrek:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.rozlytrek:0",
    "raw_biomarkers": "NTRK gene fusion",
    "raw_cancer_type": "unresectable locally advanced or metastatic extracranial solid tumours",
    "raw_therapeutics": "Rozlytrek (entrectinib)"
  },
  {
    "id": "ind:hc.rozlytrek:1",
    "document_id": "doc:hc.rozlytrek",
    "indication": "desc:ind:hc.rozlytrek:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.rozlytrek:1",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Rozlytrek (entrectinib)"
  },
  {
    "id": "ind:hc.rybrevant:0",
    "document_id": "doc:hc.rybrevant",
    "indication": "desc:ind:hc.rybrevant:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.rybrevant:0",
    "raw_biomarkers": "EGFR Eexon 19 deletions or Exon 21 L858R substitution mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Rybrevant (amivantamab), carboplatin, pemetrexed"
  },
  {
    "id": "ind:hc.rybrevant:1",
    "document_id": "doc:hc.rybrevant",
    "indication": "desc:ind:hc.rybrevant:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.rybrevant:1",
    "raw_biomarkers": "EGFR Exon 20 insertion mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Rybrevant (amivantamab), carboplatin, pemetrexed"
  },
  {
    "id": "ind:hc.rybrevant:2",
    "document_id": "doc:hc.rybrevant",
    "indication": "desc:ind:hc.rybrevant:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.rybrevant:2",
    "raw_biomarkers": "EGFR Exon 20 insertion mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Rybrevant (amivantamab)"
  },
  {
    "id": "ind:hc.rydapt:0",
    "document_id": "doc:hc.rydapt",
    "indication": "desc:ind:hc.rydapt:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.rydapt:0",
    "raw_biomarkers": "FLT3 mutation",
    "raw_cancer_type": "acute myeloid leukemia (AML)",
    "raw_therapeutics": "Rydapt (midostaurin), cytarabine, daunorubicin"
  },
  {
    "id": "ind:hc.scemblix:0",
    "document_id": "doc:hc.scemblix",
    "indication": "desc:ind:hc.scemblix:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.scemblix:0",
    "raw_biomarkers": "Philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Scemblix (asciminib)"
  },
  {
    "id": "ind:hc.sprycel:0",
    "document_id": "doc:hc.sprycel",
    "indication": "desc:ind:hc.sprycel:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.sprycel:0",
    "raw_biomarkers": "Philadelphia chromosome positive (Ph+)",
    "raw_cancer_type": "chronic myeloid leukemia (CML) in chronic phase",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:hc.sprycel:1",
    "document_id": "doc:hc.sprycel",
    "indication": "desc:ind:hc.sprycel:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.sprycel:1",
    "raw_biomarkers": "Philadelphia chromosome positive (Ph+)",
    "raw_cancer_type": "chronic, accelerated, or blast phase chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:hc.sprycel:2",
    "document_id": "doc:hc.sprycel",
    "indication": "desc:ind:hc.sprycel:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.sprycel:2",
    "raw_biomarkers": "Philadelphia chromosome positive (Ph+)",
    "raw_cancer_type": "acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:hc.tabrecta:0",
    "document_id": "doc:hc.tabrecta",
    "indication": "desc:ind:hc.tabrecta:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tabrecta:0",
    "raw_biomarkers": "MET exon 14 skipping",
    "raw_cancer_type": " locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tabrecta (capmatinib)"
  },
  {
    "id": "ind:hc.tafinlar:0",
    "document_id": "doc:hc.tafinlar",
    "indication": "desc:ind:hc.tafinlar:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tafinlar:0",
    "raw_biomarkers": "unresectable or metastatic melanoma",
    "raw_cancer_type": "BRAF V600 mutation",
    "raw_therapeutics": "Tafinlar (dabrafenib mesylate)"
  },
  {
    "id": "ind:hc.tafinlar:1",
    "document_id": "doc:hc.tafinlar",
    "indication": "desc:ind:hc.tafinlar:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tafinlar:1",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "melanoma",
    "raw_therapeutics": "Tafinlar (dabrafenib mesylate), trametinib"
  },
  {
    "id": "ind:hc.tafinlar:2",
    "document_id": "doc:hc.tafinlar",
    "indication": "desc:ind:hc.tafinlar:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tafinlar:2",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tafinlar (dabrafenib mesylate), trametinib"
  },
  {
    "id": "ind:hc.tafinlar:3",
    "document_id": "doc:hc.tafinlar",
    "indication": "desc:ind:hc.tafinlar:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tafinlar:3",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "low-grade glioma (LGG)",
    "raw_therapeutics": "Tafinlar (dabrafenib mesylate), trametinib"
  },
  {
    "id": "ind:hc.tafinlar:4",
    "document_id": "doc:hc.tafinlar",
    "indication": "desc:ind:hc.tafinlar:4",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tafinlar:4",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "high-grade glioma (HGG)",
    "raw_therapeutics": "Tafinalr (dabrafenib mesylate), trametinib"
  },
  {
    "id": "ind:hc.tagrisso:0",
    "document_id": "doc:hc.tagrisso",
    "indication": "desc:ind:hc.tagrisso:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tagrisso:0",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R substitution",
    "raw_cancer_type": "stage IB-IIIA1 non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:hc.tagrisso:1",
    "document_id": "doc:hc.tagrisso",
    "indication": "desc:ind:hc.tagrisso:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tagrisso:1",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R substitution",
    "raw_cancer_type": "locally advanced, unresectable non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:hc.tagrisso:2",
    "document_id": "doc:hc.tagrisso",
    "indication": "desc:ind:hc.tagrisso:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tagrisso:2",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R substitution",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:hc.tagrisso:3",
    "document_id": "doc:hc.tagrisso",
    "indication": "desc:ind:hc.tagrisso:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tagrisso:3",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R substitution",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tagrisso (osimertinib), pemetrexed, platinum-based chemotherapy"
  },
  {
    "id": "ind:hc.tagrisso:4",
    "document_id": "doc:hc.tagrisso",
    "indication": "desc:ind:hc.tagrisso:4",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tagrisso:4",
    "raw_biomarkers": "EGFR T790M",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:hc.talzenna:0",
    "document_id": "doc:hc.talzenna",
    "indication": "desc:ind:hc.talzenna:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.talzenna:0",
    "raw_biomarkers": "deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Talzenna (talazoparib)"
  },
  {
    "id": "ind:hc.tasigna:0",
    "document_id": "doc:hc.tasigna",
    "indication": "desc:ind:hc.tasigna:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tasigna:0",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:hc.tasigna:1",
    "document_id": "doc:hc.tasigna",
    "indication": "desc:ind:hc.tasigna:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tasigna:1",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:hc.tasigna:2",
    "document_id": "doc:hc.tasigna",
    "indication": "desc:ind:hc.tasigna:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tasigna:2",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:hc.tasigna:3",
    "document_id": "doc:hc.tasigna",
    "indication": "desc:ind:hc.tasigna:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tasigna:3",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:hc.tecentriq:0",
    "document_id": "doc:hc.tecentriq",
    "indication": "desc:ind:hc.tecentriq:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tecentriq:0",
    "raw_biomarkers": "PD-L1 \u2265 50%",
    "raw_cancer_type": "non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:hc.tecentriq:1",
    "document_id": "doc:hc.tecentriq",
    "indication": "desc:ind:hc.tecentriq:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tecentriq:1",
    "raw_biomarkers": "PD-L1 >= 50% or PD-L1 >= 10% TIIC, no EGFR or ALK genomic tumour aberrations.",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:hc.tecentriq:2",
    "document_id": "doc:hc.tecentriq",
    "indication": "desc:ind:hc.tecentriq:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tecentriq:2",
    "raw_biomarkers": "no EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-squamous non small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tecentriq (atezolizumab), bevacizumab, paclitaxel, carboplatin"
  },
  {
    "id": "ind:hc.tecentriq:3",
    "document_id": "doc:hc.tecentriq",
    "indication": "desc:ind:hc.tecentriq:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tecentriq:3",
    "raw_biomarkers": "no EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-squamous, non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tecentriq (atezolizumab), nab-paclitaxel, carboplatin"
  },
  {
    "id": "ind:hc.tecentriq:4",
    "document_id": "doc:hc.tecentriq",
    "indication": "desc:ind:hc.tecentriq:4",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tecentriq:4",
    "raw_biomarkers": "EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:hc.tecentriq:5",
    "document_id": "doc:hc.tecentriq",
    "indication": "desc:ind:hc.tecentriq:5",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tecentriq:5",
    "raw_biomarkers": "PD-L1 >= 1%",
    "raw_cancer_type": "unresectable locally advanced or metastatic triple-negative breast cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab), nab-paclitaxel"
  },
  {
    "id": "ind:hc.tepmetko:0",
    "document_id": "doc:hc.tepmetko",
    "indication": "desc:ind:hc.tepmetko:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tepmetko:0",
    "raw_biomarkers": "MET exon 14 skipping",
    "raw_cancer_type": "locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "TEPMETKO (tepotinib)"
  },
  {
    "id": "ind:hc.tibsovo:0",
    "document_id": "doc:hc.tibsovo",
    "indication": "desc:ind:hc.tibsovo:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tibsovo:0",
    "raw_biomarkers": "IDH1 R132 mutation",
    "raw_cancer_type": "acute myeloid leukemia (AML)",
    "raw_therapeutics": "Tibsovo (ivosidenib), azacitidine"
  },
  {
    "id": "ind:hc.tibsovo:1",
    "document_id": "doc:hc.tibsovo",
    "indication": "desc:ind:hc.tibsovo:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tibsovo:1",
    "raw_biomarkers": "IDH1 R132",
    "raw_cancer_type": "locally advanced or metastatic cholangiocarcinoma",
    "raw_therapeutics": "Tibsovo (ivosidenib)"
  },
  {
    "id": "ind:hc.trodelvy:0",
    "document_id": "doc:hc.trodelvy",
    "indication": "desc:ind:hc.trodelvy:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.trodelvy:0",
    "raw_biomarkers": "HR-positive, HER2-negative,",
    "raw_cancer_type": "unresectable locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Trodelvy (sacituzumab govitecan)"
  },
  {
    "id": "ind:hc.truqap:0",
    "document_id": "doc:hc.truqap",
    "indication": "desc:ind:hc.truqap:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.truqap:0",
    "raw_biomarkers": "HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Truqap (capivasertib), fulvestrant"
  },
  {
    "id": "ind:hc.tukysa:0",
    "document_id": "doc:hc.tukysa",
    "indication": "desc:ind:hc.tukysa:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tukysa:0",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "locally advanced unresectable or metastatic breast cancer",
    "raw_therapeutics": "Tukysa (tucatinib), trastuzumab, capecitabine"
  },
  {
    "id": "ind:hc.tykerb:0",
    "document_id": "doc:hc.tykerb",
    "indication": "desc:ind:hc.tykerb:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.tykerb:0",
    "raw_biomarkers": "HER2 overexpression",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Tykerb (lapatinib), capecitabine"
  },
  {
    "id": "ind:hc.vectibix:0",
    "document_id": "doc:hc.vectibix",
    "indication": "desc:ind:hc.vectibix:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.vectibix:0",
    "raw_biomarkers": "wild-type KRAS, wild-type NRAS",
    "raw_cancer_type": "metastatic colorectal carcinoma (mCRC)",
    "raw_therapeutics": "Vectibix (panitumumab), FOLFOX (infusional 5-fluorouracil, leucovorin, and oxaliplatin)."
  },
  {
    "id": "ind:hc.vectibix:1",
    "document_id": "doc:hc.vectibix",
    "indication": "desc:ind:hc.vectibix:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.vectibix:1",
    "raw_biomarkers": "wild-type KRAS, wild-type NRAS",
    "raw_cancer_type": "metastatic colorectal carcinoma (mCRC)",
    "raw_therapeutics": "Vectibix (panitumumab)"
  },
  {
    "id": "ind:hc.verzenio:0",
    "document_id": "doc:hc.verzenio",
    "indication": "desc:ind:hc.verzenio:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.verzenio:0",
    "raw_biomarkers": "HR-positive, HER2-negative",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Verzenio (abemaciclib), endocrine therapy"
  },
  {
    "id": "ind:hc.verzenio:1",
    "document_id": "doc:hc.verzenio",
    "indication": "desc:ind:hc.verzenio:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.verzenio:1",
    "raw_biomarkers": "HR-positive, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Verzenio (abemaciclib), aromatase inhibitor, fulvestrant"
  },
  {
    "id": "ind:hc.vitrakvi:0",
    "document_id": "doc:hc.vitrakvi",
    "indication": "desc:ind:hc.vitrakvi:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.vitrakvi:0",
    "raw_biomarkers": "NTRK gene fusion",
    "raw_cancer_type": "solid tumours",
    "raw_therapeutics": "Vitrakvi (larotrectinib)"
  },
  {
    "id": "ind:hc.voranigo:0",
    "document_id": "doc:hc.voranigo",
    "indication": "desc:ind:hc.voranigo:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.voranigo:0",
    "raw_biomarkers": "IDH1 mutation or IDH2 mutation",
    "raw_cancer_type": "Grade 2a astrocytoma or oligodendroglioma",
    "raw_therapeutics": "Voranigo (vorasidenib)"
  },
  {
    "id": "ind:hc.vyloy:0",
    "document_id": "doc:hc.vyloy",
    "indication": "desc:ind:hc.vyloy:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.vyloy:0",
    "raw_biomarkers": "HER2-negative, CLDN18.2 >= 75%",
    "raw_cancer_type": "locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma",
    "raw_therapeutics": "Vyloy (zolbetuximab), fluoropyrimidine, platinum-containing chemotherapy"
  },
  {
    "id": "ind:hc.xalkori:0",
    "document_id": "doc:hc.xalkori",
    "indication": "desc:ind:hc.xalkori:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.xalkori:0",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "XALKORI (crizotinib)"
  },
  {
    "id": "ind:hc.xalkori:1",
    "document_id": "doc:hc.xalkori",
    "indication": "desc:ind:hc.xalkori:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.xalkori:1",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "XALKORI (crizotinib)"
  },
  {
    "id": "ind:hc.xospata:0",
    "document_id": "doc:hc.xospata",
    "indication": "desc:ind:hc.xospata:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.xospata:0",
    "raw_biomarkers": "FLT3 mutation",
    "raw_cancer_type": "relapsed or refactory acute myeloid leukemia (AML)",
    "raw_therapeutics": "Xospata (gilteritinib)"
  },
  {
    "id": "ind:hc.yervoy:0",
    "document_id": "doc:hc.yervoy",
    "indication": "desc:ind:hc.yervoy:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.yervoy:0",
    "raw_biomarkers": "PD-L1 \u2265 1% with no EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Yervoy (ipilimumab), nivolumab"
  },
  {
    "id": "ind:hc.yervoy:1",
    "document_id": "doc:hc.yervoy",
    "indication": "desc:ind:hc.yervoy:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.yervoy:1",
    "raw_biomarkers": "no EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Yervoy (ipilimumab), nivolumab, 2 cycles of platinum-doublet chemotherapy"
  },
  {
    "id": "ind:hc.yervoy:2",
    "document_id": "doc:hc.yervoy",
    "indication": "desc:ind:hc.yervoy:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.yervoy:2",
    "raw_biomarkers": "MSI-H, dMMR",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Yervoy (ipilimumab), nivolumab"
  },
  {
    "id": "ind:hc.yervoy:3",
    "document_id": "doc:hc.yervoy",
    "indication": "desc:ind:hc.yervoy:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.yervoy:3",
    "raw_biomarkers": "PD-L1 \u2265 1%",
    "raw_cancer_type": "unresectable or metastatic esophageal squamous cell carcinoma (ESCC)",
    "raw_therapeutics": "Yervoy (ipilimumab), nivolumab"
  },
  {
    "id": "ind:hc.zelboraf:0",
    "document_id": "doc:hc.zelboraf",
    "indication": "desc:ind:hc.zelboraf:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.zelboraf:0",
    "raw_biomarkers": "BRAF V600",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Zelboraf (vemurafenib)"
  },
  {
    "id": "ind:hc.zykadia:0",
    "document_id": "doc:hc.zykadia",
    "indication": "desc:ind:hc.zykadia:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.zykadia:0",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastaic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Zykadia (ceritinib)"
  },
  {
    "id": "ind:hc.zykadia:1",
    "document_id": "doc:hc.zykadia",
    "indication": "desc:ind:hc.zykadia:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hc.zykadia:1",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "locally advanced or metastatic NSCLC",
    "raw_therapeutics": "Zykadia (ceritinib)"
  },
  {
    "id": "ind:fda.modeyso:0",
    "document_id": "doc:fda.modeyso",
    "indication": "desc:ind:fda.modeyso:0",
    "initial_approval_date": "2025-08-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219876s000lbl.pdf",
    "description": "desc:stmt:fda.modeyso:0",
    "raw_biomarkers": "H3 K27M",
    "raw_cancer_type": "diffuse midline glioma",
    "raw_therapeutics": "Modeyso (dordaviprone)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2025-08-06",
    "status": "Accelerated"
  },
  {
    "id": "ind:fda.inluriyo:0",
    "document_id": "doc:fda.inluriyo",
    "indication": "desc:ind:fda.inluriyo:0",
    "initial_approval_date": "2025-09-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218881s000lbl.pdf",
    "description": "desc:stmt:fda.inluriyo:0",
    "raw_biomarkers": "ER-positive, HER2-negative, ESR1-mutated",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Inluriyo (imlunestrant)",
    "date_regular_approval": "2025-09-25",
    "date_accelerated_approval": null,
    "status": "Approved"
  },
  {
    "id": "ind:ema.voranigo:0",
    "document_id": "doc:ema.voranigo",
    "indication": "desc:ind:ema.voranigo:0",
    "initial_approval_date": "2025-09-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/voranigo-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.voranigo:0",
    "raw_biomarkers": "IDH1 R132 or IDH2 R172",
    "raw_cancer_type": "astrocytoma or oligodendroglioma",
    "raw_therapeutics": "Voranigo (vorasidenib)",
    "date_regular_approval": "2025-09-26",
    "date_accelerated_approval": null,
    "status": "Approved"
  },
  {
    "id": "ind:fda.vanflyta:0",
    "document_id": "doc:fda.vanflyta",
    "indication": "desc:ind:fda.vanflyta:0",
    "initial_approval_date": "2023-07-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216993s000lbl.pdf",
    "description": "desc:stmt:fda.vanflyta:0",
    "raw_biomarkers": "FLT3 internal tandem duplication (ITD)-positive",
    "raw_cancer_type": "newly diagnosed acute myeloid leukemia (AML)",
    "raw_therapeutics": "quizartinib in combination with standard cytarabine and anthracycline induction and cytarabine consolidation",
    "date_regular_approval": "2023-07-20",
    "date_accelerated_approval": null,
    "status": "Approved"
  },
  {
    "id": "ind:fda.imbruvica:0",
    "document_id": "doc:fda.imbruvica",
    "indication": "desc:ind:fda.imbruvica:0",
    "initial_approval_date": "2018-02-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210563s000lbl.pdf",
    "description": "desc:stmt:fda.imbruvica:0",
    "raw_biomarkers": "17p deletion",
    "raw_cancer_type": "chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL)",
    "raw_therapeutics": "Imbruvica (ibrutinib)",
    "date_regular_approval": "2018-02-16",
    "date_accelerated_approval": null,
    "status": "Approved"
  },
  {
    "id": "ind:fda.komzifti:0",
    "document_id": "doc:fda.komzifti",
    "indication": "desc:ind:fda.komzifti:0",
    "initial_approval_date": "2025-11-13",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220305s000lbl.pdf",
    "description": "desc:stmt:fda.komzifti:0",
    "raw_biomarkers": "susceptible nucleophosmin 1 (NPM1) mutation",
    "raw_cancer_type": "acute myeloid leukemia (AML)",
    "raw_therapeutics": "Komzifti (ziftomenib)",
    "date_regular_approval": "2025-11-13",
    "date_accelerated_approval": null,
    "status": "Approved"
  },
  {
    "id": "ind:fda.hyrnuo:0",
    "document_id": "doc:fda.hyrnuo",
    "indication": "desc:ind:fda.hyrnuo:0",
    "initial_approval_date": "2025-11-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219972s000lblCorrected.pdf",
    "description": "desc:stmt:fda.hyrnuo:0",
    "raw_biomarkers": "ERBB2 TKD activating variants",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Hyrnuo (sevabertinib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2025-11-19",
    "status": "Accelerated"
  },
  {
    "id": "ind:fda.tevimbra:0",
    "document_id": "doc:fda.tevimbra",
    "indication": "desc:ind:fda.tevimbra:0",
    "initial_approval_date": "2025-04-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s002lbl.pdf",
    "description": "desc:stmt:fda.tevimbra:0",
    "raw_biomarkers": "express PD-L1 (>= 1)",
    "raw_cancer_type": "esophageal cancer",
    "raw_therapeutics": "TEVIMBRA (tislelizumab) in combination with platinum containing chemotherapy",
    "date_regular_approval": "2025-04-22",
    "date_accelerated_approval": null,
    "status": "Approved"
  },
  {
    "id": "ind:fda.tevimbra:1",
    "document_id": "doc:fda.tevimbra",
    "indication": "desc:ind:fda.tevimbra:1",
    "initial_approval_date": "2025-04-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s002lbl.pdf",
    "description": "desc:stmt:fda.tevimbra:1",
    "raw_biomarkers": "HER2-negative and express PD-L1 (>= 1)",
    "raw_cancer_type": "gatric or gastroesophageal junction adenocarcinoma",
    "raw_therapeutics": "TEVIMBRA (tislelizumab) in combination with platinum and fluoropyrimidine-based chemotherapy",
    "date_regular_approval": "2025-04-22",
    "date_accelerated_approval": null,
    "status": "Approved"
  },
  {
    "id": "ind:hse.00221:a",
    "document_id": "doc:hse.00221",
    "indication": "desc:ind:hse.00221:a",
    "initial_approval_date": "2013-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00221:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Afatinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00401:a",
    "document_id": "doc:hse.00401",
    "indication": "desc:ind:hse.00401:a",
    "initial_approval_date": "2017-11-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00401:a",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Alectinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00401:b",
    "document_id": "doc:hse.00401",
    "indication": "desc:ind:hse.00401:b",
    "initial_approval_date": "2019-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00401:b",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Alectinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00847:a",
    "document_id": "doc:hse.00847",
    "indication": "desc:ind:hse.00847:a",
    "initial_approval_date": "2023-11-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00847:a",
    "raw_biomarkers": "Ph+",
    "raw_cancer_type": "Chronic Myeloid Leukemia",
    "raw_therapeutics": "Asciminib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00224:a",
    "document_id": "doc:hse.00224",
    "indication": "desc:ind:hse.00224:a",
    "initial_approval_date": "2013-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00224:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Bosutinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00562:a",
    "document_id": "doc:hse.00562",
    "indication": "desc:ind:hse.00562:a",
    "initial_approval_date": "2019-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00562:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Brigatinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00562:b",
    "document_id": "doc:hse.00562",
    "indication": "desc:ind:hse.00562:b",
    "initial_approval_date": "2020-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00562:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Brigatinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00340:a",
    "document_id": "doc:hse.00340",
    "indication": "desc:ind:hse.00340:a",
    "initial_approval_date": "2016-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00340:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Ceritinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00373:a",
    "document_id": "doc:hse.00373",
    "indication": "desc:ind:hse.00373:a",
    "initial_approval_date": "2018-04-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00373:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Cobimetinib in combination with Vemurafenib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00243:a",
    "document_id": "doc:hse.00243",
    "indication": "desc:ind:hse.00243:a",
    "initial_approval_date": "2014-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00243:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Crizotinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00237:a",
    "document_id": "doc:hse.00237",
    "indication": "desc:ind:hse.00237:a",
    "initial_approval_date": "2015-01-10",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00237:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Dabrafenib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00565:a",
    "document_id": "doc:hse.00565",
    "indication": "desc:ind:hse.00565:a",
    "initial_approval_date": "2019-11-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00565:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Dacomitinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00563:a",
    "document_id": "doc:hse.00563",
    "indication": "desc:ind:hse.00563:a",
    "initial_approval_date": "2019-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00563:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Encorafenib and Binimetinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00702:a",
    "document_id": "doc:hse.00702",
    "indication": "desc:ind:hse.00702:a",
    "initial_approval_date": "2022-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00702:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Entrectinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00570:a",
    "document_id": "doc:hse.00570",
    "indication": "desc:ind:hse.00570:a",
    "initial_approval_date": "2019-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00570:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Lorlatinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00570:b",
    "document_id": "doc:hse.00570",
    "indication": "desc:ind:hse.00570:b",
    "initial_approval_date": "2022-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00570:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Lorlatinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00682:a",
    "document_id": "doc:hse.00682",
    "indication": "desc:ind:hse.00682:a",
    "initial_approval_date": "2021-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00682:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute Myeloid Leukemia",
    "raw_therapeutics": "Midostaurin, DAUNOrubicin and Cytarabine",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Midostaurin - CDS; DAUNOrubicin, Cyarabine - N/A"
  },
  {
    "id": "ind:hse.00720:a",
    "document_id": "doc:hse.00720",
    "indication": "desc:ind:hse.00720:a",
    "initial_approval_date": "2022-03-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00720:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast Cancer",
    "raw_therapeutics": "Neratinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00848:a",
    "document_id": "doc:hse.00848",
    "indication": "desc:ind:hse.00848:a",
    "initial_approval_date": "2023-11-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00848:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Metastatic castration resistant prostate cancer (mCRPC)",
    "raw_therapeutics": "Niraparib and Abiraterone acetate and prednisoLONE",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00746:abc",
    "document_id": "doc:hse.00746",
    "indication": "desc:ind:hse.00746:abc",
    "initial_approval_date": "2023-09-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00746:abc",
    "raw_biomarkers": null,
    "raw_cancer_type": "Adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer",
    "raw_therapeutics": "Olaparib in combination with bevacizumab",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Olaparib - CDS; Bevacizumab - N/A"
  },
  {
    "id": "ind:hse.00588:abc",
    "document_id": "doc:hse.00588",
    "indication": "desc:ind:hse.00588:abc",
    "initial_approval_date": "2020-12-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00588:abc",
    "raw_biomarkers": null,
    "raw_cancer_type": "Adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer",
    "raw_therapeutics": "olaparib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00588:def",
    "document_id": "doc:hse.00588",
    "indication": "desc:ind:hse.00588:def",
    "initial_approval_date": "2021-12-21",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00588:def",
    "raw_biomarkers": null,
    "raw_cancer_type": "Adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer",
    "raw_therapeutics": "olaparib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00588:g",
    "document_id": "doc:hse.00588",
    "indication": "desc:ind:hse.00588:g",
    "initial_approval_date": "2023-03-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00588:g",
    "raw_biomarkers": null,
    "raw_cancer_type": "Adult patients with metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Olaparib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00353:a",
    "document_id": "doc:hse.00353",
    "indication": "desc:ind:hse.00353:a",
    "initial_approval_date": "2020-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00353:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Osimertinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00353:b",
    "document_id": "doc:hse.00353",
    "indication": "desc:ind:hse.00353:b",
    "initial_approval_date": "2020-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00353:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Osimertinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00353:c",
    "document_id": "doc:hse.00353",
    "indication": "desc:ind:hse.00353:c",
    "initial_approval_date": "2024-03-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00353:c",
    "raw_biomarkers": null,
    "raw_cancer_type": "stage IB-IIA non-small cell lung cancer",
    "raw_therapeutics": "Osimertinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00302:a",
    "document_id": "doc:hse.00302",
    "indication": "desc:ind:hse.00302:a",
    "initial_approval_date": "2016-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00302:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic phase, accelerated phase, or blast phase CML",
    "raw_therapeutics": "Ponatinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00302:b",
    "document_id": "doc:hse.00302",
    "indication": "desc:ind:hse.00302:b",
    "initial_approval_date": "2016-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00302:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)",
    "raw_therapeutics": "Ponatinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00605:a",
    "document_id": "doc:hse.00605",
    "indication": "desc:ind:hse.00605:a",
    "initial_approval_date": "2021-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00605:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Talazoparib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00415:a",
    "document_id": "doc:hse.00415",
    "indication": "desc:ind:hse.00415:a",
    "initial_approval_date": "2018-04-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00415:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Trametinib and Dabrafenib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00415:b",
    "document_id": "doc:hse.00415",
    "indication": "desc:ind:hse.00415:b",
    "initial_approval_date": "2021-12-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00415:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Trametinib and Dabrafenib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00102:a",
    "document_id": "doc:hse.00102",
    "indication": "desc:ind:hse.00102:a",
    "initial_approval_date": "2013-03-07",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00102:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Vemurafenib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00400:a",
    "document_id": "doc:hse.00400",
    "indication": "desc:ind:hse.00400:a",
    "initial_approval_date": "2018-12-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00400:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)",
    "raw_therapeutics": "Venetoclax",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00400:b",
    "document_id": "doc:hse.00400",
    "indication": "desc:ind:hse.00400:b",
    "initial_approval_date": "2018-12-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00400:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)",
    "raw_therapeutics": "Venetoclax",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00708:b",
    "document_id": "doc:hse.00708",
    "indication": "desc:ind:hse.00708:b",
    "initial_approval_date": "2023-09-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00708:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)",
    "raw_therapeutics": "Zanubrutinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00840:b",
    "document_id": "doc:hse.00840",
    "indication": "desc:ind:hse.00840:b",
    "initial_approval_date": "2023-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00840:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)",
    "raw_therapeutics": "Acalabrutinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00296:b",
    "document_id": "doc:hse.00296",
    "indication": "desc:ind:hse.00296:b",
    "initial_approval_date": "2016-07-19",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00296:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)",
    "raw_therapeutics": "Ibrutinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00389:b",
    "document_id": "doc:hse.00389",
    "indication": "desc:ind:hse.00389:b",
    "initial_approval_date": "2017-01-05",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00389:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)",
    "raw_therapeutics": "Idelalisib and RiTUXimab",
    "reimbursement_scheme": "Hybrid",
    "reimbursement_comment": "Idelalisib - CDS; riTUXimab - Hospital"
  },
  {
    "id": "ind:hse.00551:c",
    "document_id": "doc:hse.00551",
    "indication": "desc:ind:hse.00551:c",
    "initial_approval_date": "2023-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00551:c",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Nivolumab 3mg/kg with Ipilimumab 1mg/kg",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00455:a",
    "document_id": "doc:hse.00455",
    "indication": "desc:ind:hse.00455:a",
    "initial_approval_date": "2018-04-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00455:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "non-small cell lung carcinoma",
    "raw_therapeutics": "Pembrolizumab 200mg monotherapy",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00455:f",
    "document_id": "doc:hse.00455",
    "indication": "desc:ind:hse.00455:f",
    "initial_approval_date": "2021-02-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00455:f",
    "raw_biomarkers": null,
    "raw_cancer_type": "urothelial carcinoma",
    "raw_therapeutics": "Pembrolizumab 200mg monotherapy",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00455:h",
    "document_id": "doc:hse.00455",
    "indication": "desc:ind:hse.00455:h",
    "initial_approval_date": "2021-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00455:h",
    "raw_biomarkers": null,
    "raw_cancer_type": "head and neck squamous cell carcinoma",
    "raw_therapeutics": "Pembrolizumab 200mg monotherapy",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00455:j",
    "document_id": "doc:hse.00455",
    "indication": "desc:ind:hse.00455:j",
    "initial_approval_date": "2023-04-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00455:j",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cervical cancer",
    "raw_therapeutics": "Pembrolizumab 200mg monotherapy",
    "reimbursement_scheme": "Reimbursement by exception",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00455:k",
    "document_id": "doc:hse.00455",
    "indication": "desc:ind:hse.00455:k",
    "initial_approval_date": "2023-04-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00455:k",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Pembrolizumab 200mg monotherapy",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.P00760:a",
    "document_id": "doc:hse.P00760",
    "indication": "desc:ind:hse.P00760:a",
    "initial_approval_date": "2023-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.P00760:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Any solid tumor",
    "raw_therapeutics": "Larotrectinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": "Subject to a managed access protocol"
  },
  {
    "id": "ind:hse.00758:a",
    "document_id": "doc:hse.00758",
    "indication": "desc:ind:hse.00758:a",
    "initial_approval_date": "2023-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00758:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Any solid tumor",
    "raw_therapeutics": "Larotrectinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00219:a",
    "document_id": "doc:hse.00219",
    "indication": "desc:ind:hse.00219:a",
    "initial_approval_date": "2014-04-05",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00219:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Erlotinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00219:b",
    "document_id": "doc:hse.00219",
    "indication": "desc:ind:hse.00219:b",
    "initial_approval_date": "2014-04-05",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00219:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Erlotinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00206:a",
    "document_id": "doc:hse.00206",
    "indication": "desc:ind:hse.00206:a",
    "initial_approval_date": "2015-09-15",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00206:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Trastuzumab Emtansine",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00414:a",
    "document_id": "doc:hse.00414",
    "indication": "desc:ind:hse.00414:a",
    "initial_approval_date": "2018-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00414:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Palbociclib in combination with an aromatase inhibitor",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00414:b",
    "document_id": "doc:hse.00414",
    "indication": "desc:ind:hse.00414:b",
    "initial_approval_date": "2018-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00414:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Palbociclib in combination with fulvestrant",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00525:a",
    "document_id": "doc:hse.00525",
    "indication": "desc:ind:hse.00525:a",
    "initial_approval_date": "2019-02-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00525:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Ribociclib in combination with an aromatase inhibitor",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00525:b",
    "document_id": "doc:hse.00525",
    "indication": "desc:ind:hse.00525:b",
    "initial_approval_date": "2020-09-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00525:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Ribociclib in combination with an aromatase inhibitor",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00537:a",
    "document_id": "doc:hse.00537",
    "indication": "desc:ind:hse.00537:a",
    "initial_approval_date": "2019-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00537:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Inotuzumab ozogamicin",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.P0567:a",
    "document_id": "doc:hse.P0567",
    "indication": "desc:ind:hse.P0567:a",
    "initial_approval_date": "2019-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.P0567:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "blinatumomab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00530:a",
    "document_id": "doc:hse.00530",
    "indication": "desc:ind:hse.00530:a",
    "initial_approval_date": "2021-09-30",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00530:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Hodgkin Lymphoma (HL)",
    "raw_therapeutics": "Brentuximab vedotin and ESHAP therapy",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Brentuximab vedotin - ODMS; Etoposide, Cisplatin, Cytarabine - N/A"
  },
  {
    "id": "ind:hse.00350:a",
    "document_id": "doc:hse.00350",
    "indication": "desc:ind:hse.00350:a",
    "initial_approval_date": "2020-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00350:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Pertuzumab and trastuzumab and chemotherapy",
    "reimbursement_scheme": "Hybrid",
    "reimbursement_comment": "Pertuzumab - ODMS 2020-07-01; Trastuzumab, Chemotherapy - Hospital"
  },
  {
    "id": "ind:hse.00350:b",
    "document_id": "doc:hse.00350",
    "indication": "desc:ind:hse.00350:b",
    "initial_approval_date": "2020-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00350:b",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Pertuzumab and trastuzumab and chemotherapy",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pertuzumab - Reimbursement not approved; Trastuzumab, Chemotherapy - Hospital"
  },
  {
    "id": "ind:hse.00612:a",
    "document_id": "doc:hse.00612",
    "indication": "desc:ind:hse.00612:a",
    "initial_approval_date": "2020-11-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00612:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "gemtuzumab ozogamicin in combination with daunorubicin and cytarabine",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00568:a",
    "document_id": "doc:hse.00568",
    "indication": "desc:ind:hse.00568:a",
    "initial_approval_date": "2021-02-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00568:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "non-small cell lung carcinoma",
    "raw_therapeutics": "Pembrolizumab in combination with PEMEtrexed and CARBOplatin",
    "reimbursement_scheme": "Hybrid",
    "reimbursement_comment": "Pembrolizumab - ODMS; Pemetrexed, Carboplatin - Hospital"
  },
  {
    "id": "ind:hse.00569:a",
    "document_id": "doc:hse.00569",
    "indication": "desc:ind:hse.00569:a",
    "initial_approval_date": "2021-02-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00569:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "non-small cell lung carcinoma",
    "raw_therapeutics": "Pembrolizumab in combination with PEMEtrexed and CISplatin",
    "reimbursement_scheme": "Hybrid",
    "reimbursement_comment": "Pembrolizumab - ODMS; Pemetrexed, Cisplatin - Hospital"
  },
  {
    "id": "ind:hse.00576:a",
    "document_id": "doc:hse.00576",
    "indication": "desc:ind:hse.00576:a",
    "initial_approval_date": "2021-02-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00576:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "non-small cell lung carcinoma",
    "raw_therapeutics": "Durvalumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00544:a",
    "document_id": "doc:hse.00544",
    "indication": "desc:ind:hse.00544:a",
    "initial_approval_date": "2019-03-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00544:a",
    "raw_biomarkers": "EGFR mutations or ALK fusion",
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": "ODMS; 2019-03-01 (IV); 2024-06-01 (SC)"
  },
  {
    "id": "ind:hse.00544:c",
    "document_id": "doc:hse.00544",
    "indication": "desc:ind:hse.00544:c",
    "initial_approval_date": "2021-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00544:c",
    "raw_biomarkers": null,
    "raw_cancer_type": "urothelial carcinoma",
    "raw_therapeutics": "Atezolizumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": "ODMS; 2021-07-01 (IV); 2024-06-01 (SC)"
  },
  {
    "id": "ind:hse.00544:d",
    "document_id": "doc:hse.00544",
    "indication": "desc:ind:hse.00544:d",
    "initial_approval_date": "2021-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00544:d",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Atezolizumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": "ODMS; 2021-10-01 (IV); 2024-06-01 (SC)"
  },
  {
    "id": "ind:hse.00544:e",
    "document_id": "doc:hse.00544",
    "indication": "desc:ind:hse.00544:e",
    "initial_approval_date": "2024-03-05",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00544:e",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Atezolizumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": "ODMS; 2024-03-05 (IV); 2024-06-01 (SC)"
  },
  {
    "id": "ind:hse.00659:a",
    "document_id": "doc:hse.00659",
    "indication": "desc:ind:hse.00659:a",
    "initial_approval_date": "2021-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00659:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Trastuzumab emtansine",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00705:a",
    "document_id": "doc:hse.00705",
    "indication": "desc:ind:hse.00705:a",
    "initial_approval_date": "2021-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00705:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "head and neck squamous cell carcinoma",
    "raw_therapeutics": "Pembrolizumab in combination with carboplatin and 5-fluorouracil",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pembrolizumab - ODMS; Carboplatin, 5-Fluorouracil - N/A"
  },
  {
    "id": "ind:hse.00706:a",
    "document_id": "doc:hse.00706",
    "indication": "desc:ind:hse.00706:a",
    "initial_approval_date": "2021-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00706:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "head and neck squamous cell carcinoma",
    "raw_therapeutics": "Pembrolizumab in combination with cisplatin and 5-fluorouracil",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pembrolizumab - ODMS; Cisplatin, 5-Fluorouracil - N/A"
  },
  {
    "id": "ind:hse.00712:a",
    "document_id": "doc:hse.00712",
    "indication": "desc:ind:hse.00712:a",
    "initial_approval_date": "2022-03-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00712:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Nivolumab in combination with ipilimumab, carboplatin, and paclitaxel",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pembrolizumab - ODMS; Carboplatin, Paclitaxel - N/A"
  },
  {
    "id": "ind:hse.00713:a",
    "document_id": "doc:hse.00713",
    "indication": "desc:ind:hse.00713:a",
    "initial_approval_date": "2022-03-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00713:a",
    "raw_biomarkers": "no sensitising EGFR mutation or ALK translocation.",
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Nivolumab in combination with ipilimumab, carboplatin, and pemetrexed",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pembrolizumab - ODMS; Carboplatin, Pemetrexed - N/A"
  },
  {
    "id": "ind:hse.00714:a",
    "document_id": "doc:hse.00714",
    "indication": "desc:ind:hse.00714:a",
    "initial_approval_date": "2022-03-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00714:a",
    "raw_biomarkers": "no sensitising EGFR mutation or ALK translocation.",
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Nivolumab in combination with ipilimumab, cisplatin, and pemetrexed",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pembrolizumab - ODMS; Cisplatin, Pemetrexed - N/A"
  },
  {
    "id": "ind:hse.00688:a",
    "document_id": "doc:hse.00688",
    "indication": "desc:ind:hse.00688:a",
    "initial_approval_date": "2022-03-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00688:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Triple-negative breast cancer",
    "raw_therapeutics": "Atezolizumab in combination with nab-paclitaxel",
    "reimbursement_scheme": "Hybrid",
    "reimbursement_comment": "Atezolizumab - ODMS 2022-03-01; nab-Paclitaxel - Hospital"
  },
  {
    "id": "ind:hse.00590:a",
    "document_id": "doc:hse.00590",
    "indication": "desc:ind:hse.00590:a",
    "initial_approval_date": "2021-02-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00590:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "blinatumomab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.P00707:a",
    "document_id": "doc:hse.P00707",
    "indication": "desc:ind:hse.P00707:a",
    "initial_approval_date": "2022-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.P00707:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "blinatumomab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00790:a",
    "document_id": "doc:hse.00790",
    "indication": "desc:ind:hse.00790:a",
    "initial_approval_date": "2022-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00790:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with paclitaxel and carboplatin",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pertuzumab/Trastuzumab - ODMS; Carboplatin and Cisplatin - N/A"
  },
  {
    "id": "ind:hse.00234:d",
    "document_id": "doc:hse.00234",
    "indication": "desc:ind:hse.00234:d",
    "initial_approval_date": "2022-12-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00234:d",
    "raw_biomarkers": "CD30+",
    "raw_cancer_type": "Cutaneous T-cell lymphoma (CTCL)",
    "raw_therapeutics": "Brentuximab vedotin",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00234:e",
    "document_id": "doc:hse.00234",
    "indication": "desc:ind:hse.00234:e",
    "initial_approval_date": "2022-12-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00234:e",
    "raw_biomarkers": "CD30+",
    "raw_cancer_type": "Hodgkin Lymphoma (HL)",
    "raw_therapeutics": "Brentuximab vedotin",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00234:a",
    "document_id": "doc:hse.00234",
    "indication": "desc:ind:hse.00234:a",
    "initial_approval_date": "2014-08-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00234:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Hodgkin Lymphoma (HL)",
    "raw_therapeutics": "Brentuximab vedotin",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00234:b",
    "document_id": "doc:hse.00234",
    "indication": "desc:ind:hse.00234:b",
    "initial_approval_date": "2014-08-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00234:b",
    "raw_biomarkers": "CD30+",
    "raw_cancer_type": "Hodgkin Lymphoma (HL)",
    "raw_therapeutics": "Brentuximab vedotin",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00528:a",
    "document_id": "doc:hse.00528",
    "indication": "desc:ind:hse.00528:a",
    "initial_approval_date": "2021-11-12",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00528:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Hodgkin Lymphoma (HL)",
    "raw_therapeutics": "Brentuximab vedotin and ICE therapy",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Brentuximab - ODMS; Carboplatin, Etoposide, Ifosfamide - N/A"
  },
  {
    "id": "ind:hse.00739:a",
    "document_id": "doc:hse.00739",
    "indication": "desc:ind:hse.00739:a",
    "initial_approval_date": "2023-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00739:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma",
    "raw_therapeutics": "Pembrolizumab 200mg in combination with cisplatin and 5-fluorouracil infusional therapy",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pembrolizumab - ODMS; Cisplatin, 5-Fluorouracil - N/A"
  },
  {
    "id": "ind:hse.00832:a",
    "document_id": "doc:hse.00832",
    "indication": "desc:ind:hse.00832:a",
    "initial_approval_date": "2023-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00832:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "oesophageal squamous cell carcinoma",
    "raw_therapeutics": "Nivolumab 480 mg, cisplatin 80mg/m2 and 5-fluorouracil infusional therapy",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Nivolumab - ODMS; Cisplatin, 5-Fluorouracil - N/A"
  },
  {
    "id": "ind:hse.00593:a",
    "document_id": "doc:hse.00593",
    "indication": "desc:ind:hse.00593:a",
    "initial_approval_date": "2019-03-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00593:a",
    "raw_biomarkers": "EGFR mutations or ALK fusion",
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00593:c",
    "document_id": "doc:hse.00593",
    "indication": "desc:ind:hse.00593:c",
    "initial_approval_date": "2021-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00593:c",
    "raw_biomarkers": null,
    "raw_cancer_type": "urothelial carcinoma",
    "raw_therapeutics": "Atezolizumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00593:d",
    "document_id": "doc:hse.00593",
    "indication": "desc:ind:hse.00593:d",
    "initial_approval_date": "2021-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00593:d",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Atezolizumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00593:f",
    "document_id": "doc:hse.00593",
    "indication": "desc:ind:hse.00593:f",
    "initial_approval_date": "2024-03-05",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00593:f",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Atezolizumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00839:a",
    "document_id": "doc:hse.00839",
    "indication": "desc:ind:hse.00839:a",
    "initial_approval_date": "2023-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00839:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastric or gastro-esophagael junction (GEJ) adenocracinoma",
    "raw_therapeutics": "Pembrolizumab and FOLFOX-6",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pembrolizumab - ODMS; Oxaliplatin, 5-Fluorouracil - N/A"
  },
  {
    "id": "ind:hse.00538:a",
    "document_id": "doc:hse.00538",
    "indication": "desc:ind:hse.00538:a",
    "initial_approval_date": "2019-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00538:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blinatumomab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00797:a",
    "document_id": "doc:hse.00797",
    "indication": "desc:ind:hse.00797:a",
    "initial_approval_date": "2022-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00797:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Pertuzumab / trastuzumab (phesgo) in combination with paclitaxel",
    "reimbursement_scheme": "Hybrid",
    "reimbursement_comment": "Pertuzumab / Trastuzumab (Phesgo) - ODMS 2022-12-20; Paclitaxel - Hospital"
  },
  {
    "id": "ind:hse.00507:a",
    "document_id": "doc:hse.00507",
    "indication": "desc:ind:hse.00507:a",
    "initial_approval_date": "2014-02-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00507:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Pertuzumab and trastuzumab in combination with paclitaxel",
    "reimbursement_scheme": "Hybrid",
    "reimbursement_comment": "Pertuzumab - ODMS 2014-02-01; Trastuzumab, Paclitaxel - Hospital"
  },
  {
    "id": "ind:hse.00796:a",
    "document_id": "doc:hse.00796",
    "indication": "desc:ind:hse.00796:a",
    "initial_approval_date": "2022-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00796:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Pertuzumab / trastuzumab (phesgo) in combination with docetaxel",
    "reimbursement_scheme": "Hybrid",
    "reimbursement_comment": "Pertuzumab / Trastuzumab (Phesgo) - ODMS 2022-12-20; Docetaxel - Hospital"
  },
  {
    "id": "ind:hse.00204:a",
    "document_id": "doc:hse.00204",
    "indication": "desc:ind:hse.00204:a",
    "initial_approval_date": "2024-02-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00204:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Pertuzumab in combination with trastuzumab and docetaxel",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00798:a",
    "document_id": "doc:hse.00798",
    "indication": "desc:ind:hse.00798:a",
    "initial_approval_date": "2022-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00798:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Pertuzumab / trastuzumab (phesgo) in combination with vinorelbine",
    "reimbursement_scheme": "Hybrid",
    "reimbursement_comment": "Pertuzumab / Trastuzumab (Phesgo) - ODMS 2022-12-20; Vinorelbine - Hospital"
  },
  {
    "id": "ind:hse.00526:a",
    "document_id": "doc:hse.00526",
    "indication": "desc:ind:hse.00526:a",
    "initial_approval_date": "2018-11-07",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00526:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Pertuzumab in combination trastuzumab and vinorelbine",
    "reimbursement_scheme": "Hybrid",
    "reimbursement_comment": "Pertuzumab - ODMS; Trastuzumab, Vinorelbine - Hospital"
  },
  {
    "id": "ind:hse.00785:a",
    "document_id": "doc:hse.00785",
    "indication": "desc:ind:hse.00785:a",
    "initial_approval_date": "2022-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00785:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Pertuzumab / trastuzumab (phesgo)",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00722:a",
    "document_id": "doc:hse.00722",
    "indication": "desc:ind:hse.00722:a",
    "initial_approval_date": "2020-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00722:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "docetaxel, carboplatin, trastuuzmab, and pertuzumab",
    "reimbursement_scheme": "Hybrid",
    "reimbursement_comment": "Pertuzumab - ODMS; Trastuzumab, Carboplatin, Docetaxel - Hospital"
  },
  {
    "id": "ind:hse.00849:a",
    "document_id": "doc:hse.00849",
    "indication": "desc:ind:hse.00849:a",
    "initial_approval_date": "2024-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00849:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Nivolumab 360mg and Chemotherapy",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Nivolumab - ODMS; Chemotherapy - N/A"
  },
  {
    "id": "ind:hse.00858:a",
    "document_id": "doc:hse.00858",
    "indication": "desc:ind:hse.00858:a",
    "initial_approval_date": "2024-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00858:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "pembroliuzmab in combination with carboplatin and paclitaxel and doxorubicin and cyclophosphamide",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00200:a",
    "document_id": "doc:hse.00200",
    "indication": "desc:ind:hse.00200:a",
    "initial_approval_date": "2014-02-10",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00200:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Metastatic Breast Cancer",
    "raw_therapeutics": "Trastuzumab",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00200:b",
    "document_id": "doc:hse.00200",
    "indication": "desc:ind:hse.00200:b",
    "initial_approval_date": "2014-02-10",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00200:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Trastuzumab",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00212:c",
    "document_id": "doc:hse.00212",
    "indication": "desc:ind:hse.00212:c",
    "initial_approval_date": "2015-06-12",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00212:c",
    "raw_biomarkers": "HER2-negative",
    "raw_cancer_type": "Metastatic Breast Cancer",
    "raw_therapeutics": "Bevacizumab in combination with paclitaxel",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00215:e",
    "document_id": "doc:hse.00215",
    "indication": "desc:ind:hse.00215:e",
    "initial_approval_date": "2015-06-12",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00215:e",
    "raw_biomarkers": "HER2-negative",
    "raw_cancer_type": "Metastatic Breast Cancer",
    "raw_therapeutics": "Bevacizumab in combination with paclitaxel",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00215:g",
    "document_id": "doc:hse.00215",
    "indication": "desc:ind:hse.00215:g",
    "initial_approval_date": "2015-06-12",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00215:g",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Small Cell Lung Cancer",
    "raw_therapeutics": "Bevacizumab in combination with erlotinib",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00217:a",
    "document_id": "doc:hse.00217",
    "indication": "desc:ind:hse.00217:a",
    "initial_approval_date": "2015-01-10",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00217:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Lapatinib in combination with Capecitabine",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00253:a",
    "document_id": "doc:hse.00253",
    "indication": "desc:ind:hse.00253:a",
    "initial_approval_date": "2014-11-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00253:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Tamoxifen",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00253:b",
    "document_id": "doc:hse.00253",
    "indication": "desc:ind:hse.00253:b",
    "initial_approval_date": "2014-11-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00253:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Tamoxifen",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00254:a",
    "document_id": "doc:hse.00254",
    "indication": "desc:ind:hse.00254:a",
    "initial_approval_date": "2014-11-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00254:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Anastrozole",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00254:b",
    "document_id": "doc:hse.00254",
    "indication": "desc:ind:hse.00254:b",
    "initial_approval_date": "2014-11-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00254:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Anastrozole",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00272:a",
    "document_id": "doc:hse.00272",
    "indication": "desc:ind:hse.00272:a",
    "initial_approval_date": "2019-09-21",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00272:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Trastuzumab",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00272:b",
    "document_id": "doc:hse.00272",
    "indication": "desc:ind:hse.00272:b",
    "initial_approval_date": "2019-09-21",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00272:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "trastuzumab in combination with paclitaxel",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00272:c",
    "document_id": "doc:hse.00272",
    "indication": "desc:ind:hse.00272:c",
    "initial_approval_date": "2019-09-21",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00272:c",
    "raw_biomarkers": null,
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Trastuzumab in combination with docetaxel",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00272:d",
    "document_id": "doc:hse.00272",
    "indication": "desc:ind:hse.00272:d",
    "initial_approval_date": "2019-09-21",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00272:d",
    "raw_biomarkers": null,
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Trastuzumab in combination with an aromatase inhibitor",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00285:a",
    "document_id": "doc:hse.00285",
    "indication": "desc:ind:hse.00285:a",
    "initial_approval_date": "2015-09-15",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00285:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "trastuzumab",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00285:b",
    "document_id": "doc:hse.00285",
    "indication": "desc:ind:hse.00285:b",
    "initial_approval_date": "2015-09-15",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00285:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "trastuzumab in combination with paclitaxel or docetaxel",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00285:c",
    "document_id": "doc:hse.00285",
    "indication": "desc:ind:hse.00285:c",
    "initial_approval_date": "2015-09-15",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00285:c",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00285:d",
    "document_id": "doc:hse.00285",
    "indication": "desc:ind:hse.00285:d",
    "initial_approval_date": "2015-09-15",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00285:d",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "neoadjuvant chemotherapy followed by adjuvant trastuzumab",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00361:a",
    "document_id": "doc:hse.00361",
    "indication": "desc:ind:hse.00361:a",
    "initial_approval_date": "2016-11-11",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00361:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Fulvestrant",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00361:b",
    "document_id": "doc:hse.00361",
    "indication": "desc:ind:hse.00361:b",
    "initial_approval_date": "2016-11-11",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00361:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Fulvestrant",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00371:a",
    "document_id": "doc:hse.00371",
    "indication": "desc:ind:hse.00371:a",
    "initial_approval_date": "2018-11-11",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00371:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Letrozole",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00371:d",
    "document_id": "doc:hse.00371",
    "indication": "desc:ind:hse.00371:d",
    "initial_approval_date": "2018-11-11",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00371:d",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Letrozole",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00376:a",
    "document_id": "doc:hse.00376",
    "indication": "desc:ind:hse.00376:a",
    "initial_approval_date": "2016-11-11",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00376:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Exemestane",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00430:a",
    "document_id": "doc:hse.00430",
    "indication": "desc:ind:hse.00430:a",
    "initial_approval_date": "2017-06-14",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00430:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Triple-negative breast cancer",
    "raw_therapeutics": "Gemcitabine and CARBOplatin (AUC2)",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00619:a",
    "document_id": "doc:hse.00619",
    "indication": "desc:ind:hse.00619:a",
    "initial_approval_date": "2024-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00619:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Abemaciclib in combination with endocrine therapy",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00726:a",
    "document_id": "doc:hse.00726",
    "indication": "desc:ind:hse.00726:a",
    "initial_approval_date": "2014-02-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00726:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "metastatic or locally recurrent unresectable breast cancer",
    "raw_therapeutics": "Pertuzumab in combination with trastuzumab",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pertuzumab - ODMS Feb 2014; Trastuzumab - N/A"
  },
  {
    "id": "ind:hse.00731:a",
    "document_id": "doc:hse.00731",
    "indication": "desc:ind:hse.00731:a",
    "initial_approval_date": "2020-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00731:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced, inflammatory or early breast cancer",
    "raw_therapeutics": "DOCEtaxel, CARBOplatin, Trastuzumab (S/C) and Pertuzumab (TCH(S/C)P) Therapy",
    "reimbursement_scheme": "Hybrid",
    "reimbursement_comment": "Pertuzumab - ODMS; Trastuzumab, Carboplatin, and Docetaxel - Hospital"
  },
  {
    "id": "ind:hse.00775:a",
    "document_id": "doc:hse.00775",
    "indication": "desc:ind:hse.00775:a",
    "initial_approval_date": "2020-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00775:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced, inflammatory, or early stage breast cancer",
    "raw_therapeutics": "pertuzumab, trastuzumab, paclitaxel, and carboplatin therapy (train-2)",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pertuzumab - ODMS; Trastuzumab, Carboplatin, and Paclitaxel - N/A"
  },
  {
    "id": "ind:hse.00789:a",
    "document_id": "doc:hse.00789",
    "indication": "desc:ind:hse.00789:a",
    "initial_approval_date": "2022-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00789:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced, inflammatory, or early stage breast cancer",
    "raw_therapeutics": "DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo)(TCHP) Therapy",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pertuzumab / Trastuzumab (Phesgo) - ODMS 2022-12-20; Carboplatin and Docetaxel - N/A"
  },
  {
    "id": "ind:hse.00857:a",
    "document_id": "doc:hse.00857",
    "indication": "desc:ind:hse.00857:a",
    "initial_approval_date": "2024-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00857:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Triple-negative breast cancer",
    "raw_therapeutics": "Pembrolizumab (200mg), carboplatin AUC 5 and weekly paclitaxel 80mg/m^2 followed by doxorubicin and cyclophosphamide (ac 60/600) therapy.",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00225:c",
    "document_id": "doc:hse.00225",
    "indication": "desc:ind:hse.00225:c",
    "initial_approval_date": "2014-04-05",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00225:c",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Panitumumab",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00328:a",
    "document_id": "doc:hse.00328",
    "indication": "desc:ind:hse.00328:a",
    "initial_approval_date": "2016-06-03",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00328:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Cetuximab (7 days) and FOLFIRI (14 days) Therapy",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00816:a",
    "document_id": "doc:hse.00816",
    "indication": "desc:ind:hse.00816:a",
    "initial_approval_date": "2023-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00816:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Oesophageal squamous cell carcinoma",
    "raw_therapeutics": "Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Nivolumab - ODMS; Cisplatin, 5-Flourouracil - N/A"
  },
  {
    "id": "ind:hse.00844:a",
    "document_id": "doc:hse.00844",
    "indication": "desc:ind:hse.00844:a",
    "initial_approval_date": "2023-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00844:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Oesophageal squamous cell carcinoma",
    "raw_therapeutics": "nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy (FOLFOX-6)",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Nivolumab - ODMS; Oxaliplatin, 5-Flourouracil - N/A"
  },
  {
    "id": "ind:hse.00558:a",
    "document_id": "doc:hse.00558",
    "indication": "desc:ind:hse.00558:a",
    "initial_approval_date": "2018-04-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00558:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "non-small cell lung carcinoma",
    "raw_therapeutics": "Pembrolizumab 400mg monotherapy",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00558:f",
    "document_id": "doc:hse.00558",
    "indication": "desc:ind:hse.00558:f",
    "initial_approval_date": "2021-02-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00558:f",
    "raw_biomarkers": null,
    "raw_cancer_type": "urothelial carcinoma",
    "raw_therapeutics": "Pembrolizumab 400mg monotherapy",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00558:h",
    "document_id": "doc:hse.00558",
    "indication": "desc:ind:hse.00558:h",
    "initial_approval_date": "2021-12-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00558:h",
    "raw_biomarkers": null,
    "raw_cancer_type": "head and neck squamous cell carcinoma",
    "raw_therapeutics": "Pembrolizumab 400mg monotherapy",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00558:j",
    "document_id": "doc:hse.00558",
    "indication": "desc:ind:hse.00558:j",
    "initial_approval_date": "2023-04-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00558:j",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cervical cancer",
    "raw_therapeutics": "Pembrolizumab 400mg monotherapy",
    "reimbursement_scheme": "Reimbursement by exception",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00558:k",
    "document_id": "doc:hse.00558",
    "indication": "desc:ind:hse.00558:k",
    "initial_approval_date": "2023-04-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00558:k",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Pembrolizumab 400mg monotherapy",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00811:a",
    "document_id": "doc:hse.00811",
    "indication": "desc:ind:hse.00811:a",
    "initial_approval_date": "2023-04-17",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00811:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cervical cancer",
    "raw_therapeutics": "Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pembrolizumab - Reimbursement by exception; Paclitaxel, Carboplatin, Bevacizumab - N/A"
  },
  {
    "id": "ind:hse.00817:a",
    "document_id": "doc:hse.00817",
    "indication": "desc:ind:hse.00817:a",
    "initial_approval_date": "2023-04-17",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00817:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cervical cancer",
    "raw_therapeutics": "Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Pembrolizumab - Reimbursement by exception; Paclitaxel, Carboplatin - N/A"
  },
  {
    "id": "ind:hse.00661:a",
    "document_id": "doc:hse.00661",
    "indication": "desc:ind:hse.00661:a",
    "initial_approval_date": "2021-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00661:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute myeloid leukaemia",
    "raw_therapeutics": "Midostaurin",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00683:a",
    "document_id": "doc:hse.00683",
    "indication": "desc:ind:hse.00683:a",
    "initial_approval_date": "2021-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00683:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute myeloid leukaemia",
    "raw_therapeutics": "Midostaurin",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Midostaurin - CDS 2021-10-01; Cytarabine - N/A"
  },
  {
    "id": "ind:hse.00281:b",
    "document_id": "doc:hse.00281",
    "indication": "desc:ind:hse.00281:b",
    "initial_approval_date": "2024-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00281:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy - 21 day in combination with nivolumab",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Nivolumab - ODMS 2024-05-01; Chemotherapy - N/A"
  },
  {
    "id": "ind:hse.00304:c",
    "document_id": "doc:hse.00304",
    "indication": "desc:ind:hse.00304:c",
    "initial_approval_date": "2024-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00304:c",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "CARBOplatin (AUC 6) and PACLitaxel 200mg/m2 Therapy in combination with nivolumab",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Nivolumab - ODMS 2024-05-01; Chemotherapy - N/A"
  },
  {
    "id": "ind:hse.00310:c",
    "document_id": "doc:hse.00310",
    "indication": "desc:ind:hse.00310:c",
    "initial_approval_date": "2024-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00310:c",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Gemcitabine (1000mg/m2) and Carboplatin (AUC 5) Therapy - 21 day in combination with nivolumab",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Nivolumab - ODMS 2024-05-01; Chemotherapy - N/A"
  },
  {
    "id": "ind:hse.00317:c",
    "document_id": "doc:hse.00317",
    "indication": "desc:ind:hse.00317:c",
    "initial_approval_date": "2024-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00317:c",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Pemetrexed in combination with cisplatin and nivolumab",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Nivolumab - ODMS 2024-05-01; Chemotherapy - N/A"
  },
  {
    "id": "ind:hse.00318:c",
    "document_id": "doc:hse.00318",
    "indication": "desc:ind:hse.00318:c",
    "initial_approval_date": "2024-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00318:c",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Pemetrexed in combination with carboplatin and nivolumab",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Nivolumab - ODMS 2024-05-01; Chemotherapy - N/A"
  },
  {
    "id": "ind:hse.00592:c",
    "document_id": "doc:hse.00592",
    "indication": "desc:ind:hse.00592:c",
    "initial_approval_date": "2021-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00592:c",
    "raw_biomarkers": null,
    "raw_cancer_type": "urothelial carcinoma",
    "raw_therapeutics": "Atezolizumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00592:d",
    "document_id": "doc:hse.00592",
    "indication": "desc:ind:hse.00592:d",
    "initial_approval_date": "2021-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00592:d",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Atezolizumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00592:e",
    "document_id": "doc:hse.00592",
    "indication": "desc:ind:hse.00592:e",
    "initial_approval_date": "2024-03-05",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00592:e",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Atezolizumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00655:a",
    "document_id": "doc:hse.00655",
    "indication": "desc:ind:hse.00655:a",
    "initial_approval_date": "2021-02-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00655:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Durvalumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00307:a",
    "document_id": "doc:hse.00307",
    "indication": "desc:ind:hse.00307:a",
    "initial_approval_date": "2017-01-18",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00307:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Hodgkin's lymphoma (NHL)",
    "raw_therapeutics": "(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP) Therapy",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00397:a",
    "document_id": "doc:hse.00397",
    "indication": "desc:ind:hse.00397:a",
    "initial_approval_date": "2017-07-08",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00397:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Hodgkin's lymphoma (NHL)",
    "raw_therapeutics": "(R*)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00409:a",
    "document_id": "doc:hse.00409",
    "indication": "desc:ind:hse.00409:a",
    "initial_approval_date": "2017-03-15",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00409:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Hodgkin's lymphoma (NHL)",
    "raw_therapeutics": "(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP Therapy - 14 day",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00436:a",
    "document_id": "doc:hse.00436",
    "indication": "desc:ind:hse.00436:a",
    "initial_approval_date": "2018-11-05",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00436:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Hodgkin's lymphoma (NHL)",
    "raw_therapeutics": "(R*)-miniCHOP therapy - 21 days",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00506:a",
    "document_id": "doc:hse.00506",
    "indication": "desc:ind:hse.00506:a",
    "initial_approval_date": "2018-08-13",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00506:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "diffuse large B-cell lymphoma",
    "raw_therapeutics": "R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00510:a",
    "document_id": "doc:hse.00510",
    "indication": "desc:ind:hse.00510:a",
    "initial_approval_date": "2019-01-29",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00510:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Hodgkin",
    "raw_therapeutics": "R-CEOP",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00529:a",
    "document_id": "doc:hse.00529",
    "indication": "desc:ind:hse.00529:a",
    "initial_approval_date": "2021-10-18",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00529:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Hodgkin Lymphoma (HL)",
    "raw_therapeutics": "Brentuximab vedotin and Bendamustine Therapy",
    "reimbursement_scheme": "Incomplete Reimbursement",
    "reimbursement_comment": "Brentuximab - ODMS; Bendamustine - N/A"
  },
  {
    "id": "ind:hse.00542:a",
    "document_id": "doc:hse.00542",
    "indication": "desc:ind:hse.00542:a",
    "initial_approval_date": "2019-02-05",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00542:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "follicular lymphoma",
    "raw_therapeutics": "rituximab in combination with chemotherapy",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00543:a",
    "document_id": "doc:hse.00543",
    "indication": "desc:ind:hse.00543:a",
    "initial_approval_date": "2019-02-05",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00543:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "follicular CD20 positive, B-cell Non Hodgkin Lymphoma",
    "raw_therapeutics": "Rituximab",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00599:a",
    "document_id": "doc:hse.00599",
    "indication": "desc:ind:hse.00599:a",
    "initial_approval_date": "2021-03-09",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00599:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "follicular CD20 positive, B-cell Non Hodgkin Lymphoma",
    "raw_therapeutics": "Rituximab",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00600:a",
    "document_id": "doc:hse.00600",
    "indication": "desc:ind:hse.00600:a",
    "initial_approval_date": "2021-03-09",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00600:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "follicular CD20 positive, B-cell Non Hodgkin Lymphoma",
    "raw_therapeutics": "Rituximab",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00672:a",
    "document_id": "doc:hse.00672",
    "indication": "desc:ind:hse.00672:a",
    "initial_approval_date": "2021-07-27",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00672:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "diffuse large B-cell Non Hodgkin's Lymphoma",
    "raw_therapeutics": "Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00293:a",
    "document_id": "doc:hse.00293",
    "indication": "desc:ind:hse.00293:a",
    "initial_approval_date": "2017-03-08",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00293:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Hodgkin",
    "raw_therapeutics": "riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00293:b",
    "document_id": "doc:hse.00293",
    "indication": "desc:ind:hse.00293:b",
    "initial_approval_date": "2017-03-08",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00293:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-Hodgkin",
    "raw_therapeutics": "riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00540:a",
    "document_id": "doc:hse.00540",
    "indication": "desc:ind:hse.00540:a",
    "initial_approval_date": "2019-02-05",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00540:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "follicular CD20 positive, B-cell Non Hodgkin Lymphoma",
    "raw_therapeutics": "Rituximab",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00335:a",
    "document_id": "doc:hse.00335",
    "indication": "desc:ind:hse.00335:a",
    "initial_approval_date": "2016-06-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00335:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastrointestinal Stromal Tumor (GIST)",
    "raw_therapeutics": "Imatinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00335:b",
    "document_id": "doc:hse.00335",
    "indication": "desc:ind:hse.00335:b",
    "initial_approval_date": "2016-06-20",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00335:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastrointestinal Stromal Tumor (GIST)",
    "raw_therapeutics": "Imatinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00823:a",
    "document_id": "doc:hse.00823",
    "indication": "desc:ind:hse.00823:a",
    "initial_approval_date": "2024-08-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00823:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tepotinib",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00776:a",
    "document_id": "doc:hse.00776",
    "indication": "desc:ind:hse.00776:a",
    "initial_approval_date": "2024-08-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00776:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "metastatic HER2-positive breast cancer",
    "raw_therapeutics": "Trastuzumab Deruxtecan (Enhertu)",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00776:b",
    "document_id": "doc:hse.00776",
    "indication": "desc:ind:hse.00776:b",
    "initial_approval_date": "2025-07-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00776:b",
    "raw_biomarkers": "HER2-low",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Trastuzumab Deruxtecan (Enhertu)",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00860:a",
    "document_id": "doc:hse.00860",
    "indication": "desc:ind:hse.00860:a",
    "initial_approval_date": "2024-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00860:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or early stage triple-negative breast cancer",
    "raw_therapeutics": "Pembrolizumab in combination with chemotherapy (carboplatin and paclitaxel followed by doxorubicin and cyclophosphamide)",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00861:a",
    "document_id": "doc:hse.00861",
    "indication": "desc:ind:hse.00861:a",
    "initial_approval_date": "2024-06-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00861:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or early stage triple-negative breast cancer",
    "raw_therapeutics": "Pembrolizumab in combination with chemotherapy (carboplatin and paclitaxel followed by doxorubicin and cyclophosphamide)",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00242:a",
    "document_id": "doc:hse.00242",
    "indication": "desc:ind:hse.00242:a",
    "initial_approval_date": "2015-01-10",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00242:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "Medullary thyroid cancer",
    "raw_therapeutics": "Vandetanib Therapy",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00356:a",
    "document_id": "doc:hse.00356",
    "indication": "desc:ind:hse.00356:a",
    "initial_approval_date": "2018-07-09",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00356:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "acute promyelocytic leukaemia",
    "raw_therapeutics": "Trentinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00356:b",
    "document_id": "doc:hse.00356",
    "indication": "desc:ind:hse.00356:b",
    "initial_approval_date": "2018-07-09",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00356:b",
    "raw_biomarkers": null,
    "raw_cancer_type": "acute promyelocytic leukaemia",
    "raw_therapeutics": "Trentinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy",
    "reimbursement_scheme": "Hospital",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00794:a",
    "document_id": "doc:hse.00794",
    "indication": "desc:ind:hse.00794:a",
    "initial_approval_date": "2024-09-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00794:a",
    "raw_biomarkers": null,
    "raw_cancer_type": "unresectable or metastatic breast cancer",
    "raw_therapeutics": "sacituzumab govitecan",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00702:b",
    "document_id": "doc:hse.00702",
    "indication": "desc:ind:hse.00702:b",
    "initial_approval_date": "2024-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00702:b",
    "raw_biomarkers": "NTRK fusion",
    "raw_cancer_type": "Any solid tumor",
    "raw_therapeutics": "Entrectinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00254:c",
    "document_id": "doc:hse.00254",
    "indication": "desc:ind:hse.00254:c",
    "initial_approval_date": "2014-11-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00254:c",
    "raw_biomarkers": "hormone dependent breast cancer",
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Anastrozole",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00371:b",
    "document_id": "doc:hse.00371",
    "indication": "desc:ind:hse.00371:b",
    "initial_approval_date": "2018-11-11",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00371:b",
    "raw_biomarkers": "hormone dependent breast cancer",
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Letrozole",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00885:a",
    "document_id": "doc:hse.00885",
    "indication": "desc:ind:hse.00885:a",
    "initial_approval_date": "2025-03-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00885:a",
    "raw_biomarkers": "susceptible FGFR3 genetic alterations",
    "raw_cancer_type": "urothelial carcinoma",
    "raw_therapeutics": "erdafitinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00684:a",
    "document_id": "doc:hse.00684",
    "indication": "desc:ind:hse.00684:a",
    "initial_approval_date": "2025-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00684:a",
    "raw_biomarkers": "FLT3 mutation",
    "raw_cancer_type": "acute myeloid leukemia",
    "raw_therapeutics": "gilteritinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00901:a",
    "document_id": "doc:hse.00901",
    "indication": "desc:ind:hse.00901:a",
    "initial_approval_date": "2025-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00901:a",
    "raw_biomarkers": "IDH1 R132 mutation",
    "raw_cancer_type": "cholangiocarcinoma",
    "raw_therapeutics": "ivosidenib",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00483:h",
    "document_id": "doc:hse.00483",
    "indication": "desc:ind:hse.00483:h",
    "initial_approval_date": "2024-12-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00483:h",
    "raw_biomarkers": "PD-L1 expression >= 1%",
    "raw_cancer_type": "invasive urothelial carcinoma",
    "raw_therapeutics": "nivolumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00900:a",
    "document_id": "doc:hse.00900",
    "indication": "desc:ind:hse.00900:a",
    "initial_approval_date": "2025-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00900:a",
    "raw_biomarkers": "dMMR or MSI-H",
    "raw_cancer_type": "colorectal cancer",
    "raw_therapeutics": "nivolumab in combination with ipilimumab",
    "reimbursement_scheme": "ODMS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00588:h",
    "document_id": "doc:hse.00588",
    "indication": "desc:ind:hse.00588:h",
    "initial_approval_date": "2025-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00588:h",
    "raw_biomarkers": "germline BRCA1/2-mutations, HER2-negative",
    "raw_cancer_type": "high risk early breast cancer",
    "raw_therapeutics": "olaparib monotherapy or in combination with endocrine therapy",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00588:i",
    "document_id": "doc:hse.00588",
    "indication": "desc:ind:hse.00588:i",
    "initial_approval_date": "2025-05-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00588:i",
    "raw_biomarkers": "germline BRCA1/2-mutations",
    "raw_cancer_type": "adenocarcinoma of the pancreas",
    "raw_therapeutics": "olaparib monotherapy",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00889:a",
    "document_id": "doc:hse.00889",
    "indication": "desc:ind:hse.00889:a",
    "initial_approval_date": "2025-08-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00889:a",
    "raw_biomarkers": "FGFR2 fusion or rearrangement",
    "raw_cancer_type": "cholangiocarcinoma",
    "raw_therapeutics": "pemigatinib",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00886:a",
    "document_id": "doc:hse.00886",
    "indication": "desc:ind:hse.00886:a",
    "initial_approval_date": "2025-02-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00886:a",
    "raw_biomarkers": "FLT3-ITD",
    "raw_cancer_type": "acute myeloid leukaemia",
    "raw_therapeutics": "quizartinib in combination with standard DAUNOrubicin and cytarabine induction chemotherapy",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hse.00892:a",
    "document_id": "doc:hse.00892",
    "indication": "desc:ind:hse.00892:a",
    "initial_approval_date": "2025-10-01",
    "initial_approval_url": null,
    "description": "desc:stmt:hse.00892:a",
    "raw_biomarkers": "HR+, HER2-",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "ribociclib in combination with an aromatase inhibitor",
    "reimbursement_scheme": "CDS",
    "reimbursement_comment": null
  },
  {
    "id": "ind:hpra.arimidex:0",
    "document_id": "doc:hpra.arimidex",
    "indication": "desc:ind:hpra.arimidex:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hpra.arimidex:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Anastrozole"
  },
  {
    "id": "ind:hpra.arimidex:1",
    "document_id": "doc:hpra.arimidex",
    "indication": "desc:ind:hpra.arimidex:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hpra.arimidex:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Anastrozole"
  },
  {
    "id": "ind:hpra.arimidex:2",
    "document_id": "doc:hpra.arimidex",
    "indication": "desc:ind:hpra.arimidex:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hpra.arimidex:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Anastrozole"
  },
  {
    "id": "ind:hpra.aromasin:0",
    "document_id": "doc:hpra.aromasin",
    "indication": "desc:ind:hpra.aromasin:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hpra.aromasin:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Exemestane"
  },
  {
    "id": "ind:hpra.femara:0",
    "document_id": "doc:hpra.femara",
    "indication": "desc:ind:hpra.femara:0",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hpra.femara:0",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Letrozole"
  },
  {
    "id": "ind:hpra.femara:1",
    "document_id": "doc:hpra.femara",
    "indication": "desc:ind:hpra.femara:1",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hpra.femara:1",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Letrozole"
  },
  {
    "id": "ind:hpra.femara:2",
    "document_id": "doc:hpra.femara",
    "indication": "desc:ind:hpra.femara:2",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hpra.femara:2",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Letrozole"
  },
  {
    "id": "ind:hpra.femara:3",
    "document_id": "doc:hpra.femara",
    "indication": "desc:ind:hpra.femara:3",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "desc:stmt:hpra.femara:3",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Letrozole"
  },
  {
    "id": "ind:ema.vanflyta:0",
    "document_id": "doc:ema.vanflyta",
    "indication": "desc:ind:ema.vanflyta:0",
    "initial_approval_date": "2023-11-21",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/vanflyta-epar-public-assessment-report_en.pdf",
    "description": "desc:stmt:ema.vanflyta:0",
    "raw_biomarkers": "FLT3-ITD",
    "raw_cancer_type": "acute myeloid leukaemia",
    "raw_therapeutics": "VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by VANFLYTA single-agent maintenance therapy"
  }
]